HIV Infections
Conditions
Keywords
Cabotegravir, Long-acting injectables, Implementation science, HIV, Pre-exposure prophylaxis
Brief summary
This is a two-arm study evaluating the impact of two implementation strategy conditions, dynamic implementation and routine implementation on the feasibility of delivering of Cabotegravir PrEP in low and high-volume PrEP sites in the United States for men who have sex with men (MSM) and Transgender men ≥ 18 years of age. There are two types of participants in the study. Patient Study Participants (PSPs) will refer to individuals who are enrolled in the study and who will receive commercially available Cabotegravir PrEP via prescription from the PrEP provider at the corresponding site. Staff Study Participants (SSPs) will refer to site staff who are involved in administrative and clinical aspects of offering and administering PrEP to PSPs and will participate in the staff study assessments. PSPs who choose to opt for 1-month oral lead-in (OLI) will receive cabotegravir tablets for PrEP at Month 1 followed by APPRETUDE intramuscular (IM) injections on Month 2, 3 and every two months thereafter up to Month 13. PSPs who opt for Direct to injections (DTI) will receive APPRETUDE IM injections on Month 1, 2 and every two months thereafter up to Month 12. Month 6/7 refers to Month 6 (DTI)/ Month 7 (OLI). Month 12/13 refers to Month 12 (DTI)/ Month 13 (OLI).
Interventions
DRUGAPRETUDE
Available as intramuscular injection.
DRUGCabotegravir OLI
Available as marketed orally administered tablets.
Sponsors
ViiV Healthcare
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Participant must be ≥ 18 years of age inclusive, at the time of signing the informed consent. * No prior history of receiving CAB PrEP * HIV negative test result at screening * Capable of giving signed informed consent form
Exclusion criteria
* HIV indeterminate or positive test result during screening and prior to initiation of CAB PrEP * A participant of concurrent interventional clinical or implementation science study at any time during the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Mean Feasibility of Intervention Measure (FIM) Score Assessed for SSPs | At Month 12 | The FIM-Intervention (INT) was a four-item measure for APRETUDE intervention (1. APRETUDE seems implementable in our clinic/practice 2. APRETUDE seems possible in our clinic/practice 3. APRETUDE seems doable in our clinic/practice 4. APRETUDE seems easy to use in our clinic/practice) and was measured on a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least feasibility and 5 the most feasibility. Timeframe for evaluation of this outcome measure is Month (M)12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of SSPs Assessed for Perceptions of Facilitators to RI, DI and Overall Implementation of PrEP Into Routine Care Through Month 12 | Up to Month 12 | Perception of facilitators to RI, DI and overall implementation of PrEP measured from themes emerging from Proctor and Consolidated Framework for Implementation Research (CFIR) guided semi-structured qualitative interviews. In this outcome measure, SSPs were asked about the facilitators of the overall implementation of APRETUDE into clinic infrastructure, evaluating feasibility of DI and RI study arms. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). |
| Number of SSPs Assessed for Perceptions of Barriers to RI, DI and Overall Implementation of PrEP Into Routine Care Through Month 12 | Up to Month 12 | Perception of barriers to RI, DI and overall implementation of PrEP measured from themes emerging from Proctor and CFIR guided semi-structured qualitative interview. In this outcome measure, SSPs were asked about the barriers/challenges of the overall implementation of APRETUDE into clinic infrastructure, evaluating feasibility of DI and RI study arms. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). |
| Mean FIM Score Assessed for PSPs | At Baseline (Month 1), Month 6 and Month 12 | The FIM-INT was a four-item measure for APRETUDE intervention (1. Receiving APRETUDE injection every 2 months seems workable in my life 2. Receiving APRETUDE injection every 2 months seems possible in my life 3. Receiving APRETUDE injection every 2 months seems doable in my life 4. Receiving APRETUDE injection every 2 months seems easy in my life) and was measured on a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least feasibility and 5 the most feasibility. Timeframe for evaluation of this outcome measure is BL, M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI). |
| Mean Acceptability of Intervention Measure (AIM) Score Assessed for PSPs | At Baseline (Month 1), Month 6 and Month 12 | The AIM-INT was employed to evaluate the perceived intervention acceptability among PSPs. The measure consists of four items (1. APRETUDE meets my approval for preventing HIV 2. APRETUDE for the prevention of HIV is appealing to me 3. I like APRETUDE for the prevention of HIV 4. I welcome APRETUDE for the prevention of HIV), each with a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least acceptability and 5 the most acceptability. Timeframe for evaluation of this outcome measure is BL, M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI). |
| Number of PSPs With Responses to Implementation Science Questionnaire (ISQ) Regarding Their Feelings About Taking APRETUDE | At Baseline (Month 1), Month 6 and Month 12 | The implementation science questionnaire (ISQ) used a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs indicated their feelings about taking APRETUDE. Timeframe for evaluation of this outcome measure is BL, M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI). |
| Number of PSPs With Responses to ISQs Regarding Acceptability of Coming to Clinic for APRETUDE Injection | At Baseline (Month 1), Month 6 and Month 12 | The ISQ used a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs indicated how acceptable it was for them to go to the clinic for APRETUDE injections. Timeframe for evaluation of this outcome measure is BL, M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI). |
| Number of PSPs With Responses to the ISQs Regarding Recommending APRETUDE | At Month 6 and Month 12 | The ISQ used a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs indicated if they would recommend APRETUDE to others. Timeframe for evaluation of this outcome measure is M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI). |
| Number of PSPs With Responses to the ISQs Regarding Appointment Scheduling | At Month 6 and Month 12 | The ISQ used a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs were asked about their opinion on the ease or difficulty of scheduling appointments at the clinic. Timeframe for evaluation of this outcome measure is M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI). |
| Number of PSPs With Responses to the ISQs Regarding Appointment Rescheduling | At Month 6 and Month 12 | The ISQ used a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs were asked about their opinion on ease or difficulty of rescheduling appointments at the clinic. Timeframe for evaluation of this outcome measure is M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI). |
| Change From Baseline in AIM Score Assessed for PSPs | At Month 6 and Month 12 compared to baseline (Month 1) | This outcome assesses the change in AIM-INT for PSPs over time. The measure consists of four items (1. APRETUDE meets my approval for preventing HIV 2. APRETUDE for the prevention of HIV is appealing to me 3. I like APRETUDE for the prevention of HIV 4. I welcome APRETUDE for the prevention of HIV), each with a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least acceptability and 5 the most acceptability. Timeframe for evaluation of this outcome measure is M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI) compared to Baseline. |
| Change From Baseline in FIM Score Assessed for PSPs | At Month 6 and Month 12 compared to baseline (Month 1) | This outcome assesses the change in FIM-INT for PSPs over time. The FIM-INT was a four-item measure for APRETUDE intervention (1. Receiving APRETUDE injection every 2 months seems workable in my life 2. Receiving APRETUDE injection every 2 months seems possible in my life 3. Receiving APRETUDE injection every 2 months seems doable in my life 4. Receiving APRETUDE injection every 2 months seems easy in my life) and was measured on a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least feasibility and 5 the most feasibility. Timeframe for evaluation of this outcome measure is M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI) compared to baseline. |
| Percentage of PSPs With Change From Baseline in ISQ Responses | At Month 6 and Month 12 compared to Baseline (Month 1) | The ISQ used a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs indicated their feelings about taking APRETUDE and how acceptable it was for them to go to the clinic for APRETUDE injections. Timeframe for evaluation of this outcome measure is BL, M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI). The change from baseline is calculated as a difference of percentages resulted at each timepoint as following: M6 minus (-) BL, and M12-BL. Q2M = a schedule of injection administration at every 2 months. |
| Number of PSPs Assessed for Perception of Facilitators to Feasibility and Acceptability of APRETUDE Through Month 12 | Up to Month 12 | Facilitators to feasibility and acceptability of APRETUDE measured from themes emerging from Proctor and Consolidated Framework for Implementation Research (CFIR) guided semi-structured qualitative interviews. In this outcome measure, PSPs were asked about their perception of the facilitators of feasibility and acceptability of APRETUDE intervention. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI). |
| Number of PSPs Assessed for Perception of Barriers to Feasibility and Acceptability of APRETUDE Through Month 12 | Up to Month 12 | Barriers to feasibility and acceptability of APRETUDE were measured from themes emerging from Proctor and Consolidated Framework for Implementation Research (CFIR) guided semi-structured qualitative interviews. In this outcome measure, PSPs were asked about their perspectives on the barriers and challenges of feasibility and acceptability of APRETUDE intervention. Timeframe for evaluation of this outcome measure is through M12 (equivalent M13 for PSPs who received OLI). |
| Mean FIM Score for Telehealth Delivery Assessed for SSPs | At Baseline (Month 1), Month 4 and Month 12 | The FIM-TEL services for SSPs were a four-item measure (1. Telehealth for APRETUDE seems implementable in our clinic/practice 2. Telehealth for APRETUDE seems possible in our clinic/practice 3. Telehealth for APRETUDE seems doable in our clinic/practice 4. Telehealth for APRETUDE seems easy to use in our clinic/practice) and was measured on a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least feasibility and 5 the most feasibility. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). |
| Mean AIM Score for Telehealth Delivery Assessed for SSPs | At Baseline (Month 1), Month 4 and Month 12 | The AIM-TEL services for SSPs were a four-item measure (1. The idea of telehealth for APRETUDE in our clinic/practice meets my approval 2. The idea of telehealth for APRETUDE in our clinic/practice is appealing to me 3. I like the idea of telehealth for APRETUDE in our clinic/practice 4. I welcome the idea of telehealth for APRETUDE in our clinic/practice), each with a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least acceptability and 5 the most acceptability. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). |
| Number of SSPs With Responses to the ISQs Regarding Use of Telehealth Delivery | At Baseline (Month 1), Month 4 and Month 12 | The ISQ used a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, SSPs were asked about the use of telehealth services at their clinic/practice. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). |
| Number of SSPs With Responses to the ISQs Indicating Which Telehealth Services Were Used | At Month 4 and Month 12 | The ISQ used a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, SSPs were asked about which telehealth services/systems were used at their clinic/practice to deliver APRETUDE during the PILLAR study. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). |
| Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | At Month 4 and Month 12 | The ISQ used a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, SSPs were asked about the helpfulness of the telehealth services/systems used at their clinic/practice. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). |
| Change From Baseline in FIM Score for Telehealth Delivery Assessed for SSPs | At Month 4 and Month 12 compared to baseline (Month 1) | The FIM telehealth services for SSPs were a four-item measure (1. Telehealth for APRETUDE seems implementable in our clinic/practice 2. Telehealth for APRETUDE seems possible in our clinic/practice 3. Telehealth for APRETUDE seems doable in our clinic/practice 4. Telehealth for APRETUDE seems easy to use in our clinic/practice) and was measured on a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least feasibility and 5 the most feasibility. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI) compared to Baseline (BL). |
| Change From Baseline in AIM Score for Telehealth Delivery Assessed for SSPs | At Month 4 and Month 12 compared to baseline (Month 1) | This outcome assesses the change in AIM telehealth services for SSPs over time. The AIM telehealth services for SSPs were a four-item measure (1. The idea of telehealth for APRETUDE in our clinic/practice meets my approval 2. The idea of telehealth for APRETUDE in our clinic/practice is appealing to me 3. I like the idea of telehealth for APRETUDE in our clinic/practice 4. I welcome the idea of telehealth for APRETUDE in our clinic/practice), each with a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least acceptability and 5 the most acceptability. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI) compared to Baseline (BL). |
| Percentage of SSPs With Change From Baseline in ISQ Responses for Telehealth Delivery | At Month 4 and Month 12 compared to Baseline (Month 1) | The ISQ used a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, SSPs were asked about the use of telehealth services at their clinic/practice. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). The change from baseline is calculated as a difference of percentages resulted at each timepoint as following: M4 minus (-) BL, and M12-BL. |
| Mean FIM Score for Telehealth Delivery Assessed for PSPs | At Baseline (Month 1), Month 6 and Month 12 | The FIM telehealth services for PSPs were a four-item measure (1. Using telehealth for APRETUDE services seems workable in my life 2. Using telehealth for APRETUDE services seems possible in my life 3. Using telehealth for APRETUDE services seems doable in my life 4. Using telehealth for APRETUDE services seems easy in my life) and was measured on a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least feasibility and 5 the most feasibility. Timeframe for evaluation of this outcome measure is BL, M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI). |
| Mean AIM Score for Telehealth Delivery Assessed for PSPs | At Baseline (Month 1), Month 6 and Month 12 | The AIM Telehealth services for PSPs were a four-item measure (1. Using telehealth for APRETUDE services meets my approval 2. Using telehealth for APRETUDE services is appealing to me 3. I like telehealth for APRETUDE services 4. I welcome using telehealth for APRETUDE services), each with a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least acceptability and 5 the most acceptability. Timepoints during which this outcome measure was evaluated were BL, M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI) |
| Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | At Baseline (Month 1), Month 6 and Month 12 | The ISQ uses a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs were asked about the use of telehealth (TEL) services such as completing forms online, video chatting with their provider, getting reminders about their injection, or scheduling injection appointments online. Timeframe for evaluation of this outcome measure is BL, M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI). |
| Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | At Month 6 and Month 12 | The ISQ uses a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs were asked about how comfortable it was to use various telehealth services for APRETUDE. Timeframe for evaluation of this outcome measure is M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI). |
| Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | At Month 6 and Month 12 | The ISQ uses a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs were asked about how convenient it was to use various telehealth services for APRETUDE. Timeframe for evaluation of this outcome measure is M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI). |
| Number of PSPs With Response to the ISQs Recommending Telehealth Delivery | At Month 6 and Month 12 | The ISQ uses a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs were asked if they would recommend telehealth services for APRETUDE to other people. Timeframe for evaluation of this outcome measure is M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI). |
| Change From Baseline in FIM Score for Telehealth Delivery Assessed for PSPs | At Month 6 and Month 12 compared to baseline (Month 1) | The FIM Telehealth services for PSPs were a four-item measure (1. Using telehealth for APRETUDE services seems workable in my life 2. Using telehealth for APRETUDE services seems possible in my life 3. Using telehealth for APRETUDE services seems doable in my life 4. Using telehealth for APRETUDE services seems easy in my life) and was measured on a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least feasibility and 5 the most feasibility. Timeframe for evaluation of this outcome measure is M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI) compared to BL. |
| Change From Baseline in AIM Score for Telehealth Delivery Assessed for PSPs | At Month 6 and Month 12 compared to baseline (Month 1) | The AIM Telehealth services for PSPs were a four-item measure (1. Using telehealth for APRETUDE services meets my approval 2. Using telehealth for APRETUDE services is appealing to me 3. I like telehealth for APRETUDE services 4. I welcome using telehealth for APRETUDE services), each with a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least acceptability and 5 the most acceptability. Timeframe for evaluation of this outcome measure is M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI) compared to BL. |
| Percentage of PSPs With Change From Baseline in ISQ Responses Regarding Telehealth Delivery | At Month 6 and Month 12 compared to Baseline (Month 1) | The ISQ used a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs were asked about the use of telehealth (TEL) services such as completing forms online, video chatting with their provider, getting reminders about their injection, or scheduling injection appointments online. Timeframe for evaluation of this outcome measure is BL, M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI). The change from baseline is calculated as a difference of percentages resulted at each timepoint as following: M6 minus (-) BL, and M12-BL. |
| Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Up to Month 12 | Barriers and facilitators to the feasibility and acceptability of telehealth use for APRETUDE were measured from themes emerging from Proctor and Consolidated Framework for Implementation Research (CFIR) guided semi-structured qualitative interviews. In this outcome measure, SSPs were asked their perceptions of these facilitators and barriers for telehealth services used. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). |
| Number of PSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Up to Month 12 | Barriers and facilitators to the feasibility and acceptability of telehealth use for APRETUDE were measured from themes emerging from Proctor and Consolidated Framework for Implementation Research (CFIR) guided semi-structured qualitative interviews. In this outcome measure, PSPs were asked their perceptions of these facilitators and barriers for telehealth services used. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). |
| Mean AIM Score Assessed for SSPs | At Baseline (Month 1), Month 4 and Month 12 | AIM score for SSPs has 2 parts- AIM-INT that evaluates perceived intervention acceptability among SSPs and consists of 4 items (1. APRETUDE in our clinic/practice meets my approval 2. APRETUDE in our clinic/practice is appealing to me 3. I like APRETUDE in our clinic/practice 4. I welcome APRETUDE in our clinic/practice), and AIM-Implementation (IMP) that evaluates perceived acceptability of DI and RI approaches among SSPs and consists of 4 items (1. The implementation support has met my approval; 2. The implementation support was appealing to me; 3. I like the implementation support I have received; 4. I welcome the implementation support I have received),each with a five-point rating scale (1=completely disagree, 2=disagree, 3=neither agree nor disagree, 4=agree, and 5=completely agree). Mean score ranges from 1 to 5 with 1=least acceptability and 5=most acceptability. Timeframe for evaluation is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). |
| Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | At Baseline (Month 1), Month 4 and Month 12 | The ISQ uses a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, SSPs were asked about the perceived barriers to managing delivery of APRETUDE. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). |
| Change From Baseline in AIM Score Assessed for SSPs | At Month 4 and Month 12 compared to baseline (Month 1) | AIM score for SSPs has 2 parts- AIM-INT that evaluates perceived intervention acceptability among SSPs and consists of 4 items (1. APRETUDE in our clinic/practice meets my approval 2. APRETUDE in our clinic/practice is appealing to me 3. I like APRETUDE in our clinic/practice 4. I welcome APRETUDE in our clinic/practice), and AIM-IMP that evaluates perceived acceptability of DI and RI approaches among SSPs and consists of 4 items (1. The implementation support has met my approval; 2. The implementation support was appealing to me; 3. I like the implementation support I have received; 4. I welcome the implementation support I have received),each with a five-point rating scale (1=completely disagree, 2=disagree, 3=neither agree nor disagree, 4=agree, and 5=completely agree). Mean score ranges from 1 to 5 with 1=least acceptability and 5=most acceptability. Timeframe for evaluation is M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI) compared to BL. |
| Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | At Month 4 and 12 compared to Baseline (Month 1) | The ISQ used a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, SSPs were asked about the perceived barriers to managing delivery of APRETUDE (Item \[I\]1= Management of scheduling injection appointments during correct injection windows, I2= Management of rescheduling appointments during correct injection windows, I3= Ability to schedule/reschedule patients who missed APRETUDE visits, I4= Ability to identify and flag missed injection visits to providers (in a timely manner), I5= Ability to manage patients presenting to APRETUDE appointments with other care needs). Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). The change from baseline is calculated as a difference of percentages resulted at each timepoint as following: M4 minus (-) BL, and M12-BL. |
| Mean AIM Score Assessed for PSPs | At Baseline (Month 1), Month 6 and Month 12 | The AIM-INT was employed to evaluate the perceived intervention acceptability among PSPs. The measure consists of four items (1. APRETUDE meets my approval for preventing HIV 2. APRETUDE for the prevention of HIV is appealing to me 3. I like APRETUDE for the prevention of HIV 4. I welcome APRETUDE for the prevention of HIV), each with a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least acceptability and 5 the most acceptability. Timeframe for evaluation of this outcome measure is BL, M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI). |
| Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | At Baseline (Month 1) | The ISQ uses a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs were asked about the helpfulness of various knowledge materials used in learning about APRETUDE. |
| Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | At Month 6 | The ISQ uses a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs were asked about the helpfulness of various knowledge materials used in learning about APRETUDE. Timeframe for evaluation of this outcome measure is M6 (equivalent to M7 for PSPs who received OLI). |
| Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | At Month 12 | The ISQ uses a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs were asked about the helpfulness of various knowledge materials used in learning about APRETUDE. Timeframe for evaluation of this outcome measure is M12 (equivalent to M13 for PSPs who received OLI). |
| Change From Baseline in Mean AIM Score in PSPs | At Month 6 and Month 12 compared to baseline (Month 1) | This outcome assesses the change in AIM-INT for PSPs over time. The measure consists of four items (1. APRETUDE meets my approval for preventing HIV 2. APRETUDE for the prevention of HIV is appealing to me 3. I like APRETUDE for the prevention of HIV 4. I welcome APRETUDE for the prevention of HIV), each with a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least acceptability and 5 the most acceptability. Timeframe for evaluation of this outcome measure is M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI) compared to Baseline. |
| Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | At Month 6 and Month 12 compared to Baseline (Month 1) | In this outcome measure, usong the ISQ, PSPs were asked about the helpfulness of various knowledge materials (I1= Getting Started Brochure that gives an overview of how to get started with APRETUDE, I2 = Patient Brochure helps understand the process of receiving APRETUDE, I3 = HIV & PrEP video gives key facts about HIV and PrEP options (DI), I4 = APRETUDE Myths and Facts video, addressing common myths about APRETUDE (DI), I5 = The What to Expect video which shows what to expect during the APRETUDE process (DI), I6 = The ViiV Connect program Video and frequently asked questions (DI), I7 = The study website to access APRETDUE information (RI), I8 = The study app to access APRETUDE information (DI). Timeframe for evaluation of this outcome measure is M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI). The change from baseline is calculated as a difference of percentages resulted at each timepoint as following: M6 minus (-) BL, and M12-BL. |
| Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Up to Month 12 | The ISQ uses a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, SSPs were asked about the usefulness of various implementation strategies used for implementing APRETUDE in their clinic/practice. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). |
| Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Up to Month 12 | The ISQ uses a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs were asked about how useful various implementation strategies have been in supporting them while taking APRETUDE. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI). |
| Number of SSPs Assessed for Perceptions of Utility of Implementation Strategies and Facilitators and Barriers to Acceptability of RI and DI | Up to Month 12 | Perceptions of Utility of Implementation Strategies and Facilitators and Barriers to Acceptability of RI and DI measured from themes emerging from Proctor and CFIR guided semi-structured qualitative interview. In this outcome measure, SSPs provided their insights on the tools and strategies used for implementing APRETUDE during the PILLAR study. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). |
| Number of PSPs Assessed for Perceptions of Utility of Implementation Strategies Through Semi-Structured Interviews (SSIs) | Up to Month 12 | Perceptions of Utility of Implementation Strategies and Facilitators and Barriers to Acceptability of RI and DI measured from themes emerging from Proctor and CFIR guided semi-structured qualitative interview. In this outcome measure, PSPs provided their insights regarding the tools and strategies used for delivering APRETUDE. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI). |
| Number of Injections Occurring Within Target Window From Target Date | Up to Month 12 | This outcome measure evaluates the number of injections occurring within the target window. The target window is defined as ± 7 days from target date of injection for Dose 2 and subsequent injections. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI). |
| Number of PSPs Completing Target Number of Injections | Up to Month 12 | Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI). |
| Number of PSPs With Perceptions of Facilitators to Fidelity to Injections | Up to Month 12 | Perceptions of utility of implementation strategies and facilitators and barriers to acceptability of RI and DI measured from themes emerging from Proctor and CFIR guided semi-structured qualitative interviews. In this outcome measure, PSPs provided their insights into how APRETUDE has been incorporated into their daily lives, including factors that supported its delivery. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI). |
| Number of PSPs With Perceptions of Barriers to Fidelity to Injections | Up to Month 12 | Perceptions of utility of implementation strategies and facilitators and barriers to acceptability of RI and DI measured from themes emerging from Proctor and CFIR guided semi-structured qualitative interviews. In this outcome measure, PSPs reported several challenges related to incorporating APRETUDE into their daily lives. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI). |
| Number of SSPs With Perceptions of Facilitators to Fidelity to Injections | Up to Month 12 | Perceptions of utility of implementation strategies and facilitators and barriers to acceptability of RI and DI measured from themes emerging from Proctor and CFIR guided semi-structured qualitative interviews. In this outcome measure, SSPs provided insights regarding the facilitators for adherence to APRETUDE and the support provided to enable patient adherence. These facilitators were categorized as resources, support, patient communication and patient feasibility. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). |
| Number of SSPs With Perceptions of Barriers to Fidelity to Injections | Up to Month 12 | Perceptions of utility of implementation strategies and facilitators and barriers to acceptability of RI and DI measured from themes emerging from Proctor and CFIR guided semi-structured qualitative interviews. In this outcome measure, SSPs provided insights regarding the barriers and challenges in enabling patient adherence to APRETUDE. The barriers were categorized as patient barriers and staff challenges. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). |
| Number of SSPs Who Administer Sexual Health Assessment (SHA) | Up to Month 12 | In this outcome measure, SSPs answered questions about their administration of the sexual health assessment (SHA). The SHA was only administered by SSPs at the DI sites, hence it was not assessed for RI sites. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). |
| Number of Eligible PSPs for Which SHA Are Administered | Up to Month 12 | In this outcome measure, data shown below describes the number of PSPs to which the SHA was administered. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI). |
| Number of Men Who Have Sex With Men (MSM) and Transgender Men (TGM) Who Take the SHA Through M12 | Up to Month 12 | The ISQ uses a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. Timeframe for evaluation of this outcome measure is M12 (equivalent to M13 for PSPs who received OLI). |
| Number of MSM and TGM Who Report Having Had Sex in the Last 6 Months on the SHA | Up to Month 12 | In this outcome measure, data shown below describes the number of MSM and TGM who reported having had sex in the last 6 months. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI). |
| Number of PSPs Who Expressed Interest in PrEP or Never Heard of PrEP Out of Those Who Report Having Had Sex in the Last 6 Months | Up to Month 12 | In this outcome measure, data presented below shows the number of PSPs who expressed interest in PreP by responding to the question Have you taken oral PreP in the last 6 months and number of PSPs who had not heard of PreP. |
| Number of PSPs Who Initiate APRETUDE After Taking the SHA | Up to Month 12 | In this outcome measure, PSPs were asked if they had taken oral PreP in the last 6 months. PSPs who answered 'No' or 'I prefer not to answer' were further asked if they had ever taken oral PreP. Timeframe for evaluation of this outcome measure is through M12(equivalent to M13 for PSPs who received OLI). |
| Number of PSPs With Perceptions of SHA | Up to Month 12 | Perceptions of the sexual health assessment (SHA) among PSPs were measured from themes emerging from Proctor and CFIR guided semi-structured qualitative interviews. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI). |
| Number of SSPs With Perceptions of SHA | Up to Month 12 | In this outcome measure, SSPs provided insights regarding the use and implementation of SHA tool in their clinic/practice. The SHA was only administered by SSPs at the DI sites, hence it was not assessed for RI sites. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). |
| Number of Modifications Reported by SSPs Using FRAME-IS | At Month 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12 | The Framework for Reporting Adaptations and Modifications to Evidence-based Implementation Strategies (FRAME-IS) is a measure that provides a precise understanding of modifications, the process of modifying or adapting, and the relationship between different forms of modification and subsequent health and implementation outcomes. Data below summarize all modifications reported by SSPs during PILLAR study. Timeframe for evaluation of this outcome measure is from M2 to M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). |
| Number of Modifications for Each Category Reported by SSPs Using FRAME-IS | Up to Month 12 | The FRAME-IS is a measure that provides a precise understanding of modifications, the process of modifying or adapting, and the relationship between different forms of modification and subsequent health and implementation outcomes. Data below summarize the types of modifications and adaptations reported by SSPs during PILLAR study. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). |
| Change From Baseline in FIM Score Assessed for SSPs | At Month 4 and Month 12 compared to baseline (Month 1) | This outcome assesses the change in FIM-INT for SSPs over time. The FIM-INT was a four-item measure for APRETUDE intervention (1. APRETUDE seems implementable in our clinic/practice 2. APRETUDE seems possible in our clinic/practice 3. APRETUDE seems doable in our clinic/practice 4. APRETUDE seems easy to use in our clinic/practice) and was measured on a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least feasibility and 5 the most feasibility. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI) compared to Baseline (BL). |
| Number of PSPs Assessed for Perceptions of Adaptations to Implementation Strategies | Up to Month 12 | PSP perceptions of adaptations to implementation strategies were measured from themes emerging from Proctor and CFIR guided semi-structured qualitative interviews. In this outcome measure, PSPs discussed their use of study resources and recommendations to staff for delivery of APRETUDE. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI). |
| Number of PSPs With History of PrEP Use That Complete the SHA and ISQ and Start APRETUDE | Up to Month 12 | In this outcome measure, PSPs who completed the SHA and ISQ, describe the history of PrEP use and of sexual health assessment use for determination of PreP use during PILLAR study. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI). |
| Number of PSPs With Reasons for Choosing and Switching to APRETUDE Assessed by Semi-Structured Interviews (SSIs) | Up to Month 12 | Reasons for choosing and switching to APRETUDE were measured from themes emerging from Proctor and CFIR guided semi-structured qualitative interviews among PSPs. In this outcome measure, PSPs shared previous oral PrEP experiences, comparisons of other forms of PrEP to APRETUDE, and reasons for preferring APRETUDE. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI). |
| Number of PSPs With Reasons for Choosing and Switching to APRETUDE Assessed by ISQs | Up to Month 12 | The ISQ uses a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs answered ISQ regarding reasons for choosing to take APRETUDE. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI). |
| Number of PSPs Assessed for Perception of Facilitators | Up to Month 12 | General perceptions of facilitators for APRETUDE delivery and use were measured among PSPs from themes emerging from Proctor and CFIR guided semi-structured qualitative interviews. In this outcome measure, PSPs discuss views of long-term use of APRETUDE, reasons to choose APRETUDE, and experiences with clinic staff. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI). |
| Number of PSPs Assessed for Perception of Barriers | Up to Month 12 | General perceptions of barriers for APRETUDE delivery and use were measured among PSPs from themes emerging from Proctor and CFIR guided semi-structured qualitative interviews. In this outcome measure, PSPs discuss challenging views of or experiences with APRETUDE receipt. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI). |
| Number of SSPs Assessed for Perception of Facilitators | Up to Month 12 | General perceptions of facilitators for APRETUDE intervention and implementation were measured among SSPs from themes emerging from Proctor and CFIR guided semi-structured qualitative interviews. In this outcome measure, SSPs discuss clinic culture and implementation motivations. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). |
| Number of SSPs Assessed for Perception of Barriers | Up to Month 12 | General perceptions of barriers for APRETUDE intervention and implementation were measured among SSPs from themes emerging from Proctor and CFIR guided semi-structured qualitative interviews. In this outcome measure, SSPs discuss feelings and perspectives while implementing APRETUDE. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). |
| Number of Modifications Made for Adaptations to Implementation Reported by SSPs Using FRAME-IS | Up to Month 12 | The FRAME-IS is a measure that provides a precise understanding of modifications, the process of modifying or adapting, and the relationship between different forms of modification and subsequent health and implementation outcomes. Data below summarize the perceptions and motivations of adaptations to implementation reported by SSPs using FRAME-IS. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). |
Countries
United States
Participant flow
Recruitment details
A total of 17 Clinics were randomized to Dynamic Implementation and Routine Implementation arms. In these clinics, a total of 201 patient study participants (PSPs) were enrolled in the study and all of them received study treatment and 86 Staff Study Participants (SSPs) were enrolled that included healthcare providers, nurses, staff performing injections, clinic administrators, pharmacists and laboratory staff.
Pre-assignment details
SSPs provided input through surveys and semi-structured interviews. Baseline characteristics and adverse events for SSP were not collected as it was not required per study design.
Participants by arm
| Arm | Count |
|---|---|
| Dynamic Implementation (DI) - PSP Men who have sex with men (MSM) and transgender men (TGM) who were HIV negative as PSPs received APRETUDE injection (Direct to Injection - DTI) and had the choice to receive an optional cabotegravir tablets as oral lead in (OLI). PSPs had access to enhanced toolkits and digital health implementation supports. | 117 |
| Routine Implementation (RI) - PSP MSM and transgender men who were HIV negative as PSPs received APRETUDE injection (DTI) and had the choice to use an optional cabotegravir tablets as OLI. PSPs had access to standard toolkits for APRETUDE to use as needed. | 84 |
| Total | 201 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Adverse Event | 5 | 6 |
| Overall Study | Lost to Follow-up | 3 | 3 |
| Overall Study | Physician Decision | 2 | 2 |
| Overall Study | Withdrawal by Subject | 26 | 8 |
Baseline characteristics
| Characteristic | Dynamic Implementation (DI) - PSP | Routine Implementation (RI) - PSP | Total |
|---|---|---|---|
| Age, Continuous | 37.6 Years STANDARD_DEVIATION 11.16 | 37.8 Years STANDARD_DEVIATION 10.76 | 37.7 Years STANDARD_DEVIATION 10.97 |
| Race/Ethnicity, Customized American Indian or Alaska Native | 1 Participants | 0 Participants | 1 Participants |
| Race/Ethnicity, Customized Asian | 6 Participants | 2 Participants | 8 Participants |
| Race/Ethnicity, Customized Black of African American | 19 Participants | 29 Participants | 48 Participants |
| Race/Ethnicity, Customized Multiple Races | 2 Participants | 4 Participants | 6 Participants |
| Race/Ethnicity, Customized Other, not specified | 2 Participants | 0 Participants | 2 Participants |
| Race/Ethnicity, Customized Unknown | 15 Participants | 2 Participants | 17 Participants |
| Race/Ethnicity, Customized White | 72 Participants | 47 Participants | 119 Participants |
| Sex/Gender, Customized Cisgender Man | 107 Participants | 82 Participants | 189 Participants |
| Sex/Gender, Customized Transgender Man | 10 Participants | 2 Participants | 12 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 117 | 0 / 84 |
| other Total, other adverse events | 5 / 117 | 6 / 84 |
| serious Total, serious adverse events | 1 / 117 | 0 / 84 |
Outcome results
Primary
Mean Feasibility of Intervention Measure (FIM) Score Assessed for SSPs
The FIM-Intervention (INT) was a four-item measure for APRETUDE intervention (1. APRETUDE seems implementable in our clinic/practice 2. APRETUDE seems possible in our clinic/practice 3. APRETUDE seems doable in our clinic/practice 4. APRETUDE seems easy to use in our clinic/practice) and was measured on a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least feasibility and 5 the most feasibility. Timeframe for evaluation of this outcome measure is Month (M)12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI)
Time frame: At Month 12
Population: Analysis was performed on the SSPs who completed at least one survey at any time point. Only those participants with data available for the specified analysis at the specified time points were included.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| DI - SSP | Mean Feasibility of Intervention Measure (FIM) Score Assessed for SSPs | 4.37 Scores on a scale | Standard Deviation 0.68 |
| RI - SSP | Mean Feasibility of Intervention Measure (FIM) Score Assessed for SSPs | 4.27 Scores on a scale | Standard Deviation 0.68 |
Secondary
Change From Baseline in AIM Score Assessed for PSPs
This outcome assesses the change in AIM-INT for PSPs over time. The measure consists of four items (1. APRETUDE meets my approval for preventing HIV 2. APRETUDE for the prevention of HIV is appealing to me 3. I like APRETUDE for the prevention of HIV 4. I welcome APRETUDE for the prevention of HIV), each with a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least acceptability and 5 the most acceptability. Timeframe for evaluation of this outcome measure is M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI) compared to Baseline.
Time frame: At Month 6 and Month 12 compared to baseline (Month 1)
Population: Analysis was performed on PSPs who were administered at least one dose of APRETUDE injection or of CAB tablets for PrEP and who successfully completed a portion of the survey. Only those participants with data available for the specified analysis at the specified time points were included.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| DI - SSP | Change From Baseline in AIM Score Assessed for PSPs | Month 6 compared to BL | 0.17 Scores on a scale | Standard Deviation 0.66 |
| DI - SSP | Change From Baseline in AIM Score Assessed for PSPs | Month 12 compared to BL | 0.27 Scores on a scale | Standard Deviation 0.63 |
| RI - SSP | Change From Baseline in AIM Score Assessed for PSPs | Month 6 compared to BL | 0.20 Scores on a scale | Standard Deviation 0.72 |
| RI - SSP | Change From Baseline in AIM Score Assessed for PSPs | Month 12 compared to BL | 0.19 Scores on a scale | Standard Deviation 0.87 |
Secondary
Change From Baseline in AIM Score Assessed for SSPs
AIM score for SSPs has 2 parts- AIM-INT that evaluates perceived intervention acceptability among SSPs and consists of 4 items (1. APRETUDE in our clinic/practice meets my approval 2. APRETUDE in our clinic/practice is appealing to me 3. I like APRETUDE in our clinic/practice 4. I welcome APRETUDE in our clinic/practice), and AIM-IMP that evaluates perceived acceptability of DI and RI approaches among SSPs and consists of 4 items (1. The implementation support has met my approval; 2. The implementation support was appealing to me; 3. I like the implementation support I have received; 4. I welcome the implementation support I have received),each with a five-point rating scale (1=completely disagree, 2=disagree, 3=neither agree nor disagree, 4=agree, and 5=completely agree). Mean score ranges from 1 to 5 with 1=least acceptability and 5=most acceptability. Timeframe for evaluation is M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI) compared to BL.
Time frame: At Month 4 and Month 12 compared to baseline (Month 1)
Population: Analysis was performed on the SSPs who completed at least one survey at any time point. Only those participants with data available for the specified analysis at the specified time points were included.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| DI - SSP | Change From Baseline in AIM Score Assessed for SSPs | AIM-INT, Month 4 compared to BL | -0.36 Scores on a scale | Standard Deviation 0.66 |
| DI - SSP | Change From Baseline in AIM Score Assessed for SSPs | AIM-IMP, Month 4 compared to BL | -0.06 Scores on a scale | Standard Deviation 0.77 |
| DI - SSP | Change From Baseline in AIM Score Assessed for SSPs | AIM-INT, Month 12 compared to BL | -0.33 Scores on a scale | Standard Deviation 0.5 |
| DI - SSP | Change From Baseline in AIM Score Assessed for SSPs | AIM-IMP, Month 12 compared to BL | 0.04 Scores on a scale | Standard Deviation 0.84 |
| RI - SSP | Change From Baseline in AIM Score Assessed for SSPs | AIM-IMP, Month 12 compared to BL | -0.20 Scores on a scale | Standard Deviation 1.24 |
| RI - SSP | Change From Baseline in AIM Score Assessed for SSPs | AIM-INT, Month 4 compared to BL | -0.22 Scores on a scale | Standard Deviation 0.67 |
| RI - SSP | Change From Baseline in AIM Score Assessed for SSPs | AIM-INT, Month 12 compared to BL | -0.11 Scores on a scale | Standard Deviation 0.74 |
| RI - SSP | Change From Baseline in AIM Score Assessed for SSPs | AIM-IMP, Month 4 compared to BL | -0.16 Scores on a scale | Standard Deviation 0.81 |
Secondary
Change From Baseline in AIM Score for Telehealth Delivery Assessed for PSPs
The AIM Telehealth services for PSPs were a four-item measure (1. Using telehealth for APRETUDE services meets my approval 2. Using telehealth for APRETUDE services is appealing to me 3. I like telehealth for APRETUDE services 4. I welcome using telehealth for APRETUDE services), each with a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least acceptability and 5 the most acceptability. Timeframe for evaluation of this outcome measure is M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI) compared to BL.
Time frame: At Month 6 and Month 12 compared to baseline (Month 1)
Population: Analysis was performed on PSPs who were administered at least one dose of APRETUDE injection or of CAB tablets for PrEP and who successfully completed a portion of the survey. Only those participants with data available for the specified analysis at the specified time points were included.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| DI - SSP | Change From Baseline in AIM Score for Telehealth Delivery Assessed for PSPs | Month 6 compared to BL | 0.09 Scores on a scale | Standard Deviation 0.64 |
| DI - SSP | Change From Baseline in AIM Score for Telehealth Delivery Assessed for PSPs | Month 12 compared to BL | -0.39 Scores on a scale | Standard Deviation 0.92 |
| RI - SSP | Change From Baseline in AIM Score for Telehealth Delivery Assessed for PSPs | Month 6 compared to BL | 0.26 Scores on a scale | Standard Deviation 1.26 |
| RI - SSP | Change From Baseline in AIM Score for Telehealth Delivery Assessed for PSPs | Month 12 compared to BL | 0.21 Scores on a scale | Standard Deviation 1.11 |
Secondary
Change From Baseline in AIM Score for Telehealth Delivery Assessed for SSPs
This outcome assesses the change in AIM telehealth services for SSPs over time. The AIM telehealth services for SSPs were a four-item measure (1. The idea of telehealth for APRETUDE in our clinic/practice meets my approval 2. The idea of telehealth for APRETUDE in our clinic/practice is appealing to me 3. I like the idea of telehealth for APRETUDE in our clinic/practice 4. I welcome the idea of telehealth for APRETUDE in our clinic/practice), each with a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least acceptability and 5 the most acceptability. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI) compared to Baseline (BL).
Time frame: At Month 4 and Month 12 compared to baseline (Month 1)
Population: Analysis was performed on the SSPs who completed at least one survey at any time point. Only those participants with data available for the specified analysis at the specified time points were included.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| DI - SSP | Change From Baseline in AIM Score for Telehealth Delivery Assessed for SSPs | Month 4 compared to BL | -0.13 Scores on a scale | Standard Deviation 0.92 |
| DI - SSP | Change From Baseline in AIM Score for Telehealth Delivery Assessed for SSPs | Month 12 compared to BL | -0.38 Scores on a scale | Standard Deviation 0.97 |
| RI - SSP | Change From Baseline in AIM Score for Telehealth Delivery Assessed for SSPs | Month 4 compared to BL | 0.53 Scores on a scale | Standard Deviation 1.21 |
| RI - SSP | Change From Baseline in AIM Score for Telehealth Delivery Assessed for SSPs | Month 12 compared to BL | 0.41 Scores on a scale | Standard Deviation 1.02 |
Secondary
Change From Baseline in FIM Score Assessed for PSPs
This outcome assesses the change in FIM-INT for PSPs over time. The FIM-INT was a four-item measure for APRETUDE intervention (1. Receiving APRETUDE injection every 2 months seems workable in my life 2. Receiving APRETUDE injection every 2 months seems possible in my life 3. Receiving APRETUDE injection every 2 months seems doable in my life 4. Receiving APRETUDE injection every 2 months seems easy in my life) and was measured on a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least feasibility and 5 the most feasibility. Timeframe for evaluation of this outcome measure is M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI) compared to baseline.
Time frame: At Month 6 and Month 12 compared to baseline (Month 1)
Population: Analysis was performed on PSPs who were administered at least one dose of APRETUDE injection or of CAB tablets for PrEP and who successfully completed a portion of the survey. Only those participants with data available for the specified analysis at the specified time points were included.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| DI - SSP | Change From Baseline in FIM Score Assessed for PSPs | Month 6 compared to BL | 0.01 Scores on a scale | Standard Deviation 0.8 |
| DI - SSP | Change From Baseline in FIM Score Assessed for PSPs | Month 12 compared to BL | 0.01 Scores on a scale | Standard Deviation 0.71 |
| RI - SSP | Change From Baseline in FIM Score Assessed for PSPs | Month 12 compared to BL | -0.01 Scores on a scale | Standard Deviation 0.92 |
| RI - SSP | Change From Baseline in FIM Score Assessed for PSPs | Month 6 compared to BL | 0.00 Scores on a scale | Standard Deviation 0.89 |
Secondary
Change From Baseline in FIM Score Assessed for SSPs
This outcome assesses the change in FIM-INT for SSPs over time. The FIM-INT was a four-item measure for APRETUDE intervention (1. APRETUDE seems implementable in our clinic/practice 2. APRETUDE seems possible in our clinic/practice 3. APRETUDE seems doable in our clinic/practice 4. APRETUDE seems easy to use in our clinic/practice) and was measured on a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least feasibility and 5 the most feasibility. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI) compared to Baseline (BL).
Time frame: At Month 4 and Month 12 compared to baseline (Month 1)
Population: Analysis was performed on the SSPs who completed at least one survey at any time point. Only those participants with data available for the specified analysis at the specified time points were included.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| DI - SSP | Change From Baseline in FIM Score Assessed for SSPs | Month 4 compared to baseline (BL) | -0.29 Scores on a scale | Standard Deviation 0.92 |
| DI - SSP | Change From Baseline in FIM Score Assessed for SSPs | Month 12 compared to BL | -0.01 Scores on a scale | Standard Deviation 0.69 |
| RI - SSP | Change From Baseline in FIM Score Assessed for SSPs | Month 4 compared to baseline (BL) | 0.08 Scores on a scale | Standard Deviation 0.59 |
| RI - SSP | Change From Baseline in FIM Score Assessed for SSPs | Month 12 compared to BL | -0.11 Scores on a scale | Standard Deviation 0.86 |
Secondary
Change From Baseline in FIM Score for Telehealth Delivery Assessed for PSPs
The FIM Telehealth services for PSPs were a four-item measure (1. Using telehealth for APRETUDE services seems workable in my life 2. Using telehealth for APRETUDE services seems possible in my life 3. Using telehealth for APRETUDE services seems doable in my life 4. Using telehealth for APRETUDE services seems easy in my life) and was measured on a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least feasibility and 5 the most feasibility. Timeframe for evaluation of this outcome measure is M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI) compared to BL.
Time frame: At Month 6 and Month 12 compared to baseline (Month 1)
Population: Analysis was performed on PSPs who were administered at least one dose of APRETUDE injection or of CAB tablets for PrEP and who successfully completed a portion of the survey. Only those participants with data available for the specified analysis at the specified time points were included.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| DI - SSP | Change From Baseline in FIM Score for Telehealth Delivery Assessed for PSPs | Month 6 compared to BL | 0.08 Scores on a scale | Standard Deviation 0.65 |
| DI - SSP | Change From Baseline in FIM Score for Telehealth Delivery Assessed for PSPs | Month 12 compared to BL | -0.35 Scores on a scale | Standard Deviation 0.78 |
| RI - SSP | Change From Baseline in FIM Score for Telehealth Delivery Assessed for PSPs | Month 6 compared to BL | 0.25 Scores on a scale | Standard Deviation 1.23 |
| RI - SSP | Change From Baseline in FIM Score for Telehealth Delivery Assessed for PSPs | Month 12 compared to BL | 0.17 Scores on a scale | Standard Deviation 1.21 |
Secondary
Change From Baseline in FIM Score for Telehealth Delivery Assessed for SSPs
The FIM telehealth services for SSPs were a four-item measure (1. Telehealth for APRETUDE seems implementable in our clinic/practice 2. Telehealth for APRETUDE seems possible in our clinic/practice 3. Telehealth for APRETUDE seems doable in our clinic/practice 4. Telehealth for APRETUDE seems easy to use in our clinic/practice) and was measured on a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least feasibility and 5 the most feasibility. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI) compared to Baseline (BL).
Time frame: At Month 4 and Month 12 compared to baseline (Month 1)
Population: Analysis was performed on the SSPs who completed at least one survey at any time point. Only those participants with data available for the specified analysis at the specified time points were included.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| DI - SSP | Change From Baseline in FIM Score for Telehealth Delivery Assessed for SSPs | Month 4 compared to BL | -0.11 Scores on a scale | Standard Deviation 1.21 |
| DI - SSP | Change From Baseline in FIM Score for Telehealth Delivery Assessed for SSPs | Month 12 compared to BL | -0.06 Scores on a scale | Standard Deviation 1.03 |
| RI - SSP | Change From Baseline in FIM Score for Telehealth Delivery Assessed for SSPs | Month 4 compared to BL | 0.20 Scores on a scale | Standard Deviation 1.21 |
| RI - SSP | Change From Baseline in FIM Score for Telehealth Delivery Assessed for SSPs | Month 12 compared to BL | 0.16 Scores on a scale | Standard Deviation 0.64 |
Secondary
Change From Baseline in Mean AIM Score in PSPs
This outcome assesses the change in AIM-INT for PSPs over time. The measure consists of four items (1. APRETUDE meets my approval for preventing HIV 2. APRETUDE for the prevention of HIV is appealing to me 3. I like APRETUDE for the prevention of HIV 4. I welcome APRETUDE for the prevention of HIV), each with a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least acceptability and 5 the most acceptability. Timeframe for evaluation of this outcome measure is M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI) compared to Baseline.
Time frame: At Month 6 and Month 12 compared to baseline (Month 1)
Population: Analysis was performed on PSPs who were administered at least one dose of APRETUDE injection or of CAB tablets for PrEP and who successfully completed a portion of the survey. Only those participants with data available for the specified analysis at the specified time points were included.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| DI - SSP | Change From Baseline in Mean AIM Score in PSPs | Month 6 compared to BL | 0.17 Scores on a scale | Standard Deviation 0.66 |
| DI - SSP | Change From Baseline in Mean AIM Score in PSPs | Month 12 compared to BL | 0.27 Scores on a scale | Standard Deviation 0.63 |
| RI - SSP | Change From Baseline in Mean AIM Score in PSPs | Month 6 compared to BL | 0.20 Scores on a scale | Standard Deviation 0.72 |
| RI - SSP | Change From Baseline in Mean AIM Score in PSPs | Month 12 compared to BL | 0.19 Scores on a scale | Standard Deviation 0.87 |
Secondary
Mean Acceptability of Intervention Measure (AIM) Score Assessed for PSPs
The AIM-INT was employed to evaluate the perceived intervention acceptability among PSPs. The measure consists of four items (1. APRETUDE meets my approval for preventing HIV 2. APRETUDE for the prevention of HIV is appealing to me 3. I like APRETUDE for the prevention of HIV 4. I welcome APRETUDE for the prevention of HIV), each with a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least acceptability and 5 the most acceptability. Timeframe for evaluation of this outcome measure is BL, M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI).
Time frame: At Baseline (Month 1), Month 6 and Month 12
Population: Analysis was performed on PSPs who were administered at least one dose of APRETUDE injection or of CAB tablets for PrEP and who successfully completed a portion of the survey. Only those participants with data available for the specified analysis at the specified time points were included.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| DI - SSP | Mean Acceptability of Intervention Measure (AIM) Score Assessed for PSPs | Baseline | 4.46 Scores on a scale | Standard Deviation 0.69 |
| DI - SSP | Mean Acceptability of Intervention Measure (AIM) Score Assessed for PSPs | Month 6 | 4.57 Scores on a scale | Standard Deviation 0.64 |
| DI - SSP | Mean Acceptability of Intervention Measure (AIM) Score Assessed for PSPs | Month 12 | 4.61 Scores on a scale | Standard Deviation 0.63 |
| RI - SSP | Mean Acceptability of Intervention Measure (AIM) Score Assessed for PSPs | Baseline | 4.41 Scores on a scale | Standard Deviation 0.68 |
| RI - SSP | Mean Acceptability of Intervention Measure (AIM) Score Assessed for PSPs | Month 6 | 4.57 Scores on a scale | Standard Deviation 0.55 |
| RI - SSP | Mean Acceptability of Intervention Measure (AIM) Score Assessed for PSPs | Month 12 | 4.60 Scores on a scale | Standard Deviation 0.67 |
Secondary
Mean AIM Score Assessed for PSPs
The AIM-INT was employed to evaluate the perceived intervention acceptability among PSPs. The measure consists of four items (1. APRETUDE meets my approval for preventing HIV 2. APRETUDE for the prevention of HIV is appealing to me 3. I like APRETUDE for the prevention of HIV 4. I welcome APRETUDE for the prevention of HIV), each with a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least acceptability and 5 the most acceptability. Timeframe for evaluation of this outcome measure is BL, M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI).
Time frame: At Baseline (Month 1), Month 6 and Month 12
Population: Analysis was performed on PSPs who were administered at least one dose of APRETUDE injection or of CAB tablets for PrEP and who successfully completed a portion of the survey. Only those participants with data available for the specified analysis at the specified time points were included.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| DI - SSP | Mean AIM Score Assessed for PSPs | Baseline | 4.46 Scores on a scale | Standard Deviation 0.69 |
| DI - SSP | Mean AIM Score Assessed for PSPs | Month 6 | 4.57 Scores on a scale | Standard Deviation 0.64 |
| DI - SSP | Mean AIM Score Assessed for PSPs | Month 12 | 4.61 Scores on a scale | Standard Deviation 0.63 |
| RI - SSP | Mean AIM Score Assessed for PSPs | Baseline | 4.41 Scores on a scale | Standard Deviation 0.68 |
| RI - SSP | Mean AIM Score Assessed for PSPs | Month 6 | 4.57 Scores on a scale | Standard Deviation 0.55 |
| RI - SSP | Mean AIM Score Assessed for PSPs | Month 12 | 4.60 Scores on a scale | Standard Deviation 0.67 |
Secondary
Mean AIM Score Assessed for SSPs
AIM score for SSPs has 2 parts- AIM-INT that evaluates perceived intervention acceptability among SSPs and consists of 4 items (1. APRETUDE in our clinic/practice meets my approval 2. APRETUDE in our clinic/practice is appealing to me 3. I like APRETUDE in our clinic/practice 4. I welcome APRETUDE in our clinic/practice), and AIM-Implementation (IMP) that evaluates perceived acceptability of DI and RI approaches among SSPs and consists of 4 items (1. The implementation support has met my approval; 2. The implementation support was appealing to me; 3. I like the implementation support I have received; 4. I welcome the implementation support I have received),each with a five-point rating scale (1=completely disagree, 2=disagree, 3=neither agree nor disagree, 4=agree, and 5=completely agree). Mean score ranges from 1 to 5 with 1=least acceptability and 5=most acceptability. Timeframe for evaluation is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI).
Time frame: At Baseline (Month 1), Month 4 and Month 12
Population: Analysis was performed on the SSPs who completed at least one survey at any time point. Only those participants with data available for the specified analysis at the specified time points were included.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| DI - SSP | Mean AIM Score Assessed for SSPs | AIM-INT (Baseline) | 4.69 Scores on a scale | Standard Deviation 0.43 |
| DI - SSP | Mean AIM Score Assessed for SSPs | AIM-INT (Month 4) | 4.33 Scores on a scale | Standard Deviation 0.68 |
| DI - SSP | Mean AIM Score Assessed for SSPs | AIM-INT (Month 12) | 4.41 Scores on a scale | Standard Deviation 0.57 |
| DI - SSP | Mean AIM Score Assessed for SSPs | AIM-IMP (Baseline) | 3.97 Scores on a scale | Standard Deviation 0.83 |
| DI - SSP | Mean AIM Score Assessed for SSPs | AIM-IMP (Month 4) | 3.92 Scores on a scale | Standard Deviation 0.8 |
| DI - SSP | Mean AIM Score Assessed for SSPs | AIM-IMP (Month 12) | 4.09 Scores on a scale | Standard Deviation 0.67 |
| RI - SSP | Mean AIM Score Assessed for SSPs | AIM-IMP (Month 4) | 3.86 Scores on a scale | Standard Deviation 0.84 |
| RI - SSP | Mean AIM Score Assessed for SSPs | AIM-INT (Baseline) | 4.66 Scores on a scale | Standard Deviation 0.48 |
| RI - SSP | Mean AIM Score Assessed for SSPs | AIM-IMP (Baseline) | 4.05 Scores on a scale | Standard Deviation 0.76 |
| RI - SSP | Mean AIM Score Assessed for SSPs | AIM-INT (Month 4) | 4.43 Scores on a scale | Standard Deviation 0.56 |
| RI - SSP | Mean AIM Score Assessed for SSPs | AIM-IMP (Month 12) | 3.90 Scores on a scale | Standard Deviation 1.08 |
| RI - SSP | Mean AIM Score Assessed for SSPs | AIM-INT (Month 12) | 4.52 Scores on a scale | Standard Deviation 0.56 |
Secondary
Mean AIM Score for Telehealth Delivery Assessed for PSPs
The AIM Telehealth services for PSPs were a four-item measure (1. Using telehealth for APRETUDE services meets my approval 2. Using telehealth for APRETUDE services is appealing to me 3. I like telehealth for APRETUDE services 4. I welcome using telehealth for APRETUDE services), each with a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least acceptability and 5 the most acceptability. Timepoints during which this outcome measure was evaluated were BL, M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI)
Time frame: At Baseline (Month 1), Month 6 and Month 12
Population: Analysis was performed on PSPs who were administered at least one dose of APRETUDE injection or of CAB tablets for PrEP and who successfully completed a portion of the survey. Only those participants with data available for the specified analysis at the specified time points were included.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| DI - SSP | Mean AIM Score for Telehealth Delivery Assessed for PSPs | Month 12 | 4.21 Scores on a scale | Standard Deviation 0.93 |
| DI - SSP | Mean AIM Score for Telehealth Delivery Assessed for PSPs | Baseline | 4.32 Scores on a scale | Standard Deviation 0.76 |
| DI - SSP | Mean AIM Score for Telehealth Delivery Assessed for PSPs | Month 6 | 4.56 Scores on a scale | Standard Deviation 0.57 |
| RI - SSP | Mean AIM Score for Telehealth Delivery Assessed for PSPs | Month 12 | 4.27 Scores on a scale | Standard Deviation 0.67 |
| RI - SSP | Mean AIM Score for Telehealth Delivery Assessed for PSPs | Baseline | 4.13 Scores on a scale | Standard Deviation 0.91 |
| RI - SSP | Mean AIM Score for Telehealth Delivery Assessed for PSPs | Month 6 | 4.25 Scores on a scale | Standard Deviation 0.7 |
Secondary
Mean AIM Score for Telehealth Delivery Assessed for SSPs
The AIM-TEL services for SSPs were a four-item measure (1. The idea of telehealth for APRETUDE in our clinic/practice meets my approval 2. The idea of telehealth for APRETUDE in our clinic/practice is appealing to me 3. I like the idea of telehealth for APRETUDE in our clinic/practice 4. I welcome the idea of telehealth for APRETUDE in our clinic/practice), each with a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least acceptability and 5 the most acceptability. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI).
Time frame: At Baseline (Month 1), Month 4 and Month 12
Population: Analysis was performed on the SSPs who completed at least one survey at any time point. Only those participants with data available for the specified analysis at the specified time points were included.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| DI - SSP | Mean AIM Score for Telehealth Delivery Assessed for SSPs | Baseline | 4.09 Scores on a scale | Standard Deviation 0.82 |
| DI - SSP | Mean AIM Score for Telehealth Delivery Assessed for SSPs | Month 4 | 4.16 Scores on a scale | Standard Deviation 0.78 |
| DI - SSP | Mean AIM Score for Telehealth Delivery Assessed for SSPs | Month 12 | 4.07 Scores on a scale | Standard Deviation 0.78 |
| RI - SSP | Mean AIM Score for Telehealth Delivery Assessed for SSPs | Baseline | 3.26 Scores on a scale | Standard Deviation 1.38 |
| RI - SSP | Mean AIM Score for Telehealth Delivery Assessed for SSPs | Month 4 | 3.98 Scores on a scale | Standard Deviation 1.16 |
| RI - SSP | Mean AIM Score for Telehealth Delivery Assessed for SSPs | Month 12 | 4.17 Scores on a scale | Standard Deviation 1.28 |
Secondary
Mean FIM Score Assessed for PSPs
The FIM-INT was a four-item measure for APRETUDE intervention (1. Receiving APRETUDE injection every 2 months seems workable in my life 2. Receiving APRETUDE injection every 2 months seems possible in my life 3. Receiving APRETUDE injection every 2 months seems doable in my life 4. Receiving APRETUDE injection every 2 months seems easy in my life) and was measured on a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least feasibility and 5 the most feasibility. Timeframe for evaluation of this outcome measure is BL, M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI).
Time frame: At Baseline (Month 1), Month 6 and Month 12
Population: Analysis was performed on PSPs who were administered at least one dose of APRETUDE injection or of CAB tablets for PrEP and who successfully completed a portion of the survey. Only those participants with data available for the specified analysis at the specified time points were included.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| DI - SSP | Mean FIM Score Assessed for PSPs | Month 6 | 4.35 Scores on a scale | Standard Deviation 0.75 |
| DI - SSP | Mean FIM Score Assessed for PSPs | Baseline | 4.33 Scores on a scale | Standard Deviation 0.77 |
| DI - SSP | Mean FIM Score Assessed for PSPs | Month 12 | 4.36 Scores on a scale | Standard Deviation 0.79 |
| RI - SSP | Mean FIM Score Assessed for PSPs | Baseline | 4.51 Scores on a scale | Standard Deviation 0.7 |
| RI - SSP | Mean FIM Score Assessed for PSPs | Month 6 | 4.46 Scores on a scale | Standard Deviation 0.73 |
| RI - SSP | Mean FIM Score Assessed for PSPs | Month 12 | 4.46 Scores on a scale | Standard Deviation 0.72 |
Secondary
Mean FIM Score for Telehealth Delivery Assessed for PSPs
The FIM telehealth services for PSPs were a four-item measure (1. Using telehealth for APRETUDE services seems workable in my life 2. Using telehealth for APRETUDE services seems possible in my life 3. Using telehealth for APRETUDE services seems doable in my life 4. Using telehealth for APRETUDE services seems easy in my life) and was measured on a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least feasibility and 5 the most feasibility. Timeframe for evaluation of this outcome measure is BL, M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI).
Time frame: At Baseline (Month 1), Month 6 and Month 12
Population: Analysis was performed on PSPs who were administered at least one dose of APRETUDE injection or of CAB tablets for PrEP and who successfully completed a portion of the survey. Only those participants with data available for the specified analysis at the specified time points were included.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| DI - SSP | Mean FIM Score for Telehealth Delivery Assessed for PSPs | Baseline | 4.40 Scores on a scale | Standard Deviation 0.72 |
| DI - SSP | Mean FIM Score for Telehealth Delivery Assessed for PSPs | Month 6 | 4.56 Scores on a scale | Standard Deviation 0.56 |
| DI - SSP | Mean FIM Score for Telehealth Delivery Assessed for PSPs | Month 12 | 4.25 Scores on a scale | Standard Deviation 0.89 |
| RI - SSP | Mean FIM Score for Telehealth Delivery Assessed for PSPs | Baseline | 4.15 Scores on a scale | Standard Deviation 0.97 |
| RI - SSP | Mean FIM Score for Telehealth Delivery Assessed for PSPs | Month 6 | 4.19 Scores on a scale | Standard Deviation 0.76 |
| RI - SSP | Mean FIM Score for Telehealth Delivery Assessed for PSPs | Month 12 | 4.38 Scores on a scale | Standard Deviation 0.7 |
Secondary
Mean FIM Score for Telehealth Delivery Assessed for SSPs
The FIM-TEL services for SSPs were a four-item measure (1. Telehealth for APRETUDE seems implementable in our clinic/practice 2. Telehealth for APRETUDE seems possible in our clinic/practice 3. Telehealth for APRETUDE seems doable in our clinic/practice 4. Telehealth for APRETUDE seems easy to use in our clinic/practice) and was measured on a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least feasibility and 5 the most feasibility. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI).
Time frame: At Baseline (Month 1), Month 4 and Month 12
Population: Analysis was performed on the SSPs who completed at least one survey at any time point. Only those participants with data available for the specified analysis at the specified time points were included.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| DI - SSP | Mean FIM Score for Telehealth Delivery Assessed for SSPs | Month 4 | 4.13 Scores on a scale | Standard Deviation 0.9 |
| DI - SSP | Mean FIM Score for Telehealth Delivery Assessed for SSPs | Baseline | 4.01 Scores on a scale | Standard Deviation 0.83 |
| DI - SSP | Mean FIM Score for Telehealth Delivery Assessed for SSPs | Month 12 | 4.26 Scores on a scale | Standard Deviation 0.7 |
| RI - SSP | Mean FIM Score for Telehealth Delivery Assessed for SSPs | Month 4 | 4.08 Scores on a scale | Standard Deviation 1.2 |
| RI - SSP | Mean FIM Score for Telehealth Delivery Assessed for SSPs | Baseline | 3.43 Scores on a scale | Standard Deviation 1.23 |
| RI - SSP | Mean FIM Score for Telehealth Delivery Assessed for SSPs | Month 12 | 4.22 Scores on a scale | Standard Deviation 1.3 |
Secondary
Number of Eligible PSPs for Which SHA Are Administered
In this outcome measure, data shown below describes the number of PSPs to which the SHA was administered. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).
Time frame: Up to Month 12
Population: Analysis was performed on PSPs who were administered at least one dose of APRETUDE injection or of CAB tablets for PrEP and who completed at least one SHA survey at any timepoint. Only those participants with data available for the specified analysis at the specified time points were included.
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| DI - SSP | Number of Eligible PSPs for Which SHA Are Administered | I don't know | 23 Participants |
| DI - SSP | Number of Eligible PSPs for Which SHA Are Administered | Yes | 39 Participants |
| DI - SSP | Number of Eligible PSPs for Which SHA Are Administered | Missing | 40 Participants |
| DI - SSP | Number of Eligible PSPs for Which SHA Are Administered | No | 15 Participants |
| RI - SSP | Number of Eligible PSPs for Which SHA Are Administered | Missing | 21 Participants |
| RI - SSP | Number of Eligible PSPs for Which SHA Are Administered | Yes | 35 Participants |
| RI - SSP | Number of Eligible PSPs for Which SHA Are Administered | I don't know | 15 Participants |
| RI - SSP | Number of Eligible PSPs for Which SHA Are Administered | No | 13 Participants |
Secondary
Number of Injections Occurring Within Target Window From Target Date
This outcome measure evaluates the number of injections occurring within the target window. The target window is defined as ± 7 days from target date of injection for Dose 2 and subsequent injections. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).
Time frame: Up to Month 12
Population: Analysis was performed on PSPs who were administered at least one dose of APRETUDE injection or of CAB tablets for PrEP. Only those participants with data available for the specified analysis at the specified time points were included.
| Arm | Measure | Group | Value (COUNT_OF_UNITS) |
|---|---|---|---|
| DI - SSP | Number of Injections Occurring Within Target Window From Target Date | Dose 8 | 0 Injections |
| DI - SSP | Number of Injections Occurring Within Target Window From Target Date | Dose 2 | 103 Injections |
| DI - SSP | Number of Injections Occurring Within Target Window From Target Date | Dose 3 | 77 Injections |
| DI - SSP | Number of Injections Occurring Within Target Window From Target Date | Dose 4 | 66 Injections |
| DI - SSP | Number of Injections Occurring Within Target Window From Target Date | Dose 5 | 50 Injections |
| DI - SSP | Number of Injections Occurring Within Target Window From Target Date | Dose 6 | 44 Injections |
| DI - SSP | Number of Injections Occurring Within Target Window From Target Date | Dose 7 | 35 Injections |
| RI - SSP | Number of Injections Occurring Within Target Window From Target Date | Dose 8 | 0 Injections |
| RI - SSP | Number of Injections Occurring Within Target Window From Target Date | Dose 5 | 45 Injections |
| RI - SSP | Number of Injections Occurring Within Target Window From Target Date | Dose 2 | 76 Injections |
| RI - SSP | Number of Injections Occurring Within Target Window From Target Date | Dose 7 | 27 Injections |
| RI - SSP | Number of Injections Occurring Within Target Window From Target Date | Dose 3 | 57 Injections |
| RI - SSP | Number of Injections Occurring Within Target Window From Target Date | Dose 6 | 30 Injections |
| RI - SSP | Number of Injections Occurring Within Target Window From Target Date | Dose 4 | 49 Injections |
Secondary
Number of Men Who Have Sex With Men (MSM) and Transgender Men (TGM) Who Take the SHA Through M12
The ISQ uses a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. Timeframe for evaluation of this outcome measure is M12 (equivalent to M13 for PSPs who received OLI).
Time frame: Up to Month 12
Population: The protocol-defined endpoint for this outcome specifically requires data presentation by MSM and TGM, so data here are displayed by those groups. Data for this endpoint was collected from all MSM and TGM across DI and RI arms in alignment with the objective, therefore the analysis by MSM and TGM was not completed within arms but across arms.
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| DI - SSP | Number of Men Who Have Sex With Men (MSM) and Transgender Men (TGM) Who Take the SHA Through M12 | Yes | 73 Participants |
| DI - SSP | Number of Men Who Have Sex With Men (MSM) and Transgender Men (TGM) Who Take the SHA Through M12 | No | 25 Participants |
| DI - SSP | Number of Men Who Have Sex With Men (MSM) and Transgender Men (TGM) Who Take the SHA Through M12 | I don't know | 36 Participants |
| DI - SSP | Number of Men Who Have Sex With Men (MSM) and Transgender Men (TGM) Who Take the SHA Through M12 | Missing | 55 Participants |
| RI - SSP | Number of Men Who Have Sex With Men (MSM) and Transgender Men (TGM) Who Take the SHA Through M12 | Missing | 6 Participants |
| RI - SSP | Number of Men Who Have Sex With Men (MSM) and Transgender Men (TGM) Who Take the SHA Through M12 | Yes | 1 Participants |
| RI - SSP | Number of Men Who Have Sex With Men (MSM) and Transgender Men (TGM) Who Take the SHA Through M12 | I don't know | 2 Participants |
| RI - SSP | Number of Men Who Have Sex With Men (MSM) and Transgender Men (TGM) Who Take the SHA Through M12 | No | 3 Participants |
Secondary
Number of Modifications for Each Category Reported by SSPs Using FRAME-IS
The FRAME-IS is a measure that provides a precise understanding of modifications, the process of modifying or adapting, and the relationship between different forms of modification and subsequent health and implementation outcomes. Data below summarize the types of modifications and adaptations reported by SSPs during PILLAR study. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).
Time frame: Up to Month 12
Population: Analysis was performed on data submitted from SSPs who completed at least one FRAME-IS assessment at any time point and had data available for the specified analysis at the specified time points.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| DI - SSP | Number of Modifications for Each Category Reported by SSPs Using FRAME-IS | Content: Modification made to the content of APRETUDE materials and tools | 12 Number of Modifications |
| DI - SSP | Number of Modifications for Each Category Reported by SSPs Using FRAME-IS | Evaluation: Modification made to the staff evaluate whether APPRETUDE is working | 5 Number of Modifications |
| DI - SSP | Number of Modifications for Each Category Reported by SSPs Using FRAME-IS | Training: Modification made to the staff delivering APRETUDE are trained | 22 Number of Modifications |
| DI - SSP | Number of Modifications for Each Category Reported by SSPs Using FRAME-IS | Contextual: Modification made to the overall implementation of APRETUDE injection delivered | 30 Number of Modifications |
| RI - SSP | Number of Modifications for Each Category Reported by SSPs Using FRAME-IS | Contextual: Modification made to the overall implementation of APRETUDE injection delivered | 22 Number of Modifications |
| RI - SSP | Number of Modifications for Each Category Reported by SSPs Using FRAME-IS | Content: Modification made to the content of APRETUDE materials and tools | 4 Number of Modifications |
| RI - SSP | Number of Modifications for Each Category Reported by SSPs Using FRAME-IS | Training: Modification made to the staff delivering APRETUDE are trained | 0 Number of Modifications |
| RI - SSP | Number of Modifications for Each Category Reported by SSPs Using FRAME-IS | Evaluation: Modification made to the staff evaluate whether APPRETUDE is working | 3 Number of Modifications |
Secondary
Number of Modifications Made for Adaptations to Implementation Reported by SSPs Using FRAME-IS
The FRAME-IS is a measure that provides a precise understanding of modifications, the process of modifying or adapting, and the relationship between different forms of modification and subsequent health and implementation outcomes. Data below summarize the perceptions and motivations of adaptations to implementation reported by SSPs using FRAME-IS. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).
Time frame: Up to Month 12
Population: Analysis was performed on data submitted from SSPs who completed at least one FRAME-IS assessment at any time point and had data available for the specified analysis at the specified time points.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| DI - SSP | Number of Modifications Made for Adaptations to Implementation Reported by SSPs Using FRAME-IS | Improve feasibility of the implementation effort | 19 Number of Modifications |
| DI - SSP | Number of Modifications Made for Adaptations to Implementation Reported by SSPs Using FRAME-IS | Increase satisfaction with the implementation effort | 17 Number of Modifications |
| DI - SSP | Number of Modifications Made for Adaptations to Implementation Reported by SSPs Using FRAME-IS | Improve fit with the clinical/practice setting | 18 Number of Modifications |
| DI - SSP | Number of Modifications Made for Adaptations to Implementation Reported by SSPs Using FRAME-IS | Speed up injection/implementation process | 17 Number of Modifications |
| DI - SSP | Number of Modifications Made for Adaptations to Implementation Reported by SSPs Using FRAME-IS | Increase the number of patients with access to APRETUDE | 23 Number of Modifications |
| RI - SSP | Number of Modifications Made for Adaptations to Implementation Reported by SSPs Using FRAME-IS | Speed up injection/implementation process | 12 Number of Modifications |
| RI - SSP | Number of Modifications Made for Adaptations to Implementation Reported by SSPs Using FRAME-IS | Increase the number of patients with access to APRETUDE | 5 Number of Modifications |
| RI - SSP | Number of Modifications Made for Adaptations to Implementation Reported by SSPs Using FRAME-IS | Improve feasibility of the implementation effort | 8 Number of Modifications |
| RI - SSP | Number of Modifications Made for Adaptations to Implementation Reported by SSPs Using FRAME-IS | Improve fit with the clinical/practice setting | 10 Number of Modifications |
| RI - SSP | Number of Modifications Made for Adaptations to Implementation Reported by SSPs Using FRAME-IS | Increase satisfaction with the implementation effort | 11 Number of Modifications |
Secondary
Number of Modifications Reported by SSPs Using FRAME-IS
The Framework for Reporting Adaptations and Modifications to Evidence-based Implementation Strategies (FRAME-IS) is a measure that provides a precise understanding of modifications, the process of modifying or adapting, and the relationship between different forms of modification and subsequent health and implementation outcomes. Data below summarize all modifications reported by SSPs during PILLAR study. Timeframe for evaluation of this outcome measure is from M2 to M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).
Time frame: At Month 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12
Population: Analysis was performed on data submitted from SSPs who completed at least one FRAME-IS assessment at any time point and had data available for the specified analysis at the specified time points.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| DI - SSP | Number of Modifications Reported by SSPs Using FRAME-IS | Trial Month 5 Modifications | 3 Number of Modifications |
| DI - SSP | Number of Modifications Reported by SSPs Using FRAME-IS | Trial Month 8 Modifications | 3 Number of Modifications |
| DI - SSP | Number of Modifications Reported by SSPs Using FRAME-IS | Trial Month 4 Modifications | 3 Number of Modifications |
| DI - SSP | Number of Modifications Reported by SSPs Using FRAME-IS | Trial Month 9 Modifications | 2 Number of Modifications |
| DI - SSP | Number of Modifications Reported by SSPs Using FRAME-IS | Trial Month 6 Modifications | 4 Number of Modifications |
| DI - SSP | Number of Modifications Reported by SSPs Using FRAME-IS | Trial Month 10 Modifications | 10 Number of Modifications |
| DI - SSP | Number of Modifications Reported by SSPs Using FRAME-IS | Trial Month 3 Modifications | 4 Number of Modifications |
| DI - SSP | Number of Modifications Reported by SSPs Using FRAME-IS | Trial Month 11 Modifications | 2 Number of Modifications |
| DI - SSP | Number of Modifications Reported by SSPs Using FRAME-IS | Trial Month 7 Modifications | 1 Number of Modifications |
| DI - SSP | Number of Modifications Reported by SSPs Using FRAME-IS | Trial Month 12 Modifications | 5 Number of Modifications |
| DI - SSP | Number of Modifications Reported by SSPs Using FRAME-IS | Trial Month 2 Modifications | 6 Number of Modifications |
| RI - SSP | Number of Modifications Reported by SSPs Using FRAME-IS | Trial Month 12 Modifications | 1 Number of Modifications |
| RI - SSP | Number of Modifications Reported by SSPs Using FRAME-IS | Trial Month 2 Modifications | 3 Number of Modifications |
| RI - SSP | Number of Modifications Reported by SSPs Using FRAME-IS | Trial Month 3 Modifications | 8 Number of Modifications |
| RI - SSP | Number of Modifications Reported by SSPs Using FRAME-IS | Trial Month 4 Modifications | 0 Number of Modifications |
| RI - SSP | Number of Modifications Reported by SSPs Using FRAME-IS | Trial Month 5 Modifications | 5 Number of Modifications |
| RI - SSP | Number of Modifications Reported by SSPs Using FRAME-IS | Trial Month 6 Modifications | 3 Number of Modifications |
| RI - SSP | Number of Modifications Reported by SSPs Using FRAME-IS | Trial Month 7 Modifications | 4 Number of Modifications |
| RI - SSP | Number of Modifications Reported by SSPs Using FRAME-IS | Trial Month 8 Modifications | 2 Number of Modifications |
| RI - SSP | Number of Modifications Reported by SSPs Using FRAME-IS | Trial Month 9 Modifications | 0 Number of Modifications |
| RI - SSP | Number of Modifications Reported by SSPs Using FRAME-IS | Trial Month 10 Modifications | 0 Number of Modifications |
| RI - SSP | Number of Modifications Reported by SSPs Using FRAME-IS | Trial Month 11 Modifications | 0 Number of Modifications |
Secondary
Number of MSM and TGM Who Report Having Had Sex in the Last 6 Months on the SHA
In this outcome measure, data shown below describes the number of MSM and TGM who reported having had sex in the last 6 months. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).
Time frame: Up to Month 12
Population: As pre-specified in the protocol, this outcome measure was evaluated in the MSM and TGM separately. Analysis was performed on PSPs who were administered at least one dose of APRETUDE injection or of CAB tablets for PrEP and who completed at least one SHA survey at any timepoint. Only those participants with data available for the specified analysis at the specified time points were included.
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| DI - SSP | Number of MSM and TGM Who Report Having Had Sex in the Last 6 Months on the SHA | Yes | 128 Participants |
| DI - SSP | Number of MSM and TGM Who Report Having Had Sex in the Last 6 Months on the SHA | No | 5 Participants |
| DI - SSP | Number of MSM and TGM Who Report Having Had Sex in the Last 6 Months on the SHA | I prefer not to answer | 1 Participants |
| DI - SSP | Number of MSM and TGM Who Report Having Had Sex in the Last 6 Months on the SHA | Missing | 55 Participants |
| RI - SSP | Number of MSM and TGM Who Report Having Had Sex in the Last 6 Months on the SHA | Missing | 6 Participants |
| RI - SSP | Number of MSM and TGM Who Report Having Had Sex in the Last 6 Months on the SHA | I prefer not to answer | 0 Participants |
| RI - SSP | Number of MSM and TGM Who Report Having Had Sex in the Last 6 Months on the SHA | No | 1 Participants |
| RI - SSP | Number of MSM and TGM Who Report Having Had Sex in the Last 6 Months on the SHA | Yes | 5 Participants |
Secondary
Number of PSPs Assessed for Perception of Barriers
General perceptions of barriers for APRETUDE delivery and use were measured among PSPs from themes emerging from Proctor and CFIR guided semi-structured qualitative interviews. In this outcome measure, PSPs discuss challenging views of or experiences with APRETUDE receipt. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).
Time frame: Up to Month 12
Population: Analysis was performed on PSPs who were administered at least one dose of APRETUDE injection or of CAB tablets for PrEP and who completed an interview at the specified time point. Only those participants with data available for the specified analysis at the specified time points were included.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| DI - SSP | Number of PSPs Assessed for Perception of Barriers | Would not consider APRETUDE as a long-term treatment | 1 Participants |
| DI - SSP | Number of PSPs Assessed for Perception of Barriers | Cost Challenges | 6 Participants |
| DI - SSP | Number of PSPs Assessed for Perception of Barriers | Challenges with switching insurance carriers | 0 Participants |
| RI - SSP | Number of PSPs Assessed for Perception of Barriers | Would not consider APRETUDE as a long-term treatment | 3 Participants |
| RI - SSP | Number of PSPs Assessed for Perception of Barriers | Cost Challenges | 3 Participants |
| RI - SSP | Number of PSPs Assessed for Perception of Barriers | Challenges with switching insurance carriers | 4 Participants |
Secondary
Number of PSPs Assessed for Perception of Barriers to Feasibility and Acceptability of APRETUDE Through Month 12
Barriers to feasibility and acceptability of APRETUDE were measured from themes emerging from Proctor and Consolidated Framework for Implementation Research (CFIR) guided semi-structured qualitative interviews. In this outcome measure, PSPs were asked about their perspectives on the barriers and challenges of feasibility and acceptability of APRETUDE intervention. Timeframe for evaluation of this outcome measure is through M12 (equivalent M13 for PSPs who received OLI).
Time frame: Up to Month 12
Population: Analysis was performed on PSPs who were administered at least one dose of APRETUDE injection or of CAB tablets for PrEP and who completed an interview at the specified time point. Only those participants with data available for the specified analysis at the specified time points were included.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| DI - SSP | Number of PSPs Assessed for Perception of Barriers to Feasibility and Acceptability of APRETUDE Through Month 12 | 1 Participants |
| RI - SSP | Number of PSPs Assessed for Perception of Barriers to Feasibility and Acceptability of APRETUDE Through Month 12 | 3 Participants |
Secondary
Number of PSPs Assessed for Perception of Facilitators
General perceptions of facilitators for APRETUDE delivery and use were measured among PSPs from themes emerging from Proctor and CFIR guided semi-structured qualitative interviews. In this outcome measure, PSPs discuss views of long-term use of APRETUDE, reasons to choose APRETUDE, and experiences with clinic staff. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).
Time frame: Up to Month 12
Population: Analysis was performed on PSPs who were administered at least one dose of APRETUDE injection or of CAB tablets for PrEP and who completed an interview at the specified time point. Only those participants with data available for the specified analysis at the specified time points were included.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| DI - SSP | Number of PSPs Assessed for Perception of Facilitators | Would consider APRETUDE as a long-term treatment | 19 Participants |
| DI - SSP | Number of PSPs Assessed for Perception of Facilitators | APRETUDE as long-term treatment provides protection | 12 Participants |
| DI - SSP | Number of PSPs Assessed for Perception of Facilitators | APRETUDE as long-term treatment provides peace of mind | 4 Participants |
| DI - SSP | Number of PSPs Assessed for Perception of Facilitators | APRETUDE as long-term treatment has concerns about insurance coverage long-term | 4 Participants |
| DI - SSP | Number of PSPs Assessed for Perception of Facilitators | APRETUDE as long-term treatment has convenience over oral PrEP | 5 Participants |
| DI - SSP | Number of PSPs Assessed for Perception of Facilitators | APRETUDE as long-term treatment taken as long as necessary | 0 Participants |
| DI - SSP | Number of PSPs Assessed for Perception of Facilitators | Reasons others may choose APRETUDE: Convenience and ease of use | 8 Participants |
| DI - SSP | Number of PSPs Assessed for Perception of Facilitators | Reasons others may choose APRETUDE: Health and prevention | 4 Participants |
| DI - SSP | Number of PSPs Assessed for Perception of Facilitators | Global judgement of recommend to others | 13 Participants |
| DI - SSP | Number of PSPs Assessed for Perception of Facilitators | Experiences of care: Discussed interactions with clinic staff | 21 Participants |
| DI - SSP | Number of PSPs Assessed for Perception of Facilitators | Experiences of care: Clinic staff were friendly and kind | 17 Participants |
| DI - SSP | Number of PSPs Assessed for Perception of Facilitators | Experiences of care: PSP was treated with respect | 15 Participants |
| DI - SSP | Number of PSPs Assessed for Perception of Facilitators | Experiences of care: Clinic staff were knowledgeable | 12 Participants |
| DI - SSP | Number of PSPs Assessed for Perception of Facilitators | Experiences of care: Shared decision making | 10 Participants |
| DI - SSP | Number of PSPs Assessed for Perception of Facilitators | HIV/STI testing: Testing frequency was acceptable | 13 Participants |
| DI - SSP | Number of PSPs Assessed for Perception of Facilitators | HIV/STI testing: Positive experience with scheduling HIV/ STI testing | 11 Participants |
| DI - SSP | Number of PSPs Assessed for Perception of Facilitators | Reported whether they discussed APRETUDE with family / friends | 21 Participants |
| DI - SSP | Number of PSPs Assessed for Perception of Facilitators | Has discussed APRETUDE with partner(s) | 11 Participants |
| DI - SSP | Number of PSPs Assessed for Perception of Facilitators | Peers have started PrEP | 10 Participants |
| DI - SSP | Number of PSPs Assessed for Perception of Facilitators | Uptake of PrEP by Friends | 3 Participants |
| RI - SSP | Number of PSPs Assessed for Perception of Facilitators | Has discussed APRETUDE with partner(s) | 9 Participants |
| RI - SSP | Number of PSPs Assessed for Perception of Facilitators | Would consider APRETUDE as a long-term treatment | 17 Participants |
| RI - SSP | Number of PSPs Assessed for Perception of Facilitators | Experiences of care: Clinic staff were friendly and kind | 19 Participants |
| RI - SSP | Number of PSPs Assessed for Perception of Facilitators | APRETUDE as long-term treatment provides protection | 6 Participants |
| RI - SSP | Number of PSPs Assessed for Perception of Facilitators | HIV/STI testing: Positive experience with scheduling HIV/ STI testing | 11 Participants |
| RI - SSP | Number of PSPs Assessed for Perception of Facilitators | APRETUDE as long-term treatment provides peace of mind | 6 Participants |
| RI - SSP | Number of PSPs Assessed for Perception of Facilitators | Experiences of care: PSP was treated with respect | 15 Participants |
| RI - SSP | Number of PSPs Assessed for Perception of Facilitators | APRETUDE as long-term treatment has concerns about insurance coverage long-term | 3 Participants |
| RI - SSP | Number of PSPs Assessed for Perception of Facilitators | Uptake of PrEP by Friends | 2 Participants |
| RI - SSP | Number of PSPs Assessed for Perception of Facilitators | APRETUDE as long-term treatment has convenience over oral PrEP | 1 Participants |
| RI - SSP | Number of PSPs Assessed for Perception of Facilitators | Experiences of care: Clinic staff were knowledgeable | 7 Participants |
| RI - SSP | Number of PSPs Assessed for Perception of Facilitators | APRETUDE as long-term treatment taken as long as necessary | 5 Participants |
| RI - SSP | Number of PSPs Assessed for Perception of Facilitators | Reported whether they discussed APRETUDE with family / friends | 18 Participants |
| RI - SSP | Number of PSPs Assessed for Perception of Facilitators | Reasons others may choose APRETUDE: Convenience and ease of use | 3 Participants |
| RI - SSP | Number of PSPs Assessed for Perception of Facilitators | Experiences of care: Shared decision making | 9 Participants |
| RI - SSP | Number of PSPs Assessed for Perception of Facilitators | Reasons others may choose APRETUDE: Health and prevention | 5 Participants |
| RI - SSP | Number of PSPs Assessed for Perception of Facilitators | Peers have started PrEP | 7 Participants |
| RI - SSP | Number of PSPs Assessed for Perception of Facilitators | Global judgement of recommend to others | 14 Participants |
| RI - SSP | Number of PSPs Assessed for Perception of Facilitators | HIV/STI testing: Testing frequency was acceptable | 15 Participants |
| RI - SSP | Number of PSPs Assessed for Perception of Facilitators | Experiences of care: Discussed interactions with clinic staff | 21 Participants |
Secondary
Number of PSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery
Barriers and facilitators to the feasibility and acceptability of telehealth use for APRETUDE were measured from themes emerging from Proctor and Consolidated Framework for Implementation Research (CFIR) guided semi-structured qualitative interviews. In this outcome measure, PSPs were asked their perceptions of these facilitators and barriers for telehealth services used. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).
Time frame: Up to Month 12
Population: Analysis was performed on PSPs who were administered at least one dose of APRETUDE injection or of CAB tablets for PrEP and who completed an interview at the specified time point. The use and adoption of some telehealth services were only assessed among DI PSPs. Only those participants with data available for the specified analysis at the specified time points were included.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| DI - SSP | Number of PSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Home health nurses Used | 0 Participants |
| DI - SSP | Number of PSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Not Asked About Telehealth | 18 Participants |
| DI - SSP | Number of PSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Telehealth Used for any service | 2 Participants |
| DI - SSP | Number of PSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Telehealth Used for APRETUDE | 1 Participants |
| DI - SSP | Number of PSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Telehealth used for things OTHER than APRETUDE, only | 1 Participants |
| DI - SSP | Number of PSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Telehealth Not Used | 2 Participants |
| DI - SSP | Number of PSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Telehealth used/not used- Missing | 1 Participants |
| DI - SSP | Number of PSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Telehealth DI Used | 5 Participants |
| DI - SSP | Number of PSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Teleconsultant Used | 1 Participants |
| DI - SSP | Number of PSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Online Appointment Scheduler Used | 0 Participants |
| DI - SSP | Number of PSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Reminders Used | 3 Participants |
| DI - SSP | Number of PSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Home tests Used | 0 Participants |
| DI - SSP | Number of PSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Local labs Used | 0 Participants |
| DI - SSP | Number of PSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Online portal Used | 0 Participants |
| DI - SSP | Number of PSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Screenings and assessments Used | 1 Participants |
| RI - SSP | Number of PSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Home health nurses Used | 0 Participants |
| RI - SSP | Number of PSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Teleconsultant Used | 0 Participants |
| RI - SSP | Number of PSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Local labs Used | 0 Participants |
| RI - SSP | Number of PSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Telehealth Used for any service | 5 Participants |
| RI - SSP | Number of PSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Online Appointment Scheduler Used | 0 Participants |
| RI - SSP | Number of PSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Telehealth Used for APRETUDE | 5 Participants |
| RI - SSP | Number of PSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Screenings and assessments Used | 0 Participants |
| RI - SSP | Number of PSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Telehealth used for things OTHER than APRETUDE, only | 0 Participants |
| RI - SSP | Number of PSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Reminders Used | 0 Participants |
| RI - SSP | Number of PSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Telehealth Not Used | 12 Participants |
| RI - SSP | Number of PSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Not Asked About Telehealth | 4 Participants |
| RI - SSP | Number of PSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Online portal Used | 0 Participants |
| RI - SSP | Number of PSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Telehealth used/not used- Missing | 0 Participants |
| RI - SSP | Number of PSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Home tests Used | 0 Participants |
| RI - SSP | Number of PSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Telehealth DI Used | 0 Participants |
Secondary
Number of PSPs Assessed for Perception of Facilitators to Feasibility and Acceptability of APRETUDE Through Month 12
Facilitators to feasibility and acceptability of APRETUDE measured from themes emerging from Proctor and Consolidated Framework for Implementation Research (CFIR) guided semi-structured qualitative interviews. In this outcome measure, PSPs were asked about their perception of the facilitators of feasibility and acceptability of APRETUDE intervention. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).
Time frame: Up to Month 12
Population: Analysis was performed on PSPs who were administered at least one dose of APRETUDE injection or of CAB tablets for PrEP and who completed an interview at the specified time point. Only those participants with data available for the specified analysis at the specified time points were included.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| DI - SSP | Number of PSPs Assessed for Perception of Facilitators to Feasibility and Acceptability of APRETUDE Through Month 12 | Perceived effectiveness provides peace of mind | 7 Participants |
| DI - SSP | Number of PSPs Assessed for Perception of Facilitators to Feasibility and Acceptability of APRETUDE Through Month 12 | Discomfort becoming more manageable | 1 Participants |
| DI - SSP | Number of PSPs Assessed for Perception of Facilitators to Feasibility and Acceptability of APRETUDE Through Month 12 | Positive Experiences and General Satisfaction | 14 Participants |
| DI - SSP | Number of PSPs Assessed for Perception of Facilitators to Feasibility and Acceptability of APRETUDE Through Month 12 | Reduced anxiety about taking oral PrEP | 5 Participants |
| DI - SSP | Number of PSPs Assessed for Perception of Facilitators to Feasibility and Acceptability of APRETUDE Through Month 12 | APRETUDE met their expectations | 15 Participants |
| DI - SSP | Number of PSPs Assessed for Perception of Facilitators to Feasibility and Acceptability of APRETUDE Through Month 12 | HIV protection | 10 Participants |
| DI - SSP | Number of PSPs Assessed for Perception of Facilitators to Feasibility and Acceptability of APRETUDE Through Month 12 | Convenience and Ease of Use | 15 Participants |
| DI - SSP | Number of PSPs Assessed for Perception of Facilitators to Feasibility and Acceptability of APRETUDE Through Month 12 | APRETUDE more convenient than expected | 2 Participants |
| DI - SSP | Number of PSPs Assessed for Perception of Facilitators to Feasibility and Acceptability of APRETUDE Through Month 12 | APRETUDE positive experience so far | 23 Participants |
| RI - SSP | Number of PSPs Assessed for Perception of Facilitators to Feasibility and Acceptability of APRETUDE Through Month 12 | APRETUDE more convenient than expected | 4 Participants |
| RI - SSP | Number of PSPs Assessed for Perception of Facilitators to Feasibility and Acceptability of APRETUDE Through Month 12 | APRETUDE positive experience so far | 20 Participants |
| RI - SSP | Number of PSPs Assessed for Perception of Facilitators to Feasibility and Acceptability of APRETUDE Through Month 12 | Positive Experiences and General Satisfaction | 12 Participants |
| RI - SSP | Number of PSPs Assessed for Perception of Facilitators to Feasibility and Acceptability of APRETUDE Through Month 12 | Convenience and Ease of Use | 11 Participants |
| RI - SSP | Number of PSPs Assessed for Perception of Facilitators to Feasibility and Acceptability of APRETUDE Through Month 12 | Discomfort becoming more manageable | 5 Participants |
| RI - SSP | Number of PSPs Assessed for Perception of Facilitators to Feasibility and Acceptability of APRETUDE Through Month 12 | APRETUDE met their expectations | 18 Participants |
| RI - SSP | Number of PSPs Assessed for Perception of Facilitators to Feasibility and Acceptability of APRETUDE Through Month 12 | Reduced anxiety about taking oral PrEP | 15 Participants |
| RI - SSP | Number of PSPs Assessed for Perception of Facilitators to Feasibility and Acceptability of APRETUDE Through Month 12 | HIV protection | 7 Participants |
| RI - SSP | Number of PSPs Assessed for Perception of Facilitators to Feasibility and Acceptability of APRETUDE Through Month 12 | Perceived effectiveness provides peace of mind | 2 Participants |
Secondary
Number of PSPs Assessed for Perceptions of Adaptations to Implementation Strategies
PSP perceptions of adaptations to implementation strategies were measured from themes emerging from Proctor and CFIR guided semi-structured qualitative interviews. In this outcome measure, PSPs discussed their use of study resources and recommendations to staff for delivery of APRETUDE. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).
Time frame: Up to Month 12
Population: Analysis was performed on PSPs who were administered at least one dose of APRETUDE injection or of CAB tablets for PrEP and who completed an interview at the specified time point. Only those participants with data available for the specified analysis at the specified time points were included.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| DI - SSP | Number of PSPs Assessed for Perceptions of Adaptations to Implementation Strategies | Only used tools/resources in the beginning of PILLAR | 5 Participants |
| DI - SSP | Number of PSPs Assessed for Perceptions of Adaptations to Implementation Strategies | Recommendations to staff | 16 Participants |
| DI - SSP | Number of PSPs Assessed for Perceptions of Adaptations to Implementation Strategies | Resources were helpful | 2 Participants |
| DI - SSP | Number of PSPs Assessed for Perceptions of Adaptations to Implementation Strategies | Would not change anything | 4 Participants |
| DI - SSP | Number of PSPs Assessed for Perceptions of Adaptations to Implementation Strategies | Positive feedback about tools and resources | 10 Participants |
| DI - SSP | Number of PSPs Assessed for Perceptions of Adaptations to Implementation Strategies | APRETUDE education within the community | 1 Participants |
| DI - SSP | Number of PSPs Assessed for Perceptions of Adaptations to Implementation Strategies | Negative feedback about tools and resources | 2 Participants |
| DI - SSP | Number of PSPs Assessed for Perceptions of Adaptations to Implementation Strategies | Being culturally aware and non-judgmental | 2 Participants |
| DI - SSP | Number of PSPs Assessed for Perceptions of Adaptations to Implementation Strategies | Does not remember tools or resources | 3 Participants |
| DI - SSP | Number of PSPs Assessed for Perceptions of Adaptations to Implementation Strategies | Support APRETUDE schedule | 2 Participants |
| DI - SSP | Number of PSPs Assessed for Perceptions of Adaptations to Implementation Strategies | Did not use (pay much attention to resources) | 2 Participants |
| DI - SSP | Number of PSPs Assessed for Perceptions of Adaptations to Implementation Strategies | Discussion about post-Injection discomfort | 1 Participants |
| DI - SSP | Number of PSPs Assessed for Perceptions of Adaptations to Implementation Strategies | Discussed tools and resources | 21 Participants |
| RI - SSP | Number of PSPs Assessed for Perceptions of Adaptations to Implementation Strategies | Discussion about post-Injection discomfort | 2 Participants |
| RI - SSP | Number of PSPs Assessed for Perceptions of Adaptations to Implementation Strategies | Discussed tools and resources | 20 Participants |
| RI - SSP | Number of PSPs Assessed for Perceptions of Adaptations to Implementation Strategies | Positive feedback about tools and resources | 7 Participants |
| RI - SSP | Number of PSPs Assessed for Perceptions of Adaptations to Implementation Strategies | Only used tools/resources in the beginning of PILLAR | 7 Participants |
| RI - SSP | Number of PSPs Assessed for Perceptions of Adaptations to Implementation Strategies | Does not remember tools or resources | 5 Participants |
| RI - SSP | Number of PSPs Assessed for Perceptions of Adaptations to Implementation Strategies | Resources were helpful | 4 Participants |
| RI - SSP | Number of PSPs Assessed for Perceptions of Adaptations to Implementation Strategies | Negative feedback about tools and resources | 4 Participants |
| RI - SSP | Number of PSPs Assessed for Perceptions of Adaptations to Implementation Strategies | Did not use (pay much attention to resources) | 2 Participants |
| RI - SSP | Number of PSPs Assessed for Perceptions of Adaptations to Implementation Strategies | Recommendations to staff | 14 Participants |
| RI - SSP | Number of PSPs Assessed for Perceptions of Adaptations to Implementation Strategies | Would not change anything | 3 Participants |
| RI - SSP | Number of PSPs Assessed for Perceptions of Adaptations to Implementation Strategies | APRETUDE education within the community | 3 Participants |
| RI - SSP | Number of PSPs Assessed for Perceptions of Adaptations to Implementation Strategies | Being culturally aware and non-judgmental | 2 Participants |
| RI - SSP | Number of PSPs Assessed for Perceptions of Adaptations to Implementation Strategies | Support APRETUDE schedule | 1 Participants |
Secondary
Number of PSPs Assessed for Perceptions of Utility of Implementation Strategies Through Semi-Structured Interviews (SSIs)
Perceptions of Utility of Implementation Strategies and Facilitators and Barriers to Acceptability of RI and DI measured from themes emerging from Proctor and CFIR guided semi-structured qualitative interview. In this outcome measure, PSPs provided their insights regarding the tools and strategies used for delivering APRETUDE. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).
Time frame: Up to Month 12
Population: Analysis was performed on PSPs who were administered at least one dose of APRETUDE injection or of CAB tablets for PrEP and who completed an interview at the specified time point. All questions were not administered to both RI and DI arms; hence only participants with data available for the specified analysis at the specified time points were included.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| DI - SSP | Number of PSPs Assessed for Perceptions of Utility of Implementation Strategies Through Semi-Structured Interviews (SSIs) | What to expect video (DI) | 13 Participants |
| DI - SSP | Number of PSPs Assessed for Perceptions of Utility of Implementation Strategies Through Semi-Structured Interviews (SSIs) | Myths facts video (DI) | 9 Participants |
| DI - SSP | Number of PSPs Assessed for Perceptions of Utility of Implementation Strategies Through Semi-Structured Interviews (SSIs) | HIV education video (DI) | 11 Participants |
| DI - SSP | Number of PSPs Assessed for Perceptions of Utility of Implementation Strategies Through Semi-Structured Interviews (SSIs) | Participant handbook | 7 Participants |
| DI - SSP | Number of PSPs Assessed for Perceptions of Utility of Implementation Strategies Through Semi-Structured Interviews (SSIs) | ViiV Connect Assistance Video (DI) | 6 Participants |
| DI - SSP | Number of PSPs Assessed for Perceptions of Utility of Implementation Strategies Through Semi-Structured Interviews (SSIs) | Patient brochure | 7 Participants |
| DI - SSP | Number of PSPs Assessed for Perceptions of Utility of Implementation Strategies Through Semi-Structured Interviews (SSIs) | Reminder service text (DI) | 7 Participants |
| DI - SSP | Number of PSPs Assessed for Perceptions of Utility of Implementation Strategies Through Semi-Structured Interviews (SSIs) | Patient website (RI) | 0 Participants |
| DI - SSP | Number of PSPs Assessed for Perceptions of Utility of Implementation Strategies Through Semi-Structured Interviews (SSIs) | Appointment scheduler (DI) | 5 Participants |
| DI - SSP | Number of PSPs Assessed for Perceptions of Utility of Implementation Strategies Through Semi-Structured Interviews (SSIs) | Getting Started brochure | 10 Participants |
| RI - SSP | Number of PSPs Assessed for Perceptions of Utility of Implementation Strategies Through Semi-Structured Interviews (SSIs) | Appointment scheduler (DI) | 0 Participants |
| RI - SSP | Number of PSPs Assessed for Perceptions of Utility of Implementation Strategies Through Semi-Structured Interviews (SSIs) | Patient brochure | 12 Participants |
| RI - SSP | Number of PSPs Assessed for Perceptions of Utility of Implementation Strategies Through Semi-Structured Interviews (SSIs) | What to expect video (DI) | 0 Participants |
| RI - SSP | Number of PSPs Assessed for Perceptions of Utility of Implementation Strategies Through Semi-Structured Interviews (SSIs) | Myths facts video (DI) | 0 Participants |
| RI - SSP | Number of PSPs Assessed for Perceptions of Utility of Implementation Strategies Through Semi-Structured Interviews (SSIs) | Getting Started brochure | 9 Participants |
| RI - SSP | Number of PSPs Assessed for Perceptions of Utility of Implementation Strategies Through Semi-Structured Interviews (SSIs) | Patient website (RI) | 11 Participants |
| RI - SSP | Number of PSPs Assessed for Perceptions of Utility of Implementation Strategies Through Semi-Structured Interviews (SSIs) | HIV education video (DI) | 0 Participants |
| RI - SSP | Number of PSPs Assessed for Perceptions of Utility of Implementation Strategies Through Semi-Structured Interviews (SSIs) | ViiV Connect Assistance Video (DI) | 0 Participants |
| RI - SSP | Number of PSPs Assessed for Perceptions of Utility of Implementation Strategies Through Semi-Structured Interviews (SSIs) | Reminder service text (DI) | 0 Participants |
| RI - SSP | Number of PSPs Assessed for Perceptions of Utility of Implementation Strategies Through Semi-Structured Interviews (SSIs) | Participant handbook | 10 Participants |
Secondary
Number of PSPs Completing Target Number of Injections
Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).
Time frame: Up to Month 12
Population: Analysis was performed on PSPs who were administered at least one dose of APRETUDE injection or of CAB tablets for PrEP. Only those participants with data available for the specified analysis at the specified time points were included.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| DI - SSP | Number of PSPs Completing Target Number of Injections | 81 Participants |
| RI - SSP | Number of PSPs Completing Target Number of Injections | 63 Participants |
Secondary
Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use
The ISQ uses a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs were asked about how useful various implementation strategies have been in supporting them while taking APRETUDE. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).
Time frame: Up to Month 12
Population: Analysis was performed on PSPs who were administered at least one dose of APRETUDE injection or of CAB tablets for PrEP and who completed at least one ISQ survey at any timepoint. All questions were not administered to both RI and DI arms; hence only participants with data available for the specified analysis at the specified time points were included.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| DI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Brochures and other print materials to educate you on APRETUDE | Not at all useful | 1 Participants |
| DI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Brochures and other print materials to educate you on APRETUDE | Not very useful | 2 Participants |
| DI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Brochures and other print materials to educate you on APRETUDE | Somewhat useful | 10 Participants |
| DI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Brochures and other print materials to educate you on APRETUDE | Useful | 23 Participants |
| DI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Brochures and other print materials to educate you on APRETUDE | Extremely useful | 13 Participants |
| DI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Videos to educate you on HIV, PrEP, APRETUDE materials (DI) | Not at all useful | 1 Participants |
| DI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Videos to educate you on HIV, PrEP, APRETUDE materials (DI) | Not very useful | 1 Participants |
| DI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Videos to educate you on HIV, PrEP, APRETUDE materials (DI) | Somewhat useful | 8 Participants |
| DI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Videos to educate you on HIV, PrEP, APRETUDE materials (DI) | Useful | 21 Participants |
| DI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Videos to educate you on HIV, PrEP, APRETUDE materials (DI) | Extremely useful | 9 Participants |
| DI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | A digital calendar specifically made for APRETUDE to help plan injections, found on Pillar Spot (DI) | Not at all useful | 2 Participants |
| DI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | A digital calendar specifically made for APRETUDE to help plan injections, found on Pillar Spot (DI) | Not very useful | 0 Participants |
| DI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | A digital calendar specifically made for APRETUDE to help plan injections, found on Pillar Spot (DI) | Somewhat useful | 3 Participants |
| DI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Reminders about injections | Useful | 25 Participants |
| DI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Reminders about injections | Extremely useful | 30 Participants |
| DI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Having video or telephone appointments with your doctor | Not at all useful | 1 Participants |
| DI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Having video or telephone appointments with your doctor | Not very useful | 0 Participants |
| DI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Having video or telephone appointments with your doctor | Somewhat useful | 3 Participants |
| DI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Having video or telephone appointments with your doctor | Useful | 7 Participants |
| DI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Having video or telephone appointments with your doctor | Extremely useful | 6 Participants |
| DI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Sending chats or texts to your doctor on the Pillar Spot (DI) | Not at all useful | 1 Participants |
| DI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Sending chats or texts to your doctor on the Pillar Spot (DI) | Not very useful | 0 Participants |
| DI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Sending chats or texts to your doctor on the Pillar Spot (DI) | Somewhat useful | 3 Participants |
| DI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Sending chats or texts to your doctor on the Pillar Spot (DI) | Useful | 11 Participants |
| DI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Sending chats or texts to your doctor on the Pillar Spot (DI) | Extremely useful | 8 Participants |
| DI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Having a nurse come home to conduct your HIV test (DI) | Not at all useful | 1 Participants |
| DI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Having a nurse come home to conduct your HIV test (DI) | Not very useful | 0 Participants |
| DI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Having a nurse come home to conduct your HIV test (DI) | Somewhat useful | 1 Participants |
| DI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Having a nurse come home to conduct your HIV test (DI) | Useful | 2 Participants |
| DI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Having a nurse come home to conduct your HIV test (DI) | Extremely useful | 1 Participants |
| DI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Having a nurse come home to give your injection (DI) | Not at all useful | 1 Participants |
| DI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Having a nurse come home to give your injection (DI) | Not very useful | 0 Participants |
| DI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Having a nurse come home to give your injection (DI) | Somewhat useful | 1 Participants |
| DI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Having a nurse come home to give your injection (DI) | Useful | 2 Participants |
| DI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Having a nurse come home to give your injection (DI) | Extremely useful | 1 Participants |
| DI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Receiving transportation to the clinic/doctor's office for your injection (DI) | Not at all useful | 1 Participants |
| DI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Receiving transportation to the clinic/doctor's office for your injection (DI) | Not very useful | 0 Participants |
| DI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Receiving transportation to the clinic/doctor's office for your injection (DI) | Somewhat useful | 2 Participants |
| DI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Receiving transportation to the clinic/doctor's office for your injection (DI) | Useful | 4 Participants |
| DI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Receiving transportation to the clinic/doctor's office for your injection (DI) | Extremely useful | 15 Participants |
| DI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | A website/app to access APRETUDE information- the Pillar Spot (DI) | Not at all useful | 2 Participants |
| DI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | A website/app to access APRETUDE information- the Pillar Spot (DI) | Not very useful | 1 Participants |
| DI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | A website/app to access APRETUDE information- the Pillar Spot (DI) | Somewhat useful | 8 Participants |
| DI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | A website/app to access APRETUDE information- the Pillar Spot (DI) | Useful | 14 Participants |
| DI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | A website/app to access APRETUDE information- the Pillar Spot (DI) | Extremely useful | 7 Participants |
| DI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | The website to access APRETUDE information (RI) | Not at all useful | 0 Participants |
| DI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | The website to access APRETUDE information (RI) | Somewhat useful | 0 Participants |
| DI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | The website to access APRETUDE information (RI) | Useful | 0 Participants |
| DI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | The website to access APRETUDE information (RI) | Extremely useful | 0 Participants |
| DI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | A digital calendar specifically made for APRETUDE to help plan injections, found on Pillar Spot (DI) | Useful | 6 Participants |
| DI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | A digital calendar specifically made for APRETUDE to help plan injections, found on Pillar Spot (DI) | Extremely useful | 4 Participants |
| DI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Reminders about injections | Not at all useful | 3 Participants |
| DI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Reminders about injections | Not very useful | 2 Participants |
| DI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Reminders about injections | Somewhat useful | 5 Participants |
| DI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | The website to access APRETUDE information (RI) | Not very useful | 0 Participants |
| RI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Having a nurse come home to conduct your HIV test (DI) | Useful | 0 Participants |
| RI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Brochures and other print materials to educate you on APRETUDE | Not at all useful | 0 Participants |
| RI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | A digital calendar specifically made for APRETUDE to help plan injections, found on Pillar Spot (DI) | Not very useful | 0 Participants |
| RI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Brochures and other print materials to educate you on APRETUDE | Not very useful | 1 Participants |
| RI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Having a nurse come home to conduct your HIV test (DI) | Extremely useful | 0 Participants |
| RI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Brochures and other print materials to educate you on APRETUDE | Somewhat useful | 10 Participants |
| RI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | A website/app to access APRETUDE information- the Pillar Spot (DI) | Useful | 0 Participants |
| RI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Brochures and other print materials to educate you on APRETUDE | Useful | 12 Participants |
| RI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Having a nurse come home to give your injection (DI) | Not at all useful | 0 Participants |
| RI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Brochures and other print materials to educate you on APRETUDE | Extremely useful | 12 Participants |
| RI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | A digital calendar specifically made for APRETUDE to help plan injections, found on Pillar Spot (DI) | Somewhat useful | 0 Participants |
| RI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Videos to educate you on HIV, PrEP, APRETUDE materials (DI) | Not at all useful | 0 Participants |
| RI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Having a nurse come home to give your injection (DI) | Not very useful | 0 Participants |
| RI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Videos to educate you on HIV, PrEP, APRETUDE materials (DI) | Not very useful | 0 Participants |
| RI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | A website/app to access APRETUDE information- the Pillar Spot (DI) | Extremely useful | 0 Participants |
| RI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Videos to educate you on HIV, PrEP, APRETUDE materials (DI) | Somewhat useful | 0 Participants |
| RI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Having a nurse come home to give your injection (DI) | Somewhat useful | 0 Participants |
| RI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Videos to educate you on HIV, PrEP, APRETUDE materials (DI) | Useful | 0 Participants |
| RI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Reminders about injections | Not very useful | 0 Participants |
| RI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Having a nurse come home to give your injection (DI) | Useful | 0 Participants |
| RI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | A digital calendar specifically made for APRETUDE to help plan injections, found on Pillar Spot (DI) | Not at all useful | 0 Participants |
| RI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | The website to access APRETUDE information (RI) | Not at all useful | 1 Participants |
| RI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Having a nurse come home to give your injection (DI) | Extremely useful | 0 Participants |
| RI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Reminders about injections | Somewhat useful | 3 Participants |
| RI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | The website to access APRETUDE information (RI) | Not very useful | 1 Participants |
| RI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Reminders about injections | Useful | 22 Participants |
| RI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Receiving transportation to the clinic/doctor's office for your injection (DI) | Not at all useful | 0 Participants |
| RI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Reminders about injections | Extremely useful | 26 Participants |
| RI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | A digital calendar specifically made for APRETUDE to help plan injections, found on Pillar Spot (DI) | Useful | 0 Participants |
| RI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Having video or telephone appointments with your doctor | Not at all useful | 0 Participants |
| RI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Receiving transportation to the clinic/doctor's office for your injection (DI) | Not very useful | 0 Participants |
| RI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Having video or telephone appointments with your doctor | Not very useful | 0 Participants |
| RI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | The website to access APRETUDE information (RI) | Somewhat useful | 6 Participants |
| RI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Having video or telephone appointments with your doctor | Somewhat useful | 1 Participants |
| RI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Receiving transportation to the clinic/doctor's office for your injection (DI) | Somewhat useful | 0 Participants |
| RI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Having video or telephone appointments with your doctor | Useful | 7 Participants |
| RI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Reminders about injections | Not at all useful | 0 Participants |
| RI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Having video or telephone appointments with your doctor | Extremely useful | 8 Participants |
| RI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Receiving transportation to the clinic/doctor's office for your injection (DI) | Useful | 0 Participants |
| RI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Sending chats or texts to your doctor on the Pillar Spot (DI) | Not at all useful | 0 Participants |
| RI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | The website to access APRETUDE information (RI) | Useful | 11 Participants |
| RI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Sending chats or texts to your doctor on the Pillar Spot (DI) | Not very useful | 0 Participants |
| RI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Receiving transportation to the clinic/doctor's office for your injection (DI) | Extremely useful | 0 Participants |
| RI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Sending chats or texts to your doctor on the Pillar Spot (DI) | Somewhat useful | 0 Participants |
| RI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | A digital calendar specifically made for APRETUDE to help plan injections, found on Pillar Spot (DI) | Extremely useful | 0 Participants |
| RI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Sending chats or texts to your doctor on the Pillar Spot (DI) | Useful | 0 Participants |
| RI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | A website/app to access APRETUDE information- the Pillar Spot (DI) | Not at all useful | 0 Participants |
| RI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Sending chats or texts to your doctor on the Pillar Spot (DI) | Extremely useful | 0 Participants |
| RI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | The website to access APRETUDE information (RI) | Extremely useful | 6 Participants |
| RI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Having a nurse come home to conduct your HIV test (DI) | Not at all useful | 0 Participants |
| RI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | A website/app to access APRETUDE information- the Pillar Spot (DI) | Not very useful | 0 Participants |
| RI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Having a nurse come home to conduct your HIV test (DI) | Not very useful | 0 Participants |
| RI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Videos to educate you on HIV, PrEP, APRETUDE materials (DI) | Extremely useful | 0 Participants |
| RI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Having a nurse come home to conduct your HIV test (DI) | Somewhat useful | 0 Participants |
| RI - SSP | Number of PSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | A website/app to access APRETUDE information- the Pillar Spot (DI) | Somewhat useful | 0 Participants |
Secondary
Number of PSPs Who Expressed Interest in PrEP or Never Heard of PrEP Out of Those Who Report Having Had Sex in the Last 6 Months
In this outcome measure, data presented below shows the number of PSPs who expressed interest in PreP by responding to the question Have you taken oral PreP in the last 6 months and number of PSPs who had not heard of PreP.
Time frame: Up to Month 12
Population: Analysis was performed on PSPs who were administered at least one dose of APRETUDE injection or of CAB tablets for PrEP and who completed at least one SHA survey at any timepoint. Only those participants with data available for the specified analysis at the specified time points were included.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| DI - SSP | Number of PSPs Who Expressed Interest in PrEP or Never Heard of PrEP Out of Those Who Report Having Had Sex in the Last 6 Months | Before enrolling in this study, had you heard of APRETUDE? | I don't know/prefer not to answer | 0 Participants |
| DI - SSP | Number of PSPs Who Expressed Interest in PrEP or Never Heard of PrEP Out of Those Who Report Having Had Sex in the Last 6 Months | Before enrolling in this study, you ever heard of people without HIV taking oral PrEP pills? | Missing | 10 Participants |
| DI - SSP | Number of PSPs Who Expressed Interest in PrEP or Never Heard of PrEP Out of Those Who Report Having Had Sex in the Last 6 Months | Before enrolling in this study, had you heard of APRETUDE? | Missing | 10 Participants |
| DI - SSP | Number of PSPs Who Expressed Interest in PrEP or Never Heard of PrEP Out of Those Who Report Having Had Sex in the Last 6 Months | Before enrolling in this study, you ever heard of people without HIV taking oral PrEP pills? | No | 30 Participants |
| DI - SSP | Number of PSPs Who Expressed Interest in PrEP or Never Heard of PrEP Out of Those Who Report Having Had Sex in the Last 6 Months | Have you taken oral PrEP in the last 6 months? | Yes | 77 Participants |
| DI - SSP | Number of PSPs Who Expressed Interest in PrEP or Never Heard of PrEP Out of Those Who Report Having Had Sex in the Last 6 Months | Before enrolling in this study, had you heard of APRETUDE? | Yes | 68 Participants |
| DI - SSP | Number of PSPs Who Expressed Interest in PrEP or Never Heard of PrEP Out of Those Who Report Having Had Sex in the Last 6 Months | Have you taken oral PrEP in the last 6 months? | No | 26 Participants |
| DI - SSP | Number of PSPs Who Expressed Interest in PrEP or Never Heard of PrEP Out of Those Who Report Having Had Sex in the Last 6 Months | Before enrolling in this study, you ever heard of people without HIV taking oral PrEP pills? | Yes | 70 Participants |
| DI - SSP | Number of PSPs Who Expressed Interest in PrEP or Never Heard of PrEP Out of Those Who Report Having Had Sex in the Last 6 Months | Have you taken oral PrEP in the last 6 months? | I don't know/prefer not to answer | 2 Participants |
| DI - SSP | Number of PSPs Who Expressed Interest in PrEP or Never Heard of PrEP Out of Those Who Report Having Had Sex in the Last 6 Months | Before enrolling in this study, had you heard of APRETUDE? | No | 39 Participants |
| DI - SSP | Number of PSPs Who Expressed Interest in PrEP or Never Heard of PrEP Out of Those Who Report Having Had Sex in the Last 6 Months | Have you taken oral PrEP in the last 6 months? | Missing | 12 Participants |
| DI - SSP | Number of PSPs Who Expressed Interest in PrEP or Never Heard of PrEP Out of Those Who Report Having Had Sex in the Last 6 Months | Before enrolling in this study, you ever heard of people without HIV taking oral PrEP pills? | I don't know/prefer not to answer | 7 Participants |
| RI - SSP | Number of PSPs Who Expressed Interest in PrEP or Never Heard of PrEP Out of Those Who Report Having Had Sex in the Last 6 Months | Have you taken oral PrEP in the last 6 months? | Missing | 7 Participants |
| RI - SSP | Number of PSPs Who Expressed Interest in PrEP or Never Heard of PrEP Out of Those Who Report Having Had Sex in the Last 6 Months | Before enrolling in this study, you ever heard of people without HIV taking oral PrEP pills? | Yes | 61 Participants |
| RI - SSP | Number of PSPs Who Expressed Interest in PrEP or Never Heard of PrEP Out of Those Who Report Having Had Sex in the Last 6 Months | Before enrolling in this study, you ever heard of people without HIV taking oral PrEP pills? | No | 15 Participants |
| RI - SSP | Number of PSPs Who Expressed Interest in PrEP or Never Heard of PrEP Out of Those Who Report Having Had Sex in the Last 6 Months | Before enrolling in this study, you ever heard of people without HIV taking oral PrEP pills? | Missing | 5 Participants |
| RI - SSP | Number of PSPs Who Expressed Interest in PrEP or Never Heard of PrEP Out of Those Who Report Having Had Sex in the Last 6 Months | Before enrolling in this study, had you heard of APRETUDE? | Yes | 58 Participants |
| RI - SSP | Number of PSPs Who Expressed Interest in PrEP or Never Heard of PrEP Out of Those Who Report Having Had Sex in the Last 6 Months | Before enrolling in this study, had you heard of APRETUDE? | No | 21 Participants |
| RI - SSP | Number of PSPs Who Expressed Interest in PrEP or Never Heard of PrEP Out of Those Who Report Having Had Sex in the Last 6 Months | Before enrolling in this study, had you heard of APRETUDE? | I don't know/prefer not to answer | 0 Participants |
| RI - SSP | Number of PSPs Who Expressed Interest in PrEP or Never Heard of PrEP Out of Those Who Report Having Had Sex in the Last 6 Months | Before enrolling in this study, had you heard of APRETUDE? | Missing | 5 Participants |
| RI - SSP | Number of PSPs Who Expressed Interest in PrEP or Never Heard of PrEP Out of Those Who Report Having Had Sex in the Last 6 Months | Have you taken oral PrEP in the last 6 months? | Yes | 65 Participants |
| RI - SSP | Number of PSPs Who Expressed Interest in PrEP or Never Heard of PrEP Out of Those Who Report Having Had Sex in the Last 6 Months | Have you taken oral PrEP in the last 6 months? | No | 11 Participants |
| RI - SSP | Number of PSPs Who Expressed Interest in PrEP or Never Heard of PrEP Out of Those Who Report Having Had Sex in the Last 6 Months | Have you taken oral PrEP in the last 6 months? | I don't know/prefer not to answer | 1 Participants |
| RI - SSP | Number of PSPs Who Expressed Interest in PrEP or Never Heard of PrEP Out of Those Who Report Having Had Sex in the Last 6 Months | Before enrolling in this study, you ever heard of people without HIV taking oral PrEP pills? | I don't know/prefer not to answer | 3 Participants |
Secondary
Number of PSPs Who Initiate APRETUDE After Taking the SHA
In this outcome measure, PSPs were asked if they had taken oral PreP in the last 6 months. PSPs who answered 'No' or 'I prefer not to answer' were further asked if they had ever taken oral PreP. Timeframe for evaluation of this outcome measure is through M12(equivalent to M13 for PSPs who received OLI).
Time frame: Up to Month 12
Population: Analysis was performed on PSPs who were administered at least one dose of APRETUDE injection or of CAB tablets for PrEP and who completed at least one SHA survey at any timepoint. Only those participants with data available for the specified analysis at the specified time points were included.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| DI - SSP | Number of PSPs Who Initiate APRETUDE After Taking the SHA | Have you taken oral PrEP in the last 6 months? | Yes | 77 Participants |
| DI - SSP | Number of PSPs Who Initiate APRETUDE After Taking the SHA | Have you taken oral PrEP in the last 6 months? | No | 26 Participants |
| DI - SSP | Number of PSPs Who Initiate APRETUDE After Taking the SHA | Have you taken oral PrEP in the last 6 months? | I prefer not to answer | 2 Participants |
| DI - SSP | Number of PSPs Who Initiate APRETUDE After Taking the SHA | Have you taken oral PrEP in the last 6 months? | Missing | 12 Participants |
| DI - SSP | Number of PSPs Who Initiate APRETUDE After Taking the SHA | Have you ever taken oral PrEP | Yes | 5 Participants |
| DI - SSP | Number of PSPs Who Initiate APRETUDE After Taking the SHA | Have you ever taken oral PrEP | No | 11 Participants |
| DI - SSP | Number of PSPs Who Initiate APRETUDE After Taking the SHA | Have you ever taken oral PrEP | I prefer not to answer | 1 Participants |
| DI - SSP | Number of PSPs Who Initiate APRETUDE After Taking the SHA | Have you ever taken oral PrEP | Missing | 11 Participants |
| RI - SSP | Number of PSPs Who Initiate APRETUDE After Taking the SHA | Have you ever taken oral PrEP | Missing | 11 Participants |
| RI - SSP | Number of PSPs Who Initiate APRETUDE After Taking the SHA | Have you taken oral PrEP in the last 6 months? | Yes | 65 Participants |
| RI - SSP | Number of PSPs Who Initiate APRETUDE After Taking the SHA | Have you ever taken oral PrEP | Yes | 1 Participants |
| RI - SSP | Number of PSPs Who Initiate APRETUDE After Taking the SHA | Have you taken oral PrEP in the last 6 months? | No | 11 Participants |
| RI - SSP | Number of PSPs Who Initiate APRETUDE After Taking the SHA | Have you ever taken oral PrEP | I prefer not to answer | 0 Participants |
| RI - SSP | Number of PSPs Who Initiate APRETUDE After Taking the SHA | Have you taken oral PrEP in the last 6 months? | I prefer not to answer | 1 Participants |
| RI - SSP | Number of PSPs Who Initiate APRETUDE After Taking the SHA | Have you ever taken oral PrEP | No | 0 Participants |
| RI - SSP | Number of PSPs Who Initiate APRETUDE After Taking the SHA | Have you taken oral PrEP in the last 6 months? | Missing | 7 Participants |
Secondary
Number of PSPs With History of PrEP Use That Complete the SHA and ISQ and Start APRETUDE
In this outcome measure, PSPs who completed the SHA and ISQ, describe the history of PrEP use and of sexual health assessment use for determination of PreP use during PILLAR study. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).
Time frame: Up to Month 12
Population: Analysis was performed on PSPs who were administered at least one dose of APRETUDE injection or of CAB tablets for PrEP and who completed at least one ISQ and SHA survey at any timepoint. Only those participants with data available for the specified analysis at the specified time points were included.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| DI - SSP | Number of PSPs With History of PrEP Use That Complete the SHA and ISQ and Start APRETUDE | Have you ever taken oral PrEP- No | 11 Participants |
| DI - SSP | Number of PSPs With History of PrEP Use That Complete the SHA and ISQ and Start APRETUDE | The SHA asked questions to determine if PrEP was right for me- Disagree | 0 Participants |
| DI - SSP | Number of PSPs With History of PrEP Use That Complete the SHA and ISQ and Start APRETUDE | Have you ever taken oral PrEP- Missing | 11 Participants |
| DI - SSP | Number of PSPs With History of PrEP Use That Complete the SHA and ISQ and Start APRETUDE | The SHA asked questions to determine if PrEP was right for me- Neither agree nor disagree | 5 Participants |
| DI - SSP | Number of PSPs With History of PrEP Use That Complete the SHA and ISQ and Start APRETUDE | Have you ever taken oral PrEP- Prefer not to answer | 1 Participants |
| DI - SSP | Number of PSPs With History of PrEP Use That Complete the SHA and ISQ and Start APRETUDE | The SHA asked questions to determine if PrEP was right for me- Agree | 19 Participants |
| DI - SSP | Number of PSPs With History of PrEP Use That Complete the SHA and ISQ and Start APRETUDE | The SHA asked questions to determine if PrEP was right for me- Completely disagree | 2 Participants |
| DI - SSP | Number of PSPs With History of PrEP Use That Complete the SHA and ISQ and Start APRETUDE | The SHA asked questions to determine if PrEP was right for me- Completely Agree | 13 Participants |
| DI - SSP | Number of PSPs With History of PrEP Use That Complete the SHA and ISQ and Start APRETUDE | Have you ever taken oral PrEP- Yes | 5 Participants |
| RI - SSP | Number of PSPs With History of PrEP Use That Complete the SHA and ISQ and Start APRETUDE | The SHA asked questions to determine if PrEP was right for me- Completely Agree | 15 Participants |
| RI - SSP | Number of PSPs With History of PrEP Use That Complete the SHA and ISQ and Start APRETUDE | Have you ever taken oral PrEP- Yes | 1 Participants |
| RI - SSP | Number of PSPs With History of PrEP Use That Complete the SHA and ISQ and Start APRETUDE | Have you ever taken oral PrEP- No | 0 Participants |
| RI - SSP | Number of PSPs With History of PrEP Use That Complete the SHA and ISQ and Start APRETUDE | Have you ever taken oral PrEP- Prefer not to answer | 0 Participants |
| RI - SSP | Number of PSPs With History of PrEP Use That Complete the SHA and ISQ and Start APRETUDE | Have you ever taken oral PrEP- Missing | 11 Participants |
| RI - SSP | Number of PSPs With History of PrEP Use That Complete the SHA and ISQ and Start APRETUDE | The SHA asked questions to determine if PrEP was right for me- Completely disagree | 1 Participants |
| RI - SSP | Number of PSPs With History of PrEP Use That Complete the SHA and ISQ and Start APRETUDE | The SHA asked questions to determine if PrEP was right for me- Disagree | 1 Participants |
| RI - SSP | Number of PSPs With History of PrEP Use That Complete the SHA and ISQ and Start APRETUDE | The SHA asked questions to determine if PrEP was right for me- Neither agree nor disagree | 7 Participants |
| RI - SSP | Number of PSPs With History of PrEP Use That Complete the SHA and ISQ and Start APRETUDE | The SHA asked questions to determine if PrEP was right for me- Agree | 11 Participants |
Secondary
Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline
The ISQ uses a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs were asked about the helpfulness of various knowledge materials used in learning about APRETUDE.
Time frame: At Baseline (Month 1)
Population: Analysis was performed on PSPs who were administered at least one dose of APRETUDE injection or of CAB tablets for PrEP and who completed at least one ISQ survey at any timepoint. All questions were not administered to both RI and DI arms; hence only participants with data available for the specified analysis at the specified time points were included.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | Let's talk about HIV & PrEP video that gives key facts about HIV and PrEP options (DI) | Very helpful | 32 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | Getting Started Brochure that gives an overview of how to get started with APRETUDE | Helpful | 27 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | Getting Started Brochure that gives an overview of how to get started with APRETUDE | Somewhat helpful | 12 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | Getting Started Brochure that gives an overview of how to get started with APRETUDE | A little helpful | 7 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | Getting Started Brochure that gives an overview of how to get started with APRETUDE | Not at all helpful | 1 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | Getting Started Brochure that gives an overview of how to get started with APRETUDE | Did not use it | 23 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | Getting Started Brochure that gives an overview of how to get started with APRETUDE | Missing | 12 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | Patient Brochure that helps understand the process of receiving APRETUDE injections | Very helpful | 37 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | Patient Brochure that helps understand the process of receiving APRETUDE injections | Helpful | 27 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | Patient Brochure that helps understand the process of receiving APRETUDE injections | Somewhat helpful | 11 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | Patient Brochure that helps understand the process of receiving APRETUDE injections | A little helpful | 5 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | Patient Brochure that helps understand the process of receiving APRETUDE injections | Not at all helpful | 1 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | Patient Brochure that helps understand the process of receiving APRETUDE injections | Did not use it | 24 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | Patient Brochure that helps understand the process of receiving APRETUDE injections | Missing | 12 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | Getting Started Brochure that gives an overview of how to get started with APRETUDE | Very helpful | 35 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | Let's talk about HIV & PrEP video that gives key facts about HIV and PrEP options (DI) | Helpful | 25 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | Let's talk about HIV & PrEP video that gives key facts about HIV and PrEP options (DI) | Somewhat helpful | 8 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | Let's talk about HIV & PrEP video that gives key facts about HIV and PrEP options (DI) | A little helpful | 7 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | Let's talk about HIV & PrEP video that gives key facts about HIV and PrEP options (DI) | Not at all helpful | 1 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | Let's talk about HIV & PrEP video that gives key facts about HIV and PrEP options (DI) | Did not use it | 32 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | Let's talk about HIV & PrEP video that gives key facts about HIV and PrEP options (DI) | Missing | 12 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | The APRETUDE Myths and Facts video, the game show video addressing common myths about APRETUDE (DI) | Very helpful | 30 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | The APRETUDE Myths and Facts video, the game show video addressing common myths about APRETUDE (DI) | Helpful | 22 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | The APRETUDE Myths and Facts video, the game show video addressing common myths about APRETUDE (DI) | Somewhat helpful | 8 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | The APRETUDE Myths and Facts video, the game show video addressing common myths about APRETUDE (DI) | A little helpful | 6 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | The APRETUDE Myths and Facts video, the game show video addressing common myths about APRETUDE (DI) | Not at all helpful | 1 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | The APRETUDE Myths and Facts video, the game show video addressing common myths about APRETUDE (DI) | Did not use it | 38 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | The APRETUDE Myths and Facts video, the game show video addressing common myths about APRETUDE (DI) | Missing | 12 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | The What to Expect video which shows what to expect during the APRETUDE process (DI) | Very helpful | 30 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | The What to Expect video which shows what to expect during the APRETUDE process (DI) | Helpful | 25 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | The What to Expect video which shows what to expect during the APRETUDE process (DI) | Somewhat helpful | 7 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | The What to Expect video which shows what to expect during the APRETUDE process (DI) | A little helpful | 5 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | The What to Expect video which shows what to expect during the APRETUDE process (DI) | Not at all helpful | 0 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | The What to Expect video which shows what to expect during the APRETUDE process (DI) | Did not use it | 38 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | The What to Expect video which shows what to expect during the APRETUDE process (DI) | Missing | 12 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | The ViiV Connect Video tells about the ViiV Connect program and frequently asked questions (DI) | Very helpful | 26 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | The ViiV Connect Video tells about the ViiV Connect program and frequently asked questions (DI) | Helpful | 23 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | The ViiV Connect Video tells about the ViiV Connect program and frequently asked questions (DI) | Somewhat helpful | 9 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | The ViiV Connect Video tells about the ViiV Connect program and frequently asked questions (DI) | A little helpful | 6 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | The ViiV Connect Video tells about the ViiV Connect program and frequently asked questions (DI) | Not at all helpful | 0 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | The ViiV Connect Video tells about the ViiV Connect program and frequently asked questions (DI) | Did not use it | 41 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | The ViiV Connect Video tells about the ViiV Connect program and frequently asked questions (DI) | Missing | 12 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | The study website to access APRETDUE information (RI) | Very helpful | 0 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | The study website to access APRETDUE information (RI) | Helpful | 0 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | The study website to access APRETDUE information (RI) | Somewhat helpful | 0 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | The study website to access APRETDUE information (RI) | A little helpful | 0 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | The study website to access APRETDUE information (RI) | Not at all helpful | 0 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | The study website to access APRETDUE information (RI) | Did not use it | 0 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | The study website to access APRETDUE information (RI) | Missing | 0 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | The study app to access APRETUDE information (DI) | Very helpful | 23 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | The study app to access APRETUDE information (DI) | Helpful | 22 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | The study app to access APRETUDE information (DI) | Somewhat helpful | 12 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | The study app to access APRETUDE information (DI) | A little helpful | 6 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | The study app to access APRETUDE information (DI) | Not at all helpful | 0 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | The study app to access APRETUDE information (DI) | Did not use it | 42 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | The study app to access APRETUDE information (DI) | Missing | 12 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | The study app to access APRETUDE information (DI) | A little helpful | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | Getting Started Brochure that gives an overview of how to get started with APRETUDE | Very helpful | 32 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | The What to Expect video which shows what to expect during the APRETUDE process (DI) | Very helpful | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | Getting Started Brochure that gives an overview of how to get started with APRETUDE | Helpful | 23 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | The study website to access APRETDUE information (RI) | Very helpful | 28 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | Getting Started Brochure that gives an overview of how to get started with APRETUDE | Somewhat helpful | 10 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | The What to Expect video which shows what to expect during the APRETUDE process (DI) | Helpful | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | Getting Started Brochure that gives an overview of how to get started with APRETUDE | A little helpful | 2 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | The study app to access APRETUDE information (DI) | Very helpful | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | Getting Started Brochure that gives an overview of how to get started with APRETUDE | Not at all helpful | 2 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | The What to Expect video which shows what to expect during the APRETUDE process (DI) | Somewhat helpful | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | Getting Started Brochure that gives an overview of how to get started with APRETUDE | Did not use it | 6 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | The study website to access APRETDUE information (RI) | Helpful | 19 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | Getting Started Brochure that gives an overview of how to get started with APRETUDE | Missing | 9 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | The What to Expect video which shows what to expect during the APRETUDE process (DI) | A little helpful | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | Patient Brochure that helps understand the process of receiving APRETUDE injections | Very helpful | 30 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | The study app to access APRETUDE information (DI) | Did not use it | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | Patient Brochure that helps understand the process of receiving APRETUDE injections | Helpful | 25 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | The What to Expect video which shows what to expect during the APRETUDE process (DI) | Not at all helpful | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | Patient Brochure that helps understand the process of receiving APRETUDE injections | Somewhat helpful | 10 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | The study website to access APRETDUE information (RI) | Somewhat helpful | 13 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | Patient Brochure that helps understand the process of receiving APRETUDE injections | A little helpful | 3 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | The What to Expect video which shows what to expect during the APRETUDE process (DI) | Did not use it | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | Patient Brochure that helps understand the process of receiving APRETUDE injections | Not at all helpful | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | The study app to access APRETUDE information (DI) | Helpful | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | Patient Brochure that helps understand the process of receiving APRETUDE injections | Did not use it | 7 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | The What to Expect video which shows what to expect during the APRETUDE process (DI) | Missing | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | Patient Brochure that helps understand the process of receiving APRETUDE injections | Missing | 9 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | The study website to access APRETDUE information (RI) | A little helpful | 4 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | Let's talk about HIV & PrEP video that gives key facts about HIV and PrEP options (DI) | Very helpful | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | The ViiV Connect Video tells about the ViiV Connect program and frequently asked questions (DI) | Very helpful | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | Let's talk about HIV & PrEP video that gives key facts about HIV and PrEP options (DI) | Helpful | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | The study app to access APRETUDE information (DI) | Not at all helpful | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | Let's talk about HIV & PrEP video that gives key facts about HIV and PrEP options (DI) | Somewhat helpful | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | The ViiV Connect Video tells about the ViiV Connect program and frequently asked questions (DI) | Helpful | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | Let's talk about HIV & PrEP video that gives key facts about HIV and PrEP options (DI) | A little helpful | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | The study website to access APRETDUE information (RI) | Not at all helpful | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | Let's talk about HIV & PrEP video that gives key facts about HIV and PrEP options (DI) | Not at all helpful | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | The ViiV Connect Video tells about the ViiV Connect program and frequently asked questions (DI) | Somewhat helpful | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | Let's talk about HIV & PrEP video that gives key facts about HIV and PrEP options (DI) | Did not use it | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | The study app to access APRETUDE information (DI) | Somewhat helpful | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | Let's talk about HIV & PrEP video that gives key facts about HIV and PrEP options (DI) | Missing | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | The ViiV Connect Video tells about the ViiV Connect program and frequently asked questions (DI) | A little helpful | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | The APRETUDE Myths and Facts video, the game show video addressing common myths about APRETUDE (DI) | Very helpful | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | The study website to access APRETDUE information (RI) | Did not use it | 11 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | The APRETUDE Myths and Facts video, the game show video addressing common myths about APRETUDE (DI) | Helpful | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | The ViiV Connect Video tells about the ViiV Connect program and frequently asked questions (DI) | Not at all helpful | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | The APRETUDE Myths and Facts video, the game show video addressing common myths about APRETUDE (DI) | Somewhat helpful | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | The study app to access APRETUDE information (DI) | Missing | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | The APRETUDE Myths and Facts video, the game show video addressing common myths about APRETUDE (DI) | A little helpful | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | The ViiV Connect Video tells about the ViiV Connect program and frequently asked questions (DI) | Did not use it | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | The APRETUDE Myths and Facts video, the game show video addressing common myths about APRETUDE (DI) | Not at all helpful | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | The study website to access APRETDUE information (RI) | Missing | 9 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | The APRETUDE Myths and Facts video, the game show video addressing common myths about APRETUDE (DI) | Did not use it | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | The ViiV Connect Video tells about the ViiV Connect program and frequently asked questions (DI) | Missing | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Baseline | The APRETUDE Myths and Facts video, the game show video addressing common myths about APRETUDE (DI) | Missing | 0 Participants |
Secondary
Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12
The ISQ uses a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs were asked about the helpfulness of various knowledge materials used in learning about APRETUDE. Timeframe for evaluation of this outcome measure is M12 (equivalent to M13 for PSPs who received OLI).
Time frame: At Month 12
Population: Analysis was performed on PSPs who were administered at least one dose of APRETUDE injection or of CAB tablets for PrEP and who completed at least one ISQ survey at any timepoint. All questions were not administered to both RI and DI arms; hence only participants with data available for the specified analysis at the specified time points were included.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | The study app/website to access APRETUDE information - the Pillar Spot (DI) | Missing | 40 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | Patient Brochure helps understand the process of receiving APRETUDE injections | A little helpful | 4 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | Patient Brochure helps understand the process of receiving APRETUDE injections | Not at all helpful | 0 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | Patient Brochure helps understand the process of receiving APRETUDE injections | Missing | 40 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | Let's talk about HIV & PrEP video gives key facts about HIV and PrEP options (DI) | Missing | 40 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | The What to Expect video which shows what to expect during the APRETUDE process (DI) | Very helpful | 26 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | The What to Expect video which shows what to expect during the APRETUDE process (DI) | Somewhat helpful | 6 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | The What to Expect video which shows what to expect during the APRETUDE process (DI) | A little helpful | 5 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | The What to Expect video which shows what to expect during the APRETUDE process (DI) | Not at all helpful | 0 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | The What to Expect video which shows what to expect during the APRETUDE process (DI) | Did not receive/Did not use it | 23 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | The ViiV Connect Video tells about the ViiV Connect program and frequently asked questions (DI) | Very helpful | 22 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | The ViiV Connect Video tells about the ViiV Connect program and frequently asked questions (DI) | A little helpful | 3 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | The ViiV Connect Video tells about the ViiV Connect program and frequently asked questions (DI) | Not at all helpful | 0 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | The study website to access APRETDUE information (RI) | Somewhat helpful | 0 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | The study app/website to access APRETUDE information - the Pillar Spot (DI) | Very helpful | 22 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | The study app/website to access APRETUDE information - the Pillar Spot (DI) | Helpful | 19 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | The study app/website to access APRETUDE information - the Pillar Spot (DI) | Somewhat helpful | 9 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | The study app/website to access APRETUDE information - the Pillar Spot (DI) | Did not receive/Did not use it | 18 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | Patient Brochure helps understand the process of receiving APRETUDE injections | Somewhat helpful | 6 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | Important safety information document details safety information relating to APRETUDE | Very helpful | 22 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | Important safety information document details safety information relating to APRETUDE | Not at all helpful | 0 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | Important safety information document details safety information relating to APRETUDE | Did not receive/Did not use it | 22 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | Important facts document details important facts relating to APRETUDE | Helpful | 23 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | Important facts document details important facts relating to APRETUDE | A little helpful | 1 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | Important facts document details important facts relating to APRETUDE | Not at all helpful | 0 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | Important facts document details important facts relating to APRETUDE | Did not receive/Did not use it | 24 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | A flyer on PrEP options | Somewhat helpful | 8 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | A flyer on PrEP options | Not at all helpful | 1 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | A flyer on PrEP options | Missing | 40 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | The ViiV Connect Video tells about the ViiV Connect program and frequently asked questions (DI) | Did not receive/Did not use it | 24 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | The ViiV Connect Video tells about the ViiV Connect program and frequently asked questions (DI) | Missing | 40 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | The study website to access APRETDUE information (RI) | Very helpful | 0 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | The study website to access APRETDUE information (RI) | Helpful | 0 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | The study website to access APRETDUE information (RI) | A little helpful | 0 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | The study website to access APRETDUE information (RI) | Not at all helpful | 0 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | The study website to access APRETDUE information (RI) | Did not receive/Did not use it | 0 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | The study website to access APRETDUE information (RI) | Missing | 0 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | The study app/website to access APRETUDE information - the Pillar Spot (DI) | A little helpful | 8 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | The study app/website to access APRETUDE information - the Pillar Spot (DI) | Not at all helpful | 1 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | Important safety information document details safety information relating to APRETUDE | Helpful | 22 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | Important safety information document details safety information relating to APRETUDE | Somewhat helpful | 9 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | Important safety information document details safety information relating to APRETUDE | A little helpful | 2 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | Important safety information document details safety information relating to APRETUDE | Missing | 40 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | Important facts document details important facts relating to APRETUDE | Very helpful | 21 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | Getting Started Brochure that gives an overview of how to get started with APRETUDE | Very helpful | 23 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | Getting Started Brochure that gives an overview of how to get started with APRETUDE | Helpful | 26 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | Getting Started Brochure that gives an overview of how to get started with APRETUDE | Somewhat helpful | 5 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | Getting Started Brochure that gives an overview of how to get started with APRETUDE | A little helpful | 5 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | Getting Started Brochure that gives an overview of how to get started with APRETUDE | Not at all helpful | 0 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | Getting Started Brochure that gives an overview of how to get started with APRETUDE | Did not receive/Did not use it | 18 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | Getting Started Brochure that gives an overview of how to get started with APRETUDE | Missing | 40 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | Patient Brochure helps understand the process of receiving APRETUDE injections | Very helpful | 22 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | Patient Brochure helps understand the process of receiving APRETUDE injections | Helpful | 27 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | Patient Brochure helps understand the process of receiving APRETUDE injections | Did not receive/Did not use it | 18 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | Let's talk about HIV & PrEP video gives key facts about HIV and PrEP options (DI) | Very helpful | 25 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | Let's talk about HIV & PrEP video gives key facts about HIV and PrEP options (DI) | Helpful | 20 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | Let's talk about HIV & PrEP video gives key facts about HIV and PrEP options (DI) | Somewhat helpful | 6 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | Let's talk about HIV & PrEP video gives key facts about HIV and PrEP options (DI) | A little helpful | 5 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | Let's talk about HIV & PrEP video gives key facts about HIV and PrEP options (DI) | Not at all helpful | 0 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | Let's talk about HIV & PrEP video gives key facts about HIV and PrEP options (DI) | Did not receive/Did not use it | 21 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | The APRETUDE Myths and Facts video, the game show video addressing common myths about APRETUDE (DI) | Very helpful | 25 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | The APRETUDE Myths and Facts video, the game show video addressing common myths about APRETUDE (DI) | Helpful | 18 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | The APRETUDE Myths and Facts video, the game show video addressing common myths about APRETUDE (DI) | Somewhat helpful | 7 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | The APRETUDE Myths and Facts video, the game show video addressing common myths about APRETUDE (DI) | A little helpful | 3 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | The APRETUDE Myths and Facts video, the game show video addressing common myths about APRETUDE (DI) | Not at all helpful | 0 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | The APRETUDE Myths and Facts video, the game show video addressing common myths about APRETUDE (DI) | Did not receive/Did not use it | 24 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | The APRETUDE Myths and Facts video, the game show video addressing common myths about APRETUDE (DI) | Missing | 40 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | The What to Expect video which shows what to expect during the APRETUDE process (DI) | Helpful | 17 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | The What to Expect video which shows what to expect during the APRETUDE process (DI) | Missing | 40 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | The ViiV Connect Video tells about the ViiV Connect program and frequently asked questions (DI) | Helpful | 20 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | The ViiV Connect Video tells about the ViiV Connect program and frequently asked questions (DI) | Somewhat helpful | 8 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | Important facts document details important facts relating to APRETUDE | Somewhat helpful | 8 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | Important facts document details important facts relating to APRETUDE | Missing | 40 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | A flyer on PrEP options | Very helpful | 22 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | A flyer on PrEP options | Helpful | 17 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | A flyer on PrEP options | A little helpful | 2 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | A flyer on PrEP options | Did not receive/Did not use it | 27 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | The study app/website to access APRETUDE information - the Pillar Spot (DI) | A little helpful | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | The APRETUDE Myths and Facts video, the game show video addressing common myths about APRETUDE (DI) | Not at all helpful | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | Patient Brochure helps understand the process of receiving APRETUDE injections | A little helpful | 3 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | Let's talk about HIV & PrEP video gives key facts about HIV and PrEP options (DI) | Somewhat helpful | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | Important safety information document details safety information relating to APRETUDE | Helpful | 17 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | Let's talk about HIV & PrEP video gives key facts about HIV and PrEP options (DI) | Helpful | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | The ViiV Connect Video tells about the ViiV Connect program and frequently asked questions (DI) | Helpful | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | The APRETUDE Myths and Facts video, the game show video addressing common myths about APRETUDE (DI) | Missing | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | Important safety information document details safety information relating to APRETUDE | Somewhat helpful | 9 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | The What to Expect video which shows what to expect during the APRETUDE process (DI) | Very helpful | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | The What to Expect video which shows what to expect during the APRETUDE process (DI) | Helpful | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | Let's talk about HIV & PrEP video gives key facts about HIV and PrEP options (DI) | A little helpful | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | The What to Expect video which shows what to expect during the APRETUDE process (DI) | Somewhat helpful | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | Important safety information document details safety information relating to APRETUDE | Did not receive/Did not use it | 12 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | The What to Expect video which shows what to expect during the APRETUDE process (DI) | A little helpful | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | The APRETUDE Myths and Facts video, the game show video addressing common myths about APRETUDE (DI) | Did not receive/Did not use it | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | The What to Expect video which shows what to expect during the APRETUDE process (DI) | Not at all helpful | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | Important safety information document details safety information relating to APRETUDE | Missing | 21 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | The What to Expect video which shows what to expect during the APRETUDE process (DI) | Did not receive/Did not use it | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | Let's talk about HIV & PrEP video gives key facts about HIV and PrEP options (DI) | Not at all helpful | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | The ViiV Connect Video tells about the ViiV Connect program and frequently asked questions (DI) | Somewhat helpful | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | Important facts document details important facts relating to APRETUDE | Very helpful | 20 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | The ViiV Connect Video tells about the ViiV Connect program and frequently asked questions (DI) | A little helpful | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | Important facts document details important facts relating to APRETUDE | Missing | 21 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | The ViiV Connect Video tells about the ViiV Connect program and frequently asked questions (DI) | Not at all helpful | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | Getting Started Brochure that gives an overview of how to get started with APRETUDE | Very helpful | 24 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | The study website to access APRETDUE information (RI) | Somewhat helpful | 7 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | The study website to access APRETDUE information (RI) | A little helpful | 7 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | The study website to access APRETDUE information (RI) | Missing | 21 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | Let's talk about HIV & PrEP video gives key facts about HIV and PrEP options (DI) | Did not receive/Did not use it | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | The study app/website to access APRETUDE information - the Pillar Spot (DI) | Very helpful | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | Getting Started Brochure that gives an overview of how to get started with APRETUDE | Helpful | 14 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | The study app/website to access APRETUDE information - the Pillar Spot (DI) | Helpful | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | Let's talk about HIV & PrEP video gives key facts about HIV and PrEP options (DI) | Missing | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | The study app/website to access APRETUDE information - the Pillar Spot (DI) | Somewhat helpful | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | The study app/website to access APRETUDE information - the Pillar Spot (DI) | Not at all helpful | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | Getting Started Brochure that gives an overview of how to get started with APRETUDE | Somewhat helpful | 8 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | The study app/website to access APRETUDE information - the Pillar Spot (DI) | Did not receive/Did not use it | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | A flyer on PrEP options | Somewhat helpful | 7 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | The study app/website to access APRETUDE information - the Pillar Spot (DI) | Missing | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | Getting Started Brochure that gives an overview of how to get started with APRETUDE | A little helpful | 2 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | Important safety information document details safety information relating to APRETUDE | Very helpful | 19 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | Important safety information document details safety information relating to APRETUDE | A little helpful | 5 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | The APRETUDE Myths and Facts video, the game show video addressing common myths about APRETUDE (DI) | Very helpful | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | Important safety information document details safety information relating to APRETUDE | Not at all helpful | 1 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | Getting Started Brochure that gives an overview of how to get started with APRETUDE | Not at all helpful | 2 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | Important facts document details important facts relating to APRETUDE | Somewhat helpful | 7 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | Important facts document details important facts relating to APRETUDE | Helpful | 16 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | Getting Started Brochure that gives an overview of how to get started with APRETUDE | Did not receive/Did not use it | 13 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | Important facts document details important facts relating to APRETUDE | A little helpful | 6 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | The APRETUDE Myths and Facts video, the game show video addressing common myths about APRETUDE (DI) | Helpful | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | Important facts document details important facts relating to APRETUDE | Not at all helpful | 1 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | Getting Started Brochure that gives an overview of how to get started with APRETUDE | Missing | 21 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | Important facts document details important facts relating to APRETUDE | Did not receive/Did not use it | 13 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | A flyer on PrEP options | Helpful | 14 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | The What to Expect video which shows what to expect during the APRETUDE process (DI) | Missing | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | A flyer on PrEP options | A little helpful | 5 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | Patient Brochure helps understand the process of receiving APRETUDE injections | Very helpful | 22 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | A flyer on PrEP options | Not at all helpful | 1 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | A flyer on PrEP options | Did not receive/Did not use it | 17 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | The APRETUDE Myths and Facts video, the game show video addressing common myths about APRETUDE (DI) | Somewhat helpful | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | A flyer on PrEP options | Missing | 21 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | Patient Brochure helps understand the process of receiving APRETUDE injections | Helpful | 14 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | The ViiV Connect Video tells about the ViiV Connect program and frequently asked questions (DI) | Did not receive/Did not use it | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | Patient Brochure helps understand the process of receiving APRETUDE injections | Somewhat helpful | 10 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | The ViiV Connect Video tells about the ViiV Connect program and frequently asked questions (DI) | Missing | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | Patient Brochure helps understand the process of receiving APRETUDE injections | Not at all helpful | 1 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | The study website to access APRETDUE information (RI) | Very helpful | 19 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | The ViiV Connect Video tells about the ViiV Connect program and frequently asked questions (DI) | Very helpful | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | The study website to access APRETDUE information (RI) | Helpful | 16 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | Patient Brochure helps understand the process of receiving APRETUDE injections | Did not receive/Did not use it | 13 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | Patient Brochure helps understand the process of receiving APRETUDE injections | Missing | 21 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | The study website to access APRETDUE information (RI) | Not at all helpful | 1 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | The APRETUDE Myths and Facts video, the game show video addressing common myths about APRETUDE (DI) | A little helpful | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | The study website to access APRETDUE information (RI) | Did not receive/Did not use it | 13 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | Let's talk about HIV & PrEP video gives key facts about HIV and PrEP options (DI) | Very helpful | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 12 | A flyer on PrEP options | Very helpful | 19 Participants |
Secondary
Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6
The ISQ uses a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs were asked about the helpfulness of various knowledge materials used in learning about APRETUDE. Timeframe for evaluation of this outcome measure is M6 (equivalent to M7 for PSPs who received OLI).
Time frame: At Month 6
Population: Analysis was performed on PSPs who were administered at least one dose of APRETUDE injection or of CAB tablets for PrEP and who completed at least one ISQ survey at any timepoint. All questions were not administered to both RI and DI arms; hence only participants with data available for the specified analysis at the specified time points were included.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | Important safety information document details safety information relating to APRETUDE | Did not receive/Did not use it | 28 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | Let's talk about HIV & PrEP video gives key facts about HIV and PrEP options (DI) | Did not receive/Did not use it | 32 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | Important safety information document details safety information relating to APRETUDE | A little helpful | 8 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | Let's talk about HIV & PrEP video gives key facts about HIV and PrEP options (DI) | Missing | 25 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | The study app to access APRETUDE information (DI) | Very helpful | 24 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | The APRETUDE Myths and Facts video, the game show video addressing common myths about APRETUDE (DI) | Very helpful | 23 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | Getting Started Brochure that gives an overview of how to get started with APRETUDE | Very helpful | 28 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | The APRETUDE Myths and Facts video, the game show video addressing common myths about APRETUDE (DI) | Helpful | 20 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | The study website to access APRETDUE information (RI) | Somewhat helpful | 0 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | The APRETUDE Myths and Facts video, the game show video addressing common myths about APRETUDE (DI) | Somewhat helpful | 8 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | Getting Started Brochure that gives an overview of how to get started with APRETUDE | Helpful | 17 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | The APRETUDE Myths and Facts video, the game show video addressing common myths about APRETUDE (DI) | A little helpful | 5 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | The study app to access APRETUDE information (DI) | Helpful | 17 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | The APRETUDE Myths and Facts video, the game show video addressing common myths about APRETUDE (DI) | Not at all helpful | 2 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | Getting Started Brochure that gives an overview of how to get started with APRETUDE | Somewhat helpful | 18 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | The APRETUDE Myths and Facts video, the game show video addressing common myths about APRETUDE (DI) | Did not receive/Did not use it | 34 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | A flyer on PrEP options (DI) | Not at all helpful | 2 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | The APRETUDE Myths and Facts video, the game show video addressing common myths about APRETUDE (DI) | Missing | 25 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | Getting Started Brochure that gives an overview of how to get started with APRETUDE | A little helpful | 3 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | The What to Expect video which shows what to expect during the APRETUDE process (DI) | Very helpful | 26 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | The study app to access APRETUDE information (DI) | Somewhat helpful | 15 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | The What to Expect video which shows what to expect during the APRETUDE process (DI) | Helpful | 16 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | Getting Started Brochure that gives an overview of how to get started with APRETUDE | Not at all helpful | 1 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | The What to Expect video which shows what to expect during the APRETUDE process (DI) | Somewhat helpful | 9 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | The study website to access APRETDUE information (RI) | A little helpful | 0 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | The What to Expect video which shows what to expect during the APRETUDE process (DI) | A little helpful | 4 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | Getting Started Brochure that gives an overview of how to get started with APRETUDE | Did not receive/Did not use it | 25 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | The What to Expect video which shows what to expect during the APRETUDE process (DI) | Not at all helpful | 1 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | The study app to access APRETUDE information (DI) | A little helpful | 8 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | The What to Expect video which shows what to expect during the APRETUDE process (DI) | Did not receive/Did not use it | 36 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | Getting Started Brochure that gives an overview of how to get started with APRETUDE | Missing | 25 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | The What to Expect video which shows what to expect during the APRETUDE process (DI) | Missing | 25 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | The study website to access APRETDUE information (RI) | Very helpful | 0 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | The ViiV Connect Video tells about the ViiV Connect program and frequently asked questions (DI) | Very helpful | 22 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | Patient Brochure helps understand the process of receiving APRETUDE injections | Very helpful | 29 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | The ViiV Connect Video tells about the ViiV Connect program and frequently asked questions (DI) | Helpful | 15 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | The study app to access APRETUDE information (DI) | Not at all helpful | 5 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | The ViiV Connect Video tells about the ViiV Connect program and frequently asked questions (DI) | Somewhat helpful | 10 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | The ViiV Connect Video tells about the ViiV Connect program and frequently asked questions (DI) | A little helpful | 6 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | Patient Brochure helps understand the process of receiving APRETUDE injections | Helpful | 17 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | The ViiV Connect Video tells about the ViiV Connect program and frequently asked questions (DI) | Not at all helpful | 1 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | The study website to access APRETDUE information (RI) | Not at all helpful | 0 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | The ViiV Connect Video tells about the ViiV Connect program and frequently asked questions (DI) | Did not receive/Did not use it | 38 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | Patient Brochure helps understand the process of receiving APRETUDE injections | Somewhat helpful | 14 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | The ViiV Connect Video tells about the ViiV Connect program and frequently asked questions (DI) | Missing | 25 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | The study app to access APRETUDE information (DI) | Did not receive/Did not use it | 23 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | Patient Brochure helps understand the process of receiving APRETUDE injections | A little helpful | 2 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | Important safety information document details safety information relating to APRETUDE | Not at all helpful | 2 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | Important safety information document details safety information relating to APRETUDE | Missing | 25 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | Patient Brochure helps understand the process of receiving APRETUDE injections | Not at all helpful | 1 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | Important facts document details important facts relating to APRETUDE | Very helpful | 26 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | The study app to access APRETUDE information (DI) | Missing | 25 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | Important facts document details important facts relating to APRETUDE | Helpful | 19 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | Patient Brochure helps understand the process of receiving APRETUDE injections | Did not receive/Did not use it | 29 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | Important facts document details important facts relating to APRETUDE | Somewhat helpful | 10 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | The study website to access APRETDUE information (RI) | Did not receive/Did not use it | 0 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | Important facts document details important facts relating to APRETUDE | A little helpful | 4 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | Patient Brochure helps understand the process of receiving APRETUDE injections | Missing | 25 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | Important facts document details important facts relating to APRETUDE | Not at all helpful | 1 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | Important safety information document details safety information relating to APRETUDE | Very helpful | 26 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | Important facts document details important facts relating to APRETUDE | Did not receive/Did not use it | 32 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | Let's talk about HIV & PrEP video gives key facts about HIV and PrEP options (DI) | Very helpful | 27 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | Important facts document details important facts relating to APRETUDE | Missing | 25 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | The study website to access APRETDUE information (RI) | Helpful | 0 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | A flyer on PrEP options (DI) | Very helpful | 22 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | Let's talk about HIV & PrEP video gives key facts about HIV and PrEP options (DI) | Helpful | 19 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | A flyer on PrEP options (DI) | Helpful | 16 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | Important safety information document details safety information relating to APRETUDE | Helpful | 17 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | A flyer on PrEP options (DI) | Somewhat helpful | 9 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | Let's talk about HIV & PrEP video gives key facts about HIV and PrEP options (DI) | Somewhat helpful | 8 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | A flyer on PrEP options (DI) | A little helpful | 2 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | The study website to access APRETDUE information (RI) | Missing | 0 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | Let's talk about HIV & PrEP video gives key facts about HIV and PrEP options (DI) | A little helpful | 5 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | A flyer on PrEP options (DI) | Did not receive/Did not use it | 41 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | Important safety information document details safety information relating to APRETUDE | Somewhat helpful | 11 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | A flyer on PrEP options (DI) | Missing | 25 Participants |
| DI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | Let's talk about HIV & PrEP video gives key facts about HIV and PrEP options (DI) | Not at all helpful | 1 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | A flyer on PrEP options (DI) | Missing | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | The study website to access APRETDUE information (RI) | Very helpful | 21 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | The study website to access APRETDUE information (RI) | Helpful | 16 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | The study website to access APRETDUE information (RI) | Somewhat helpful | 8 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | The study website to access APRETDUE information (RI) | A little helpful | 2 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | The study website to access APRETDUE information (RI) | Not at all helpful | 1 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | The study website to access APRETDUE information (RI) | Did not receive/Did not use it | 15 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | The study website to access APRETDUE information (RI) | Missing | 21 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | The study app to access APRETUDE information (DI) | Very helpful | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | The study app to access APRETUDE information (DI) | Helpful | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | The study app to access APRETUDE information (DI) | Somewhat helpful | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | The study app to access APRETUDE information (DI) | A little helpful | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | The study app to access APRETUDE information (DI) | Not at all helpful | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | The study app to access APRETUDE information (DI) | Did not receive/Did not use it | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | The study app to access APRETUDE information (DI) | Missing | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | Important safety information document details safety information relating to APRETUDE | Very helpful | 19 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | Important safety information document details safety information relating to APRETUDE | Helpful | 18 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | Important safety information document details safety information relating to APRETUDE | Somewhat helpful | 9 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | Important safety information document details safety information relating to APRETUDE | A little helpful | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | Getting Started Brochure that gives an overview of how to get started with APRETUDE | Very helpful | 24 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | Getting Started Brochure that gives an overview of how to get started with APRETUDE | Helpful | 17 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | Getting Started Brochure that gives an overview of how to get started with APRETUDE | Somewhat helpful | 6 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | Getting Started Brochure that gives an overview of how to get started with APRETUDE | A little helpful | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | Getting Started Brochure that gives an overview of how to get started with APRETUDE | Not at all helpful | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | Getting Started Brochure that gives an overview of how to get started with APRETUDE | Did not receive/Did not use it | 16 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | Getting Started Brochure that gives an overview of how to get started with APRETUDE | Missing | 21 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | Patient Brochure helps understand the process of receiving APRETUDE injections | Very helpful | 21 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | Patient Brochure helps understand the process of receiving APRETUDE injections | Helpful | 18 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | Patient Brochure helps understand the process of receiving APRETUDE injections | Somewhat helpful | 7 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | Patient Brochure helps understand the process of receiving APRETUDE injections | A little helpful | 1 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | Patient Brochure helps understand the process of receiving APRETUDE injections | Not at all helpful | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | Patient Brochure helps understand the process of receiving APRETUDE injections | Did not receive/Did not use it | 16 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | Patient Brochure helps understand the process of receiving APRETUDE injections | Missing | 21 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | Let's talk about HIV & PrEP video gives key facts about HIV and PrEP options (DI) | Very helpful | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | Let's talk about HIV & PrEP video gives key facts about HIV and PrEP options (DI) | Helpful | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | Let's talk about HIV & PrEP video gives key facts about HIV and PrEP options (DI) | Somewhat helpful | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | Let's talk about HIV & PrEP video gives key facts about HIV and PrEP options (DI) | A little helpful | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | Let's talk about HIV & PrEP video gives key facts about HIV and PrEP options (DI) | Not at all helpful | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | Let's talk about HIV & PrEP video gives key facts about HIV and PrEP options (DI) | Did not receive/Did not use it | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | Let's talk about HIV & PrEP video gives key facts about HIV and PrEP options (DI) | Missing | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | The APRETUDE Myths and Facts video, the game show video addressing common myths about APRETUDE (DI) | Very helpful | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | The APRETUDE Myths and Facts video, the game show video addressing common myths about APRETUDE (DI) | Helpful | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | The APRETUDE Myths and Facts video, the game show video addressing common myths about APRETUDE (DI) | Somewhat helpful | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | The APRETUDE Myths and Facts video, the game show video addressing common myths about APRETUDE (DI) | A little helpful | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | The APRETUDE Myths and Facts video, the game show video addressing common myths about APRETUDE (DI) | Not at all helpful | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | The APRETUDE Myths and Facts video, the game show video addressing common myths about APRETUDE (DI) | Did not receive/Did not use it | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | The APRETUDE Myths and Facts video, the game show video addressing common myths about APRETUDE (DI) | Missing | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | The What to Expect video which shows what to expect during the APRETUDE process (DI) | Very helpful | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | The What to Expect video which shows what to expect during the APRETUDE process (DI) | Helpful | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | The What to Expect video which shows what to expect during the APRETUDE process (DI) | Somewhat helpful | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | The What to Expect video which shows what to expect during the APRETUDE process (DI) | A little helpful | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | The What to Expect video which shows what to expect during the APRETUDE process (DI) | Not at all helpful | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | The What to Expect video which shows what to expect during the APRETUDE process (DI) | Did not receive/Did not use it | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | The What to Expect video which shows what to expect during the APRETUDE process (DI) | Missing | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | The ViiV Connect Video tells about the ViiV Connect program and frequently asked questions (DI) | Very helpful | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | The ViiV Connect Video tells about the ViiV Connect program and frequently asked questions (DI) | Helpful | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | The ViiV Connect Video tells about the ViiV Connect program and frequently asked questions (DI) | A little helpful | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | The ViiV Connect Video tells about the ViiV Connect program and frequently asked questions (DI) | Not at all helpful | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | The ViiV Connect Video tells about the ViiV Connect program and frequently asked questions (DI) | Did not receive/Did not use it | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | The ViiV Connect Video tells about the ViiV Connect program and frequently asked questions (DI) | Missing | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | Important safety information document details safety information relating to APRETUDE | Not at all helpful | 1 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | Important safety information document details safety information relating to APRETUDE | Did not receive/Did not use it | 16 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | Important safety information document details safety information relating to APRETUDE | Missing | 21 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | Important facts document details important facts relating to APRETUDE | Very helpful | 19 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | Important facts document details important facts relating to APRETUDE | Helpful | 17 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | Important facts document details important facts relating to APRETUDE | Somewhat helpful | 9 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | Important facts document details important facts relating to APRETUDE | A little helpful | 1 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | Important facts document details important facts relating to APRETUDE | Not at all helpful | 1 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | Important facts document details important facts relating to APRETUDE | Did not receive/Did not use it | 16 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | Important facts document details important facts relating to APRETUDE | Missing | 21 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | A flyer on PrEP options (DI) | Very helpful | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | A flyer on PrEP options (DI) | Helpful | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | A flyer on PrEP options (DI) | Somewhat helpful | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | A flyer on PrEP options (DI) | A little helpful | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | A flyer on PrEP options (DI) | Not at all helpful | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | A flyer on PrEP options (DI) | Did not receive/Did not use it | 0 Participants |
| RI - SSP | Number of PSPs With ISQ Responses Regarding Utility of Implementation Strategy at Month 6 | The ViiV Connect Video tells about the ViiV Connect program and frequently asked questions (DI) | Somewhat helpful | 0 Participants |
Secondary
Number of PSPs With Perceptions of Barriers to Fidelity to Injections
Perceptions of utility of implementation strategies and facilitators and barriers to acceptability of RI and DI measured from themes emerging from Proctor and CFIR guided semi-structured qualitative interviews. In this outcome measure, PSPs reported several challenges related to incorporating APRETUDE into their daily lives. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).
Time frame: Up to Month 12
Population: Analysis was performed on PSPs who were administered at least one dose of APRETUDE injection or of CAB tablets for PrEP and who completed an interview at the specified time point. Only those participants with data available for the specified analysis at the specified time points were included.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| DI - SSP | Number of PSPs With Perceptions of Barriers to Fidelity to Injections | Work challenges | 2 Participants |
| DI - SSP | Number of PSPs With Perceptions of Barriers to Fidelity to Injections | Discomfort | 14 Participants |
| DI - SSP | Number of PSPs With Perceptions of Barriers to Fidelity to Injections | Clinic challenges | 4 Participants |
| RI - SSP | Number of PSPs With Perceptions of Barriers to Fidelity to Injections | Discomfort | 11 Participants |
| RI - SSP | Number of PSPs With Perceptions of Barriers to Fidelity to Injections | Clinic challenges | 6 Participants |
| RI - SSP | Number of PSPs With Perceptions of Barriers to Fidelity to Injections | Work challenges | 5 Participants |
Secondary
Number of PSPs With Perceptions of Facilitators to Fidelity to Injections
Perceptions of utility of implementation strategies and facilitators and barriers to acceptability of RI and DI measured from themes emerging from Proctor and CFIR guided semi-structured qualitative interviews. In this outcome measure, PSPs provided their insights into how APRETUDE has been incorporated into their daily lives, including factors that supported its delivery. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).
Time frame: Up to Month 12
Population: Analysis was performed on PSPs who were administered at least one dose of APRETUDE injection or of CAB tablets for PrEP and who completed an interview at the specified time point. Only those participants with data available for the specified analysis at the specified time points were included.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| DI - SSP | Number of PSPs With Perceptions of Facilitators to Fidelity to Injections | Booking appointments in advance | 13 Participants |
| DI - SSP | Number of PSPs With Perceptions of Facilitators to Fidelity to Injections | No transportation issues | 5 Participants |
| DI - SSP | Number of PSPs With Perceptions of Facilitators to Fidelity to Injections | Clinic staff supporting incorporation of APRETUDE into schedule | 15 Participants |
| DI - SSP | Number of PSPs With Perceptions of Facilitators to Fidelity to Injections | Good fit with work schedule | 13 Participants |
| DI - SSP | Number of PSPs With Perceptions of Facilitators to Fidelity to Injections | Easy to fit into life (convenience, etc.) | 16 Participants |
| DI - SSP | Number of PSPs With Perceptions of Facilitators to Fidelity to Injections | Clinic hours aligned with patient schedule | 11 Participants |
| DI - SSP | Number of PSPs With Perceptions of Facilitators to Fidelity to Injections | APRETUDE Fitting life | 23 Participants |
| RI - SSP | Number of PSPs With Perceptions of Facilitators to Fidelity to Injections | Clinic hours aligned with patient schedule | 4 Participants |
| RI - SSP | Number of PSPs With Perceptions of Facilitators to Fidelity to Injections | APRETUDE Fitting life | 20 Participants |
| RI - SSP | Number of PSPs With Perceptions of Facilitators to Fidelity to Injections | Clinic staff supporting incorporation of APRETUDE into schedule | 10 Participants |
| RI - SSP | Number of PSPs With Perceptions of Facilitators to Fidelity to Injections | Booking appointments in advance | 11 Participants |
| RI - SSP | Number of PSPs With Perceptions of Facilitators to Fidelity to Injections | Easy to fit into life (convenience, etc.) | 8 Participants |
| RI - SSP | Number of PSPs With Perceptions of Facilitators to Fidelity to Injections | No transportation issues | 15 Participants |
| RI - SSP | Number of PSPs With Perceptions of Facilitators to Fidelity to Injections | Good fit with work schedule | 6 Participants |
Secondary
Number of PSPs With Perceptions of SHA
Perceptions of the sexual health assessment (SHA) among PSPs were measured from themes emerging from Proctor and CFIR guided semi-structured qualitative interviews. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).
Time frame: Up to Month 12
Population: Analysis was performed on PSPs who were administered at least one dose of APRETUDE injection or of CAB tablets for PrEP and who completed an interview at the specified time point. This question was not administered to the RI arm; hence they were not assessed. Only those participants with data available at the specified time points were analyzed.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| DI - SSP | Number of PSPs With Perceptions of SHA | SHA was received by PSPs | 16 Participants |
| DI - SSP | Number of PSPs With Perceptions of SHA | SHA was not received by PSPs | 3 Participants |
| DI - SSP | Number of PSPs With Perceptions of SHA | SHA received/not received- Missing | 4 Participants |
| DI - SSP | Number of PSPs With Perceptions of SHA | SHA found useful by PSPs | 15 Participants |
| DI - SSP | Number of PSPs With Perceptions of SHA | SHA not found useful by PSPs | 0 Participants |
| DI - SSP | Number of PSPs With Perceptions of SHA | SHA found useful/not useful- Missing | 1 Participants |
| RI - SSP | Number of PSPs With Perceptions of SHA | SHA not found useful by PSPs | 0 Participants |
| RI - SSP | Number of PSPs With Perceptions of SHA | SHA was received by PSPs | 0 Participants |
| RI - SSP | Number of PSPs With Perceptions of SHA | SHA found useful by PSPs | 0 Participants |
| RI - SSP | Number of PSPs With Perceptions of SHA | SHA was not received by PSPs | 0 Participants |
| RI - SSP | Number of PSPs With Perceptions of SHA | SHA found useful/not useful- Missing | 0 Participants |
| RI - SSP | Number of PSPs With Perceptions of SHA | SHA received/not received- Missing | 0 Participants |
Secondary
Number of PSPs With Reasons for Choosing and Switching to APRETUDE Assessed by ISQs
The ISQ uses a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs answered ISQ regarding reasons for choosing to take APRETUDE. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).
Time frame: Up to Month 12
Population: Analysis was performed on PSPs who were administered at least one dose of APRETUDE injection or of CAB tablets for PrEP and who completed at least one ISQ survey at any timepoint. Only those participants with data available for the specified analysis at the specified time points were included.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| DI - SSP | Number of PSPs With Reasons for Choosing and Switching to APRETUDE Assessed by ISQs | I won't have to remember to take PrEP everyday | 63 Participants |
| DI - SSP | Number of PSPs With Reasons for Choosing and Switching to APRETUDE Assessed by ISQs | I want to try a new approach and see if it fits into my life | 43 Participants |
| DI - SSP | Number of PSPs With Reasons for Choosing and Switching to APRETUDE Assessed by ISQs | I do not have to worry or stress about missing a dose like oral PrEP | 55 Participants |
| DI - SSP | Number of PSPs With Reasons for Choosing and Switching to APRETUDE Assessed by ISQs | I will not have to worry about HIV every day | 43 Participants |
| DI - SSP | Number of PSPs With Reasons for Choosing and Switching to APRETUDE Assessed by ISQs | I want a prevention option that is more convenient for my life | 66 Participants |
| RI - SSP | Number of PSPs With Reasons for Choosing and Switching to APRETUDE Assessed by ISQs | I will not have to worry about HIV every day | 27 Participants |
| RI - SSP | Number of PSPs With Reasons for Choosing and Switching to APRETUDE Assessed by ISQs | I want a prevention option that is more convenient for my life | 49 Participants |
| RI - SSP | Number of PSPs With Reasons for Choosing and Switching to APRETUDE Assessed by ISQs | I won't have to remember to take PrEP everyday | 45 Participants |
| RI - SSP | Number of PSPs With Reasons for Choosing and Switching to APRETUDE Assessed by ISQs | I do not have to worry or stress about missing a dose like oral PrEP | 47 Participants |
| RI - SSP | Number of PSPs With Reasons for Choosing and Switching to APRETUDE Assessed by ISQs | I want to try a new approach and see if it fits into my life | 27 Participants |
Secondary
Number of PSPs With Reasons for Choosing and Switching to APRETUDE Assessed by Semi-Structured Interviews (SSIs)
Reasons for choosing and switching to APRETUDE were measured from themes emerging from Proctor and CFIR guided semi-structured qualitative interviews among PSPs. In this outcome measure, PSPs shared previous oral PrEP experiences, comparisons of other forms of PrEP to APRETUDE, and reasons for preferring APRETUDE. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).
Time frame: Up to Month 12
Population: Analysis was performed on all PSPs who were administered at least one dose of APRETUDE injection or of CAB tablets for PrEP and who completed an interview at the specified time point. Only those participants with data available for the specified analysis at the specified time points were included.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| DI - SSP | Number of PSPs With Reasons for Choosing and Switching to APRETUDE Assessed by Semi-Structured Interviews (SSIs) | APRETUDE differences to oral PrEP: Better adherence and feeling more protected | 4 Participants |
| DI - SSP | Number of PSPs With Reasons for Choosing and Switching to APRETUDE Assessed by Semi-Structured Interviews (SSIs) | APRETUDE differences to oral PrEP: Less/ No side effects related to oral PrEP | 0 Participants |
| DI - SSP | Number of PSPs With Reasons for Choosing and Switching to APRETUDE Assessed by Semi-Structured Interviews (SSIs) | Oral PrEP used: Side effects of oral PrEP | 6 Participants |
| DI - SSP | Number of PSPs With Reasons for Choosing and Switching to APRETUDE Assessed by Semi-Structured Interviews (SSIs) | Prefer APRETUDE over Oral PrEP: More convenient | 14 Participants |
| DI - SSP | Number of PSPs With Reasons for Choosing and Switching to APRETUDE Assessed by Semi-Structured Interviews (SSIs) | APRETUDE differences to oral PrEP: APRETUDE More convenient than Oral | 6 Participants |
| DI - SSP | Number of PSPs With Reasons for Choosing and Switching to APRETUDE Assessed by Semi-Structured Interviews (SSIs) | Prefer APRETUDE over Oral PrEP: Less/No side effects | 1 Participants |
| DI - SSP | Number of PSPs With Reasons for Choosing and Switching to APRETUDE Assessed by Semi-Structured Interviews (SSIs) | Oral PrEP used: Challenges remembering to take pill every day | 16 Participants |
| RI - SSP | Number of PSPs With Reasons for Choosing and Switching to APRETUDE Assessed by Semi-Structured Interviews (SSIs) | Prefer APRETUDE over Oral PrEP: Less/No side effects | 5 Participants |
| RI - SSP | Number of PSPs With Reasons for Choosing and Switching to APRETUDE Assessed by Semi-Structured Interviews (SSIs) | Oral PrEP used: Challenges remembering to take pill every day | 11 Participants |
| RI - SSP | Number of PSPs With Reasons for Choosing and Switching to APRETUDE Assessed by Semi-Structured Interviews (SSIs) | Oral PrEP used: Side effects of oral PrEP | 3 Participants |
| RI - SSP | Number of PSPs With Reasons for Choosing and Switching to APRETUDE Assessed by Semi-Structured Interviews (SSIs) | APRETUDE differences to oral PrEP: Better adherence and feeling more protected | 5 Participants |
| RI - SSP | Number of PSPs With Reasons for Choosing and Switching to APRETUDE Assessed by Semi-Structured Interviews (SSIs) | APRETUDE differences to oral PrEP: APRETUDE More convenient than Oral | 2 Participants |
| RI - SSP | Number of PSPs With Reasons for Choosing and Switching to APRETUDE Assessed by Semi-Structured Interviews (SSIs) | APRETUDE differences to oral PrEP: Less/ No side effects related to oral PrEP | 5 Participants |
| RI - SSP | Number of PSPs With Reasons for Choosing and Switching to APRETUDE Assessed by Semi-Structured Interviews (SSIs) | Prefer APRETUDE over Oral PrEP: More convenient | 8 Participants |
Secondary
Number of PSPs With Responses to Implementation Science Questionnaire (ISQ) Regarding Their Feelings About Taking APRETUDE
The implementation science questionnaire (ISQ) used a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs indicated their feelings about taking APRETUDE. Timeframe for evaluation of this outcome measure is BL, M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI).
Time frame: At Baseline (Month 1), Month 6 and Month 12
Population: Analysis was performed on PSPs who were administered at least one dose of APRETUDE injection or of CAB tablets for PrEP and who completed at least one ISQ survey at any timepoint. Only those participants with data available for the specified analysis at the specified time points were included.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| DI - SSP | Number of PSPs With Responses to Implementation Science Questionnaire (ISQ) Regarding Their Feelings About Taking APRETUDE | At Month 6 - Overall, how are you feeling about taking APRETUDE? | Neither positive nor negative | 2 Participants |
| DI - SSP | Number of PSPs With Responses to Implementation Science Questionnaire (ISQ) Regarding Their Feelings About Taking APRETUDE | At Baseline - Overall, how are you feeling about taking APRETUDE? | Somewhat negative | 0 Participants |
| DI - SSP | Number of PSPs With Responses to Implementation Science Questionnaire (ISQ) Regarding Their Feelings About Taking APRETUDE | At Month 6 - Overall, how are you feeling about taking APRETUDE? | Somewhat negative | 2 Participants |
| DI - SSP | Number of PSPs With Responses to Implementation Science Questionnaire (ISQ) Regarding Their Feelings About Taking APRETUDE | At Baseline - Overall, how are you feeling about taking APRETUDE? | Somewhat Positive | 19 Participants |
| DI - SSP | Number of PSPs With Responses to Implementation Science Questionnaire (ISQ) Regarding Their Feelings About Taking APRETUDE | At Month 6 - Overall, how are you feeling about taking APRETUDE? | Very negative | 0 Participants |
| DI - SSP | Number of PSPs With Responses to Implementation Science Questionnaire (ISQ) Regarding Their Feelings About Taking APRETUDE | At Baseline - Overall, how are you feeling about taking APRETUDE? | Very negative | 0 Participants |
| DI - SSP | Number of PSPs With Responses to Implementation Science Questionnaire (ISQ) Regarding Their Feelings About Taking APRETUDE | At Month 6 - Overall, how are you feeling about taking APRETUDE? | Missing | 25 Participants |
| DI - SSP | Number of PSPs With Responses to Implementation Science Questionnaire (ISQ) Regarding Their Feelings About Taking APRETUDE | At Baseline - Overall, how are you feeling about taking APRETUDE? | Very Positive | 79 Participants |
| DI - SSP | Number of PSPs With Responses to Implementation Science Questionnaire (ISQ) Regarding Their Feelings About Taking APRETUDE | At Month 12 - Overall, how are you feeling about taking APRETUDE? | Very Positive | 66 Participants |
| DI - SSP | Number of PSPs With Responses to Implementation Science Questionnaire (ISQ) Regarding Their Feelings About Taking APRETUDE | At Baseline - Overall, how are you feeling about taking APRETUDE? | Missing | 12 Participants |
| DI - SSP | Number of PSPs With Responses to Implementation Science Questionnaire (ISQ) Regarding Their Feelings About Taking APRETUDE | At Month 12 - Overall, how are you feeling about taking APRETUDE? | Somewhat Positive | 10 Participants |
| DI - SSP | Number of PSPs With Responses to Implementation Science Questionnaire (ISQ) Regarding Their Feelings About Taking APRETUDE | At Baseline - Overall, how are you feeling about taking APRETUDE? | Neither positive nor negative | 7 Participants |
| DI - SSP | Number of PSPs With Responses to Implementation Science Questionnaire (ISQ) Regarding Their Feelings About Taking APRETUDE | At Month 12 - Overall, how are you feeling about taking APRETUDE? | Neither positive nor negative | 0 Participants |
| DI - SSP | Number of PSPs With Responses to Implementation Science Questionnaire (ISQ) Regarding Their Feelings About Taking APRETUDE | At Month 6 - Overall, how are you feeling about taking APRETUDE? | Very Positive | 72 Participants |
| DI - SSP | Number of PSPs With Responses to Implementation Science Questionnaire (ISQ) Regarding Their Feelings About Taking APRETUDE | At Month 12 - Overall, how are you feeling about taking APRETUDE? | Somewhat negative | 1 Participants |
| DI - SSP | Number of PSPs With Responses to Implementation Science Questionnaire (ISQ) Regarding Their Feelings About Taking APRETUDE | At Month 6 - Overall, how are you feeling about taking APRETUDE? | Somewhat Positive | 16 Participants |
| DI - SSP | Number of PSPs With Responses to Implementation Science Questionnaire (ISQ) Regarding Their Feelings About Taking APRETUDE | At Month 12 - Overall, how are you feeling about taking APRETUDE? | Missing | 40 Participants |
| DI - SSP | Number of PSPs With Responses to Implementation Science Questionnaire (ISQ) Regarding Their Feelings About Taking APRETUDE | At Month 12 - Overall, how are you feeling about taking APRETUDE? | Very negative | 0 Participants |
| RI - SSP | Number of PSPs With Responses to Implementation Science Questionnaire (ISQ) Regarding Their Feelings About Taking APRETUDE | At Month 12 - Overall, how are you feeling about taking APRETUDE? | Missing | 21 Participants |
| RI - SSP | Number of PSPs With Responses to Implementation Science Questionnaire (ISQ) Regarding Their Feelings About Taking APRETUDE | At Month 12 - Overall, how are you feeling about taking APRETUDE? | Somewhat negative | 0 Participants |
| RI - SSP | Number of PSPs With Responses to Implementation Science Questionnaire (ISQ) Regarding Their Feelings About Taking APRETUDE | At Baseline - Overall, how are you feeling about taking APRETUDE? | Very Positive | 64 Participants |
| RI - SSP | Number of PSPs With Responses to Implementation Science Questionnaire (ISQ) Regarding Their Feelings About Taking APRETUDE | At Baseline - Overall, how are you feeling about taking APRETUDE? | Somewhat Positive | 10 Participants |
| RI - SSP | Number of PSPs With Responses to Implementation Science Questionnaire (ISQ) Regarding Their Feelings About Taking APRETUDE | At Baseline - Overall, how are you feeling about taking APRETUDE? | Neither positive nor negative | 1 Participants |
| RI - SSP | Number of PSPs With Responses to Implementation Science Questionnaire (ISQ) Regarding Their Feelings About Taking APRETUDE | At Baseline - Overall, how are you feeling about taking APRETUDE? | Somewhat negative | 0 Participants |
| RI - SSP | Number of PSPs With Responses to Implementation Science Questionnaire (ISQ) Regarding Their Feelings About Taking APRETUDE | At Baseline - Overall, how are you feeling about taking APRETUDE? | Very negative | 0 Participants |
| RI - SSP | Number of PSPs With Responses to Implementation Science Questionnaire (ISQ) Regarding Their Feelings About Taking APRETUDE | At Baseline - Overall, how are you feeling about taking APRETUDE? | Missing | 9 Participants |
| RI - SSP | Number of PSPs With Responses to Implementation Science Questionnaire (ISQ) Regarding Their Feelings About Taking APRETUDE | At Month 6 - Overall, how are you feeling about taking APRETUDE? | Somewhat Positive | 9 Participants |
| RI - SSP | Number of PSPs With Responses to Implementation Science Questionnaire (ISQ) Regarding Their Feelings About Taking APRETUDE | At Month 6 - Overall, how are you feeling about taking APRETUDE? | Neither positive nor negative | 1 Participants |
| RI - SSP | Number of PSPs With Responses to Implementation Science Questionnaire (ISQ) Regarding Their Feelings About Taking APRETUDE | At Month 6 - Overall, how are you feeling about taking APRETUDE? | Somewhat negative | 1 Participants |
| RI - SSP | Number of PSPs With Responses to Implementation Science Questionnaire (ISQ) Regarding Their Feelings About Taking APRETUDE | At Month 6 - Overall, how are you feeling about taking APRETUDE? | Very negative | 0 Participants |
| RI - SSP | Number of PSPs With Responses to Implementation Science Questionnaire (ISQ) Regarding Their Feelings About Taking APRETUDE | At Month 6 - Overall, how are you feeling about taking APRETUDE? | Missing | 21 Participants |
| RI - SSP | Number of PSPs With Responses to Implementation Science Questionnaire (ISQ) Regarding Their Feelings About Taking APRETUDE | At Month 12 - Overall, how are you feeling about taking APRETUDE? | Very Positive | 55 Participants |
| RI - SSP | Number of PSPs With Responses to Implementation Science Questionnaire (ISQ) Regarding Their Feelings About Taking APRETUDE | At Month 12 - Overall, how are you feeling about taking APRETUDE? | Somewhat Positive | 7 Participants |
| RI - SSP | Number of PSPs With Responses to Implementation Science Questionnaire (ISQ) Regarding Their Feelings About Taking APRETUDE | At Month 12 - Overall, how are you feeling about taking APRETUDE? | Neither positive nor negative | 1 Participants |
| RI - SSP | Number of PSPs With Responses to Implementation Science Questionnaire (ISQ) Regarding Their Feelings About Taking APRETUDE | At Month 12 - Overall, how are you feeling about taking APRETUDE? | Very negative | 0 Participants |
| RI - SSP | Number of PSPs With Responses to Implementation Science Questionnaire (ISQ) Regarding Their Feelings About Taking APRETUDE | At Month 6 - Overall, how are you feeling about taking APRETUDE? | Very Positive | 52 Participants |
Secondary
Number of PSPs With Responses to ISQs Regarding Acceptability of Coming to Clinic for APRETUDE Injection
The ISQ used a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs indicated how acceptable it was for them to go to the clinic for APRETUDE injections. Timeframe for evaluation of this outcome measure is BL, M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI).
Time frame: At Baseline (Month 1), Month 6 and Month 12
Population: Analysis was performed on PSPs who were administered at least one dose of APRETUDE injection or of CAB tablets for PrEP and who completed at least one ISQ survey at any timepoint. Only those participants with data available for the specified analysis at the specified time points were included.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| DI - SSP | Number of PSPs With Responses to ISQs Regarding Acceptability of Coming to Clinic for APRETUDE Injection | At Baseline - How acceptable is coming to the clinic every 2 months for an injection? | A little acceptable | 4 Participants |
| DI - SSP | Number of PSPs With Responses to ISQs Regarding Acceptability of Coming to Clinic for APRETUDE Injection | At Month 6 - How acceptable is coming to the clinic every 2 months for an injection? | A little acceptable | 3 Participants |
| DI - SSP | Number of PSPs With Responses to ISQs Regarding Acceptability of Coming to Clinic for APRETUDE Injection | At Baseline - How acceptable is coming to the clinic every 2 months for an injection? | Acceptable | 31 Participants |
| DI - SSP | Number of PSPs With Responses to ISQs Regarding Acceptability of Coming to Clinic for APRETUDE Injection | At Month 6 - How acceptable is coming to the clinic every 2 months for an injection? | Not at all acceptable | 1 Participants |
| DI - SSP | Number of PSPs With Responses to ISQs Regarding Acceptability of Coming to Clinic for APRETUDE Injection | At Baseline - How acceptable is coming to the clinic every 2 months for an injection? | Not at all acceptable | 0 Participants |
| DI - SSP | Number of PSPs With Responses to ISQs Regarding Acceptability of Coming to Clinic for APRETUDE Injection | At Month 6 - How acceptable is coming to the clinic every 2 months for an injection? | Missing | 0 Participants |
| DI - SSP | Number of PSPs With Responses to ISQs Regarding Acceptability of Coming to Clinic for APRETUDE Injection | At Baseline - How acceptable is coming to the clinic every 2 months for an injection? | Very acceptable | 60 Participants |
| DI - SSP | Number of PSPs With Responses to ISQs Regarding Acceptability of Coming to Clinic for APRETUDE Injection | At Month 12 - How acceptable is coming to the clinic every 2 months for an injection? | Very acceptable | 41 Participants |
| DI - SSP | Number of PSPs With Responses to ISQs Regarding Acceptability of Coming to Clinic for APRETUDE Injection | At Baseline - How acceptable is coming to the clinic every 2 months for an injection? | Missing | 12 Participants |
| DI - SSP | Number of PSPs With Responses to ISQs Regarding Acceptability of Coming to Clinic for APRETUDE Injection | At Month 12 - How acceptable is coming to the clinic every 2 months for an injection? | Acceptable | 21 Participants |
| DI - SSP | Number of PSPs With Responses to ISQs Regarding Acceptability of Coming to Clinic for APRETUDE Injection | At Baseline - How acceptable is coming to the clinic every 2 months for an injection? | Somewhat acceptable | 10 Participants |
| DI - SSP | Number of PSPs With Responses to ISQs Regarding Acceptability of Coming to Clinic for APRETUDE Injection | At Month 6 - How acceptable is coming to the clinic every 2 months for an injection? | Very acceptable | 49 Participants |
| DI - SSP | Number of PSPs With Responses to ISQs Regarding Acceptability of Coming to Clinic for APRETUDE Injection | At Month 12 - How acceptable is coming to the clinic every 2 months for an injection? | A little acceptable | 3 Participants |
| DI - SSP | Number of PSPs With Responses to ISQs Regarding Acceptability of Coming to Clinic for APRETUDE Injection | At Month 12 - How acceptable is coming to the clinic every 2 months for an injection? | Somewhat acceptable | 11 Participants |
| DI - SSP | Number of PSPs With Responses to ISQs Regarding Acceptability of Coming to Clinic for APRETUDE Injection | At Month 12 - How acceptable is coming to the clinic every 2 months for an injection? | Not at all acceptable | 0 Participants |
| DI - SSP | Number of PSPs With Responses to ISQs Regarding Acceptability of Coming to Clinic for APRETUDE Injection | At Month 6 - How acceptable is coming to the clinic every 2 months for an injection? | Acceptable | 31 Participants |
| DI - SSP | Number of PSPs With Responses to ISQs Regarding Acceptability of Coming to Clinic for APRETUDE Injection | At Month 12 - How acceptable is coming to the clinic every 2 months for an injection? | Missing | 0 Participants |
| DI - SSP | Number of PSPs With Responses to ISQs Regarding Acceptability of Coming to Clinic for APRETUDE Injection | At Month 6 - How acceptable is coming to the clinic every 2 months for an injection? | Somewhat acceptable | 8 Participants |
| RI - SSP | Number of PSPs With Responses to ISQs Regarding Acceptability of Coming to Clinic for APRETUDE Injection | At Month 12 - How acceptable is coming to the clinic every 2 months for an injection? | Missing | 0 Participants |
| RI - SSP | Number of PSPs With Responses to ISQs Regarding Acceptability of Coming to Clinic for APRETUDE Injection | At Month 6 - How acceptable is coming to the clinic every 2 months for an injection? | Somewhat acceptable | 6 Participants |
| RI - SSP | Number of PSPs With Responses to ISQs Regarding Acceptability of Coming to Clinic for APRETUDE Injection | At Baseline - How acceptable is coming to the clinic every 2 months for an injection? | Very acceptable | 55 Participants |
| RI - SSP | Number of PSPs With Responses to ISQs Regarding Acceptability of Coming to Clinic for APRETUDE Injection | At Baseline - How acceptable is coming to the clinic every 2 months for an injection? | Acceptable | 19 Participants |
| RI - SSP | Number of PSPs With Responses to ISQs Regarding Acceptability of Coming to Clinic for APRETUDE Injection | At Baseline - How acceptable is coming to the clinic every 2 months for an injection? | Somewhat acceptable | 2 Participants |
| RI - SSP | Number of PSPs With Responses to ISQs Regarding Acceptability of Coming to Clinic for APRETUDE Injection | At Baseline - How acceptable is coming to the clinic every 2 months for an injection? | A little acceptable | 0 Participants |
| RI - SSP | Number of PSPs With Responses to ISQs Regarding Acceptability of Coming to Clinic for APRETUDE Injection | At Baseline - How acceptable is coming to the clinic every 2 months for an injection? | Not at all acceptable | 0 Participants |
| RI - SSP | Number of PSPs With Responses to ISQs Regarding Acceptability of Coming to Clinic for APRETUDE Injection | At Baseline - How acceptable is coming to the clinic every 2 months for an injection? | Missing | 8 Participants |
| RI - SSP | Number of PSPs With Responses to ISQs Regarding Acceptability of Coming to Clinic for APRETUDE Injection | At Month 6 - How acceptable is coming to the clinic every 2 months for an injection? | Very acceptable | 40 Participants |
| RI - SSP | Number of PSPs With Responses to ISQs Regarding Acceptability of Coming to Clinic for APRETUDE Injection | At Month 6 - How acceptable is coming to the clinic every 2 months for an injection? | Acceptable | 16 Participants |
| RI - SSP | Number of PSPs With Responses to ISQs Regarding Acceptability of Coming to Clinic for APRETUDE Injection | At Month 6 - How acceptable is coming to the clinic every 2 months for an injection? | A little acceptable | 0 Participants |
| RI - SSP | Number of PSPs With Responses to ISQs Regarding Acceptability of Coming to Clinic for APRETUDE Injection | At Month 6 - How acceptable is coming to the clinic every 2 months for an injection? | Not at all acceptable | 1 Participants |
| RI - SSP | Number of PSPs With Responses to ISQs Regarding Acceptability of Coming to Clinic for APRETUDE Injection | At Month 6 - How acceptable is coming to the clinic every 2 months for an injection? | Missing | 0 Participants |
| RI - SSP | Number of PSPs With Responses to ISQs Regarding Acceptability of Coming to Clinic for APRETUDE Injection | At Month 12 - How acceptable is coming to the clinic every 2 months for an injection? | Very acceptable | 39 Participants |
| RI - SSP | Number of PSPs With Responses to ISQs Regarding Acceptability of Coming to Clinic for APRETUDE Injection | At Month 12 - How acceptable is coming to the clinic every 2 months for an injection? | Acceptable | 18 Participants |
| RI - SSP | Number of PSPs With Responses to ISQs Regarding Acceptability of Coming to Clinic for APRETUDE Injection | At Month 12 - How acceptable is coming to the clinic every 2 months for an injection? | Somewhat acceptable | 5 Participants |
| RI - SSP | Number of PSPs With Responses to ISQs Regarding Acceptability of Coming to Clinic for APRETUDE Injection | At Month 12 - How acceptable is coming to the clinic every 2 months for an injection? | A little acceptable | 1 Participants |
| RI - SSP | Number of PSPs With Responses to ISQs Regarding Acceptability of Coming to Clinic for APRETUDE Injection | At Month 12 - How acceptable is coming to the clinic every 2 months for an injection? | Not at all acceptable | 0 Participants |
Secondary
Number of PSPs With Responses to the ISQs Regarding Appointment Rescheduling
The ISQ used a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs were asked about their opinion on ease or difficulty of rescheduling appointments at the clinic. Timeframe for evaluation of this outcome measure is M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI).
Time frame: At Month 6 and Month 12
Population: Analysis was performed on PSPs who were administered at least one dose of APRETUDE injection or of CAB tablets for PrEP and who completed at least one ISQ survey at any timepoint. Only those participants with data available for the specified analysis at the specified time points were included.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding Appointment Rescheduling | Month 6 - How easy or difficult is it to reschedule appointments for your injections? | Very easy | 44 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding Appointment Rescheduling | Month 6 - How easy or difficult is it to reschedule appointments for your injections? | Somewhat easy | 14 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding Appointment Rescheduling | Month 6 - How easy or difficult is it to reschedule appointments for your injections? | Neither easy nor difficult | 1 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding Appointment Rescheduling | Month 6 - How easy or difficult is it to reschedule appointments for your injections? | Somewhat difficult | 6 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding Appointment Rescheduling | Month 6 - How easy or difficult is it to reschedule appointments for your injections? | Very difficult | 3 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding Appointment Rescheduling | Month 6 - How easy or difficult is it to reschedule appointments for your injections? | I have not needed to reschedule any appointments | 25 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding Appointment Rescheduling | Month 12- How easy or difficult is it to reschedule appointments for your injections? | Very easy | 39 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding Appointment Rescheduling | Month 12- How easy or difficult is it to reschedule appointments for your injections? | Somewhat easy | 13 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding Appointment Rescheduling | Month 12- How easy or difficult is it to reschedule appointments for your injections? | Neither easy nor difficult | 4 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding Appointment Rescheduling | Month 12- How easy or difficult is it to reschedule appointments for your injections? | Somewhat difficult | 8 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding Appointment Rescheduling | Month 12- How easy or difficult is it to reschedule appointments for your injections? | Very difficult | 2 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding Appointment Rescheduling | Month 12- How easy or difficult is it to reschedule appointments for your injections? | I have not needed to reschedule any appointments | 10 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding Appointment Rescheduling | Month 12- How easy or difficult is it to reschedule appointments for your injections? | Very difficult | 1 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding Appointment Rescheduling | Month 6 - How easy or difficult is it to reschedule appointments for your injections? | Very easy | 25 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding Appointment Rescheduling | Month 12- How easy or difficult is it to reschedule appointments for your injections? | Very easy | 30 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding Appointment Rescheduling | Month 6 - How easy or difficult is it to reschedule appointments for your injections? | Somewhat easy | 17 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding Appointment Rescheduling | Month 12- How easy or difficult is it to reschedule appointments for your injections? | Somewhat difficult | 6 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding Appointment Rescheduling | Month 6 - How easy or difficult is it to reschedule appointments for your injections? | Neither easy nor difficult | 4 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding Appointment Rescheduling | Month 12- How easy or difficult is it to reschedule appointments for your injections? | Somewhat easy | 17 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding Appointment Rescheduling | Month 6 - How easy or difficult is it to reschedule appointments for your injections? | Somewhat difficult | 2 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding Appointment Rescheduling | Month 12- How easy or difficult is it to reschedule appointments for your injections? | I have not needed to reschedule any appointments | 5 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding Appointment Rescheduling | Month 6 - How easy or difficult is it to reschedule appointments for your injections? | Very difficult | 1 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding Appointment Rescheduling | Month 12- How easy or difficult is it to reschedule appointments for your injections? | Neither easy nor difficult | 4 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding Appointment Rescheduling | Month 6 - How easy or difficult is it to reschedule appointments for your injections? | I have not needed to reschedule any appointments | 14 Participants |
Secondary
Number of PSPs With Responses to the ISQs Regarding Appointment Scheduling
The ISQ used a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs were asked about their opinion on the ease or difficulty of scheduling appointments at the clinic. Timeframe for evaluation of this outcome measure is M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI).
Time frame: At Month 6 and Month 12
Population: Analysis was performed on PSPs who were administered at least one dose of APRETUDE injection or of CAB tablets for PrEP and who completed at least one ISQ survey at any timepoint. Only those participants with data available for the specified analysis at the specified time points were included.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding Appointment Scheduling | Month 6- How easy or difficult is it to schedule appointments for your injections? | Somewhat difficult | 6 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding Appointment Scheduling | Month 12- How easy or difficult is it to schedule appointments for your injections? | Very easy | 49 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding Appointment Scheduling | Month 6- How easy or difficult is it to schedule appointments for your injections? | Very easy | 60 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding Appointment Scheduling | Month 12- How easy or difficult is it to schedule appointments for your injections? | Somewhat easy | 15 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding Appointment Scheduling | Month 6- How easy or difficult is it to schedule appointments for your injections? | Very difficult | 2 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding Appointment Scheduling | Month 12- How easy or difficult is it to schedule appointments for your injections? | Neither easy nor difficult | 6 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding Appointment Scheduling | Month 6- How easy or difficult is it to schedule appointments for your injections? | Neither easy nor difficult | 5 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding Appointment Scheduling | Month 12- How easy or difficult is it to schedule appointments for your injections? | Somewhat difficult | 5 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding Appointment Scheduling | Month 12- How easy or difficult is it to schedule appointments for your injections? | Very difficult | 1 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding Appointment Scheduling | Month 6- How easy or difficult is it to schedule appointments for your injections? | I have not scheduled any appointments at the clinic/practice | 0 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding Appointment Scheduling | Month 12- How easy or difficult is it to schedule appointments for your injections? | I have not scheduled any appointments at the clinic/practice | 1 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding Appointment Scheduling | Month 6- How easy or difficult is it to schedule appointments for your injections? | Somewhat easy | 20 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding Appointment Scheduling | Month 12- How easy or difficult is it to schedule appointments for your injections? | Missing | 40 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding Appointment Scheduling | Month 6- How easy or difficult is it to schedule appointments for your injections? | Missing | 24 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding Appointment Scheduling | Month 12- How easy or difficult is it to schedule appointments for your injections? | Missing | 21 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding Appointment Scheduling | Month 6- How easy or difficult is it to schedule appointments for your injections? | Very easy | 46 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding Appointment Scheduling | Month 6- How easy or difficult is it to schedule appointments for your injections? | Somewhat easy | 13 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding Appointment Scheduling | Month 6- How easy or difficult is it to schedule appointments for your injections? | Neither easy nor difficult | 3 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding Appointment Scheduling | Month 6- How easy or difficult is it to schedule appointments for your injections? | Somewhat difficult | 1 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding Appointment Scheduling | Month 6- How easy or difficult is it to schedule appointments for your injections? | Very difficult | 0 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding Appointment Scheduling | Month 6- How easy or difficult is it to schedule appointments for your injections? | I have not scheduled any appointments at the clinic/practice | 0 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding Appointment Scheduling | Month 6- How easy or difficult is it to schedule appointments for your injections? | Missing | 21 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding Appointment Scheduling | Month 12- How easy or difficult is it to schedule appointments for your injections? | Very easy | 46 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding Appointment Scheduling | Month 12- How easy or difficult is it to schedule appointments for your injections? | Somewhat easy | 10 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding Appointment Scheduling | Month 12- How easy or difficult is it to schedule appointments for your injections? | Neither easy nor difficult | 4 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding Appointment Scheduling | Month 12- How easy or difficult is it to schedule appointments for your injections? | Very difficult | 1 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding Appointment Scheduling | Month 12- How easy or difficult is it to schedule appointments for your injections? | I have not scheduled any appointments at the clinic/practice | 0 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding Appointment Scheduling | Month 12- How easy or difficult is it to schedule appointments for your injections? | Somewhat difficult | 2 Participants |
Secondary
Number of PSPs With Responses to the ISQs Regarding Recommending APRETUDE
The ISQ used a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs indicated if they would recommend APRETUDE to others. Timeframe for evaluation of this outcome measure is M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI).
Time frame: At Month 6 and Month 12
Population: Analysis was performed on PSPs who were administered at least one dose of APRETUDE injection or of CAB tablets for PrEP and who completed at least one ISQ survey at any timepoint. Only those participants with data available for the specified analysis at the specified time points were included.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding Recommending APRETUDE | At Month 12 - I would recommend APRETUDE to other people who could benefit from it | Completely agree | 64 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding Recommending APRETUDE | At Month 6 - I would recommend APRETUDE to other people who could benefit from it | Disagree | 0 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding Recommending APRETUDE | At Month 12 - I would recommend APRETUDE to other people who could benefit from it | Agree | 12 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding Recommending APRETUDE | At Month 6 - I would recommend APRETUDE to other people who could benefit from it | Agree | 18 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding Recommending APRETUDE | At Month 12 - I would recommend APRETUDE to other people who could benefit from it | Neither agree nor disagree | 1 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding Recommending APRETUDE | At Month 6 - I would recommend APRETUDE to other people who could benefit from it | Completely disagree | 0 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding Recommending APRETUDE | At Month 12 - I would recommend APRETUDE to other people who could benefit from it | Disagree | 0 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding Recommending APRETUDE | At Month 6 - I would recommend APRETUDE to other people who could benefit from it | Completely agree | 72 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding Recommending APRETUDE | At Month 12 - I would recommend APRETUDE to other people who could benefit from it | Completely disagree | 0 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding Recommending APRETUDE | At Month 6 - I would recommend APRETUDE to other people who could benefit from it | Missing | 25 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding Recommending APRETUDE | At Month 12 - I would recommend APRETUDE to other people who could benefit from it | Missing | 40 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding Recommending APRETUDE | At Month 6 - I would recommend APRETUDE to other people who could benefit from it | Neither agree nor disagree | 2 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding Recommending APRETUDE | At Month 12 - I would recommend APRETUDE to other people who could benefit from it | Missing | 21 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding Recommending APRETUDE | At Month 6 - I would recommend APRETUDE to other people who could benefit from it | Completely agree | 49 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding Recommending APRETUDE | At Month 6 - I would recommend APRETUDE to other people who could benefit from it | Agree | 12 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding Recommending APRETUDE | At Month 6 - I would recommend APRETUDE to other people who could benefit from it | Disagree | 1 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding Recommending APRETUDE | At Month 6 - I would recommend APRETUDE to other people who could benefit from it | Completely disagree | 1 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding Recommending APRETUDE | At Month 6 - I would recommend APRETUDE to other people who could benefit from it | Missing | 21 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding Recommending APRETUDE | At Month 12 - I would recommend APRETUDE to other people who could benefit from it | Completely agree | 52 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding Recommending APRETUDE | At Month 12 - I would recommend APRETUDE to other people who could benefit from it | Agree | 9 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding Recommending APRETUDE | At Month 12 - I would recommend APRETUDE to other people who could benefit from it | Neither agree nor disagree | 2 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding Recommending APRETUDE | At Month 12 - I would recommend APRETUDE to other people who could benefit from it | Disagree | 0 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding Recommending APRETUDE | At Month 12 - I would recommend APRETUDE to other people who could benefit from it | Completely disagree | 0 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding Recommending APRETUDE | At Month 6 - I would recommend APRETUDE to other people who could benefit from it | Neither agree nor disagree | 0 Participants |
Secondary
Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE
The ISQ uses a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs were asked about the use of telehealth (TEL) services such as completing forms online, video chatting with their provider, getting reminders about their injection, or scheduling injection appointments online. Timeframe for evaluation of this outcome measure is BL, M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI).
Time frame: At Baseline (Month 1), Month 6 and Month 12
Population: Analysis was performed on PSPs who were administered at least one dose of APRETUDE injection or of CAB tablets for PrEP and who completed at least one ISQ survey at any timepoint. Only those participants with data available for the specified analysis at the specified time points were included.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Month 6- TEL services received: Nurse coming home to give the injection | I don't know | 0 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Month 6 - Have you used telehealth for any APRETUDE services in the last 6 months? | Missing | 23 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Month 6- TEL services received: Nurse coming home to give the injection | Missing | 1 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Month 6- TEL services received: Nurse coming home to give an HIV test | I don't know | 1 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Month 12 - Have you used telehealth for any APRETUDE services in the last 6 months? | Yes | 29 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Month 6 - Have you used telehealth for any APRETUDE services in the last 6 months? | Yes | 41 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Month 12 - Have you used telehealth for any APRETUDE services in the last 6 months? | No | 47 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Month 6- TEL services received: Nurse coming home to give an HIV test | Missing | 1 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Month 12 - Have you used telehealth for any APRETUDE services in the last 6 months? | I don't know | 1 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Month 6- TEL services received: Doctor ordering HIV test at a lab near home to take the test | Yes | 17 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Month 12 - Have you used telehealth for any APRETUDE services in the last 6 months? | Missing | 40 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Month 6- TEL services received: Receiving reminders about scheduled injection appointment | Yes | 36 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Month 12- TEL services received: Doctor ordering HIV test at a lab near home to take the test | Yes | 11 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Baseline- Have you used any of the telehealth care options that your clinic offers? | No | 14 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Month 12- TEL services received: Doctor ordering HIV test at a lab near home to take the test | No | 17 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Month 6- TEL services received: Receiving reminders about scheduled injection appointment | No | 4 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Month 12- TEL services received: Doctor ordering HIV test at a lab near home to take the test | I don't know | 1 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Month 6- TEL services received: Doctor ordering HIV test at a lab near home to take the test | No | 22 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Month 12- TEL services received: Doctor ordering HIV test at a lab near home to take the test | Missing | 0 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Month 6- TEL services received: Receiving reminders about scheduled injection appointment | I don't know | 0 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Month 12- TEL services received: Nurse coming home to give an HIV test | Yes | 3 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Month 6 - Have you used telehealth for any APRETUDE services in the last 6 months? | No | 49 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Month 12- TEL services received: Nurse coming home to give an HIV test | No | 26 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Month 6- TEL services received: Receiving reminders about scheduled injection appointment | Missing | 1 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Month 12- TEL services received: Nurse coming home to give an HIV test | I don't know | 0 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Month 6- TEL services received: Doctor ordering HIV test at a lab near home to take the test | I don't know | 1 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Month 12- TEL services received: Nurse coming home to give an HIV test | Missing | 0 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Month 6- TEL services received: Scheduling injection appointment online | Yes | 24 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Month 12- TEL services received: Receiving reminders about scheduled injection appointment | Yes | 28 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Baseline- Have you used any of the telehealth care options that your clinic offers? | Missing | 0 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Month 12- TEL services received: Receiving reminders about scheduled injection appointment | No | 1 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Month 6- TEL services received: Scheduling injection appointment online | No | 15 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Month 12- TEL services received: Receiving reminders about scheduled injection appointment | I don't know | 0 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Month 6- TEL services received: Doctor ordering HIV test at a lab near home to take the test | Missing | 1 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Month 12- TEL services received: Receiving reminders about scheduled injection appointment | Missing | 0 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Month 6- TEL services received: Scheduling injection appointment online | I don't know | 1 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Month 12- TEL services received: Scheduling injection appointment online | Yes | 16 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Month 6 - Have you used telehealth for any APRETUDE services in the last 6 months? | I don't know | 4 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Month 12- TEL services received: Scheduling injection appointment online | No | 13 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Month 6- TEL services received: Scheduling injection appointment online | Missing | 1 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Month 12- TEL services received: Scheduling injection appointment online | I don't know | 0 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Month 6- TEL services received: Nurse coming home to give an HIV test | Yes | 3 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Month 12- TEL services received: Scheduling injection appointment online | Missing | 0 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Month 6- TEL services received: Nurse coming home to give the injection | Yes | 2 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Month 12- TEL services received: Nurse coming home to give the injection | Yes | 3 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Baseline- Have you used any of the telehealth care options that your clinic offers? | I don't know | 0 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Month 12- TEL services received: Nurse coming home to give the injection | No | 25 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Month 6- TEL services received: Nurse coming home to give the injection | No | 38 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Month 12- TEL services received: Nurse coming home to give the injection | I don't know | 1 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Month 6- TEL services received: Nurse coming home to give an HIV test | No | 36 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Month 12- TEL services received: Nurse coming home to give the injection | Missing | 0 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Baseline- Have you used any of the telehealth care options that your clinic offers? | Yes | 72 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Month 12- TEL services received: Nurse coming home to give the injection | Missing | 0 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Baseline- Have you used any of the telehealth care options that your clinic offers? | Yes | 48 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Baseline- Have you used any of the telehealth care options that your clinic offers? | No | 10 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Baseline- Have you used any of the telehealth care options that your clinic offers? | I don't know | 0 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Baseline- Have you used any of the telehealth care options that your clinic offers? | Missing | 0 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Month 6 - Have you used telehealth for any APRETUDE services in the last 6 months? | Yes | 24 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Month 6 - Have you used telehealth for any APRETUDE services in the last 6 months? | No | 34 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Month 6 - Have you used telehealth for any APRETUDE services in the last 6 months? | I don't know | 7 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Month 6 - Have you used telehealth for any APRETUDE services in the last 6 months? | Missing | 19 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Month 6- TEL services received: Doctor ordering HIV test at a lab near home to take the test | Yes | 9 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Month 6- TEL services received: Doctor ordering HIV test at a lab near home to take the test | No | 14 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Month 6- TEL services received: Doctor ordering HIV test at a lab near home to take the test | I don't know | 1 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Month 6- TEL services received: Doctor ordering HIV test at a lab near home to take the test | Missing | 0 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Month 6- TEL services received: Nurse coming home to give an HIV test | Yes | 2 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Month 6- TEL services received: Nurse coming home to give an HIV test | No | 21 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Month 6- TEL services received: Nurse coming home to give an HIV test | I don't know | 1 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Month 6- TEL services received: Nurse coming home to give an HIV test | Missing | 0 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Month 6- TEL services received: Receiving reminders about scheduled injection appointment | Yes | 22 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Month 6- TEL services received: Receiving reminders about scheduled injection appointment | No | 1 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Month 6- TEL services received: Receiving reminders about scheduled injection appointment | I don't know | 1 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Month 6- TEL services received: Receiving reminders about scheduled injection appointment | Missing | 0 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Month 6- TEL services received: Scheduling injection appointment online | Yes | 15 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Month 6- TEL services received: Scheduling injection appointment online | No | 8 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Month 6- TEL services received: Scheduling injection appointment online | I don't know | 1 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Month 6- TEL services received: Scheduling injection appointment online | Missing | 0 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Month 6- TEL services received: Nurse coming home to give the injection | Yes | 2 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Month 6- TEL services received: Nurse coming home to give the injection | No | 21 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Month 6- TEL services received: Nurse coming home to give the injection | I don't know | 1 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Month 6- TEL services received: Nurse coming home to give the injection | Missing | 0 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Month 12 - Have you used telehealth for any APRETUDE services in the last 6 months? | Yes | 25 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Month 12 - Have you used telehealth for any APRETUDE services in the last 6 months? | No | 38 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Month 12 - Have you used telehealth for any APRETUDE services in the last 6 months? | I don't know | 0 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Month 12 - Have you used telehealth for any APRETUDE services in the last 6 months? | Missing | 21 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Month 12- TEL services received: Doctor ordering HIV test at a lab near home to take the test | Yes | 10 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Month 12- TEL services received: Doctor ordering HIV test at a lab near home to take the test | No | 13 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Month 12- TEL services received: Doctor ordering HIV test at a lab near home to take the test | I don't know | 2 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Month 12- TEL services received: Doctor ordering HIV test at a lab near home to take the test | Missing | 0 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Month 12- TEL services received: Nurse coming home to give an HIV test | Yes | 2 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Month 12- TEL services received: Nurse coming home to give an HIV test | No | 23 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Month 12- TEL services received: Nurse coming home to give an HIV test | I don't know | 0 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Month 12- TEL services received: Nurse coming home to give an HIV test | Missing | 0 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Month 12- TEL services received: Receiving reminders about scheduled injection appointment | Yes | 25 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Month 12- TEL services received: Receiving reminders about scheduled injection appointment | No | 0 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Month 12- TEL services received: Receiving reminders about scheduled injection appointment | I don't know | 0 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Month 12- TEL services received: Receiving reminders about scheduled injection appointment | Missing | 0 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Month 12- TEL services received: Scheduling injection appointment online | Yes | 13 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Month 12- TEL services received: Scheduling injection appointment online | No | 12 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Month 12- TEL services received: Scheduling injection appointment online | I don't know | 0 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Month 12- TEL services received: Scheduling injection appointment online | Missing | 0 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Month 12- TEL services received: Nurse coming home to give the injection | Yes | 2 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Month 12- TEL services received: Nurse coming home to give the injection | No | 23 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding Telehealth Use for APRETUDE | Month 12- TEL services received: Nurse coming home to give the injection | I don't know | 0 Participants |
Secondary
Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services
The ISQ uses a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs were asked about how comfortable it was to use various telehealth services for APRETUDE. Timeframe for evaluation of this outcome measure is M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI).
Time frame: At Month 6 and Month 12
Population: Analysis was performed on PSPs who were administered at least one dose of APRETUDE injection or of CAB tablets for PrEP and who completed at least one ISQ survey at any timepoint. Only those participants with data available for the specified analysis at the specified time points were included.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 12- Receiving reminders about scheduled injection appointment | Neither comfortable nor uncomfortable | 0 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 6- Scheduling injection appointment online | Not comfortable at all | 0 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 12- Receiving reminders about scheduled injection appointment | Very comfortable | 26 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 12- A nurse coming home to give the injection | Somewhat uncomfortable | 0 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 6- Doctor ordering HIV test at a lab near home to take the test | Very comfortable | 12 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 6- Doctor ordering HIV test at a lab near home to take the test | Somewhat comfortable | 4 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 6- Doctor ordering HIV test at a lab near home to take the test | Neither comfortable nor uncomfortable | 1 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 6- Doctor ordering HIV test at a lab near home to take the test | Somewhat uncomfortable | 0 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 6- Doctor ordering HIV test at a lab near home to take the test | Not comfortable at all | 0 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 6- A nurse coming home to give an HIV test | Very comfortable | 2 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 6- A nurse coming home to give an HIV test | Somewhat comfortable | 0 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 6- A nurse coming home to give an HIV test | Neither comfortable nor uncomfortable | 1 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 6- A nurse coming home to give an HIV test | Somewhat uncomfortable | 0 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 6- A nurse coming home to give an HIV test | Not comfortable at all | 0 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 6- Receiving reminders about scheduled injection appointment | Very comfortable | 33 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 6- Receiving reminders about scheduled injection appointment | Somewhat comfortable | 3 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 6- Receiving reminders about scheduled injection appointment | Neither comfortable nor uncomfortable | 0 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 6- Receiving reminders about scheduled injection appointment | Somewhat uncomfortable | 0 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 6- Receiving reminders about scheduled injection appointment | Not comfortable at all | 0 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 6- Scheduling injection appointment online | Very comfortable | 20 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 6- Scheduling injection appointment online | Somewhat comfortable | 3 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 6- Scheduling injection appointment online | Neither comfortable nor uncomfortable | 0 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 6- Scheduling injection appointment online | Somewhat uncomfortable | 1 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 6- A nurse coming home to give the injection | Very comfortable | 2 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 6- A nurse coming home to give the injection | Somewhat comfortable | 0 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 6- A nurse coming home to give the injection | Neither comfortable nor uncomfortable | 0 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 6- A nurse coming home to give the injection | Somewhat uncomfortable | 0 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 6- A nurse coming home to give the injection | Not comfortable at all | 0 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 12- Doctor ordering HIV test at a lab near home to take the test | Very comfortable | 11 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 12- Doctor ordering HIV test at a lab near home to take the test | Somewhat comfortable | 0 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 12- Doctor ordering HIV test at a lab near home to take the test | Neither comfortable nor uncomfortable | 0 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 12- Doctor ordering HIV test at a lab near home to take the test | Somewhat uncomfortable | 0 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 12- Doctor ordering HIV test at a lab near home to take the test | Not comfortable at all | 0 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 12- A nurse coming to home to give an HIV test | Very comfortable | 2 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 12- A nurse coming to home to give an HIV test | Somewhat comfortable | 1 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 12- A nurse coming to home to give an HIV test | Neither comfortable nor uncomfortable | 0 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 12- A nurse coming to home to give an HIV test | Somewhat uncomfortable | 0 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 12- A nurse coming to home to give an HIV test | Not comfortable at all | 0 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 12- Receiving reminders about scheduled injection appointment | Somewhat comfortable | 2 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 12- Receiving reminders about scheduled injection appointment | Somewhat uncomfortable | 0 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 12- Receiving reminders about scheduled injection appointment | Not comfortable at all | 0 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 12- Scheduling injection appointment online | Very comfortable | 15 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 12- Scheduling injection appointment online | Somewhat comfortable | 1 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 12- Scheduling injection appointment online | Neither comfortable nor uncomfortable | 0 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 12- Scheduling injection appointment online | Somewhat uncomfortable | 0 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 12- Scheduling injection appointment online | Not comfortable at all | 0 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 12- A nurse coming home to give the injection | Very comfortable | 3 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 12- A nurse coming home to give the injection | Somewhat comfortable | 0 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 12- A nurse coming home to give the injection | Neither comfortable nor uncomfortable | 0 Participants |
| DI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 12- A nurse coming home to give the injection | Not comfortable at all | 0 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 12- A nurse coming home to give the injection | Not comfortable at all | 0 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 6- A nurse coming home to give the injection | Not comfortable at all | 0 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 6- A nurse coming home to give the injection | Very comfortable | 1 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 6- A nurse coming home to give the injection | Somewhat uncomfortable | 1 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 12- Receiving reminders about scheduled injection appointment | Somewhat uncomfortable | 1 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 12- Doctor ordering HIV test at a lab near home to take the test | Very comfortable | 8 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 12- Scheduling injection appointment online | Not comfortable at all | 0 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 6- Doctor ordering HIV test at a lab near home to take the test | Very comfortable | 8 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 12- Doctor ordering HIV test at a lab near home to take the test | Somewhat comfortable | 0 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 6- Doctor ordering HIV test at a lab near home to take the test | Somewhat comfortable | 1 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 12- Receiving reminders about scheduled injection appointment | Not comfortable at all | 0 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 6- Doctor ordering HIV test at a lab near home to take the test | Neither comfortable nor uncomfortable | 0 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 12- Doctor ordering HIV test at a lab near home to take the test | Neither comfortable nor uncomfortable | 2 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 6- Doctor ordering HIV test at a lab near home to take the test | Somewhat uncomfortable | 0 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 12- A nurse coming home to give the injection | Neither comfortable nor uncomfortable | 0 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 6- Doctor ordering HIV test at a lab near home to take the test | Not comfortable at all | 0 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 12- Doctor ordering HIV test at a lab near home to take the test | Somewhat uncomfortable | 0 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 6- A nurse coming home to give an HIV test | Very comfortable | 1 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 12- Scheduling injection appointment online | Very comfortable | 11 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 6- A nurse coming home to give an HIV test | Somewhat comfortable | 1 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 12- Doctor ordering HIV test at a lab near home to take the test | Not comfortable at all | 0 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 12- A nurse coming home to give the injection | Very comfortable | 2 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 6- A nurse coming home to give an HIV test | Somewhat uncomfortable | 0 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 12- A nurse coming to home to give an HIV test | Very comfortable | 2 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 6- A nurse coming home to give an HIV test | Not comfortable at all | 0 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 12- Scheduling injection appointment online | Somewhat comfortable | 1 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 6- Receiving reminders about scheduled injection appointment | Very comfortable | 20 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 12- A nurse coming to home to give an HIV test | Somewhat comfortable | 0 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 6- Receiving reminders about scheduled injection appointment | Somewhat comfortable | 2 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 12- A nurse coming home to give the injection | Somewhat uncomfortable | 0 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 6- Receiving reminders about scheduled injection appointment | Neither comfortable nor uncomfortable | 0 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 12- A nurse coming to home to give an HIV test | Neither comfortable nor uncomfortable | 0 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 6- Receiving reminders about scheduled injection appointment | Somewhat uncomfortable | 0 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 12- Scheduling injection appointment online | Neither comfortable nor uncomfortable | 1 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 6- Receiving reminders about scheduled injection appointment | Not comfortable at all | 0 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 12- A nurse coming to home to give an HIV test | Somewhat uncomfortable | 0 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 6- Scheduling injection appointment online | Very comfortable | 13 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 12- A nurse coming home to give the injection | Somewhat comfortable | 0 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 6- Scheduling injection appointment online | Somewhat comfortable | 1 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 12- A nurse coming to home to give an HIV test | Not comfortable at all | 0 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 6- Scheduling injection appointment online | Neither comfortable nor uncomfortable | 1 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 12- Receiving reminders about scheduled injection appointment | Very comfortable | 21 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 6- Scheduling injection appointment online | Somewhat uncomfortable | 0 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 6- Scheduling injection appointment online | Not comfortable at all | 0 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 12- Scheduling injection appointment online | Somewhat uncomfortable | 0 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 12- Receiving reminders about scheduled injection appointment | Somewhat comfortable | 2 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 6- A nurse coming home to give the injection | Somewhat comfortable | 0 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 6- A nurse coming home to give an HIV test | Neither comfortable nor uncomfortable | 0 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 6- A nurse coming home to give the injection | Neither comfortable nor uncomfortable | 0 Participants |
| RI - SSP | Number of PSPs With Responses to the ISQs Regarding the Comfort of Using Telehealth Services | Month 12- Receiving reminders about scheduled injection appointment | Neither comfortable nor uncomfortable | 1 Participants |
Secondary
Number of PSPs With Response to the ISQs Recommending Telehealth Delivery
The ISQ uses a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs were asked if they would recommend telehealth services for APRETUDE to other people. Timeframe for evaluation of this outcome measure is M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI).
Time frame: At Month 6 and Month 12
Population: Analysis was performed on PSPs who were administered at least one dose of APRETUDE injection or of CAB tablets for PrEP and who completed at least one ISQ survey at any timepoint. Only those participants with data available for the specified analysis at the specified time points were included.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| DI - SSP | Number of PSPs With Response to the ISQs Recommending Telehealth Delivery | Month 6 - I would recommend telehealth services for APRETUDE to other people. | Neither agree not disagree | 1 Participants |
| DI - SSP | Number of PSPs With Response to the ISQs Recommending Telehealth Delivery | Month 12 - I would recommend telehealth services for APRETUDE to other people. | Missing | 0 Participants |
| DI - SSP | Number of PSPs With Response to the ISQs Recommending Telehealth Delivery | Month 6 - I would recommend telehealth services for APRETUDE to other people. | Completely agree | 29 Participants |
| DI - SSP | Number of PSPs With Response to the ISQs Recommending Telehealth Delivery | Month 6 - I would recommend telehealth services for APRETUDE to other people. | Agree | 9 Participants |
| DI - SSP | Number of PSPs With Response to the ISQs Recommending Telehealth Delivery | Month 6 - I would recommend telehealth services for APRETUDE to other people. | Disagree | 1 Participants |
| DI - SSP | Number of PSPs With Response to the ISQs Recommending Telehealth Delivery | Month 6 - I would recommend telehealth services for APRETUDE to other people. | Completely disagree | 0 Participants |
| DI - SSP | Number of PSPs With Response to the ISQs Recommending Telehealth Delivery | Month 6 - I would recommend telehealth services for APRETUDE to other people. | Missing | 1 Participants |
| DI - SSP | Number of PSPs With Response to the ISQs Recommending Telehealth Delivery | Month 12 - I would recommend telehealth services for APRETUDE to other people. | Completely agree | 20 Participants |
| DI - SSP | Number of PSPs With Response to the ISQs Recommending Telehealth Delivery | Month 12 - I would recommend telehealth services for APRETUDE to other people. | Agree | 7 Participants |
| DI - SSP | Number of PSPs With Response to the ISQs Recommending Telehealth Delivery | Month 12 - I would recommend telehealth services for APRETUDE to other people. | Neither agree not disagree | 2 Participants |
| DI - SSP | Number of PSPs With Response to the ISQs Recommending Telehealth Delivery | Month 12 - I would recommend telehealth services for APRETUDE to other people. | Disagree | 0 Participants |
| DI - SSP | Number of PSPs With Response to the ISQs Recommending Telehealth Delivery | Month 12 - I would recommend telehealth services for APRETUDE to other people. | Completely disagree | 0 Participants |
| RI - SSP | Number of PSPs With Response to the ISQs Recommending Telehealth Delivery | Month 12 - I would recommend telehealth services for APRETUDE to other people. | Disagree | 0 Participants |
| RI - SSP | Number of PSPs With Response to the ISQs Recommending Telehealth Delivery | Month 12 - I would recommend telehealth services for APRETUDE to other people. | Completely disagree | 0 Participants |
| RI - SSP | Number of PSPs With Response to the ISQs Recommending Telehealth Delivery | Month 6 - I would recommend telehealth services for APRETUDE to other people. | Missing | 0 Participants |
| RI - SSP | Number of PSPs With Response to the ISQs Recommending Telehealth Delivery | Month 12 - I would recommend telehealth services for APRETUDE to other people. | Neither agree not disagree | 3 Participants |
| RI - SSP | Number of PSPs With Response to the ISQs Recommending Telehealth Delivery | Month 6 - I would recommend telehealth services for APRETUDE to other people. | Completely agree | 12 Participants |
| RI - SSP | Number of PSPs With Response to the ISQs Recommending Telehealth Delivery | Month 12 - I would recommend telehealth services for APRETUDE to other people. | Completely agree | 20 Participants |
| RI - SSP | Number of PSPs With Response to the ISQs Recommending Telehealth Delivery | Month 6 - I would recommend telehealth services for APRETUDE to other people. | Agree | 9 Participants |
| RI - SSP | Number of PSPs With Response to the ISQs Recommending Telehealth Delivery | Month 6 - I would recommend telehealth services for APRETUDE to other people. | Neither agree not disagree | 3 Participants |
| RI - SSP | Number of PSPs With Response to the ISQs Recommending Telehealth Delivery | Month 12 - I would recommend telehealth services for APRETUDE to other people. | Missing | 0 Participants |
| RI - SSP | Number of PSPs With Response to the ISQs Recommending Telehealth Delivery | Month 6 - I would recommend telehealth services for APRETUDE to other people. | Disagree | 0 Participants |
| RI - SSP | Number of PSPs With Response to the ISQs Recommending Telehealth Delivery | Month 12 - I would recommend telehealth services for APRETUDE to other people. | Agree | 2 Participants |
| RI - SSP | Number of PSPs With Response to the ISQs Recommending Telehealth Delivery | Month 6 - I would recommend telehealth services for APRETUDE to other people. | Completely disagree | 0 Participants |
Secondary
Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used
The ISQ uses a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs were asked about how convenient it was to use various telehealth services for APRETUDE. Timeframe for evaluation of this outcome measure is M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI).
Time frame: At Month 6 and Month 12
Population: Analysis was performed on PSPs who were administered at least one dose of APRETUDE injection or of CAB tablets for PrEP and who completed at least one ISQ survey at any timepoint. Only those participants with data available for the specified analysis at the specified time points were included.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| DI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 6- Scheduling your injection appointment online | Somewhat convenient | 3 Participants |
| DI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 6- A nurse coming home to give an HIV test | Somewhat convenient | 1 Participants |
| DI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 6- A nurse coming home to give an HIV test | Very convenient | 1 Participants |
| DI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 6- A nurse coming home to give an HIV test | Neither convenient nor inconvenient | 1 Participants |
| DI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 6- A nurse coming home to give an HIV test | Somewhat inconvenient | 0 Participants |
| DI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 6- A nurse coming home to give an HIV test | Very inconvenient | 0 Participants |
| DI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 6- Receiving reminders about scheduled injection appointment | Very convenient | 31 Participants |
| DI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 6- Receiving reminders about scheduled injection appointment | Somewhat convenient | 4 Participants |
| DI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 6- Receiving reminders about scheduled injection appointment | Neither convenient nor inconvenient | 1 Participants |
| DI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 6- Receiving reminders about scheduled injection appointment | Somewhat inconvenient | 0 Participants |
| DI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 6- Receiving reminders about scheduled injection appointment | Very inconvenient | 0 Participants |
| DI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 6- Scheduling your injection appointment online | Very convenient | 19 Participants |
| DI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 6- Scheduling your injection appointment online | Neither convenient nor inconvenient | 2 Participants |
| DI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 6- Scheduling your injection appointment online | Somewhat inconvenient | 0 Participants |
| DI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 6- Scheduling your injection appointment online | Very inconvenient | 0 Participants |
| DI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 6- A nurse coming home to give the injection | Very convenient | 2 Participants |
| DI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 6- A nurse coming home to give the injection | Somewhat convenient | 0 Participants |
| DI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 6- A nurse coming home to give the injection | Neither convenient nor inconvenient | 0 Participants |
| DI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 6- A nurse coming home to give the injection | Somewhat inconvenient | 0 Participants |
| DI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 6- A nurse coming home to give the injection | Very inconvenient | 0 Participants |
| DI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 12- Doctor ordering HIV test at a lab near home to take the test | Very convenient | 11 Participants |
| DI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 12- Doctor ordering HIV test at a lab near home to take the test | Somewhat convenient | 0 Participants |
| DI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 12- Doctor ordering HIV test at a lab near home to take the test | Neither convenient nor inconvenient | 0 Participants |
| DI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 12- Doctor ordering HIV test at a lab near home to take the test | Somewhat inconvenient | 0 Participants |
| DI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 12- Doctor ordering HIV test at a lab near home to take the test | Very inconvenient | 0 Participants |
| DI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 12- A nurse coming home to give an HIV test | Very convenient | 2 Participants |
| DI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 12- A nurse coming home to give an HIV test | Somewhat convenient | 1 Participants |
| DI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 12- A nurse coming home to give an HIV test | Neither convenient nor inconvenient | 0 Participants |
| DI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 12- A nurse coming home to give an HIV test | Somewhat inconvenient | 0 Participants |
| DI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 12- A nurse coming home to give an HIV test | Very inconvenient | 0 Participants |
| DI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 12- Receiving reminders about scheduled injection appointment | Very convenient | 28 Participants |
| DI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 12- Receiving reminders about scheduled injection appointment | Somewhat convenient | 0 Participants |
| DI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 12- Receiving reminders about scheduled injection appointment | Neither convenient nor inconvenient | 0 Participants |
| DI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 12- Receiving reminders about scheduled injection appointment | Somewhat inconvenient | 0 Participants |
| DI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 12- Receiving reminders about scheduled injection appointment | Very inconvenient | 0 Participants |
| DI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 12- Scheduling your injection appointment online | Very convenient | 14 Participants |
| DI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 12- Scheduling your injection appointment online | Somewhat convenient | 1 Participants |
| DI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 12- Scheduling your injection appointment online | Neither convenient nor inconvenient | 1 Participants |
| DI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 12- Scheduling your injection appointment online | Somewhat inconvenient | 0 Participants |
| DI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 12- Scheduling your injection appointment online | Very inconvenient | 0 Participants |
| DI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 6- Doctor ordering HIV test at a lab near home to take the test | Very convenient | 12 Participants |
| DI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 6- Doctor ordering HIV test at a lab near home to take the test | Somewhat convenient | 3 Participants |
| DI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 6- Doctor ordering HIV test at a lab near home to take the test | Neither convenient nor inconvenient | 2 Participants |
| DI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 6- Doctor ordering HIV test at a lab near home to take the test | Somewhat inconvenient | 0 Participants |
| DI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 6- Doctor ordering HIV test at a lab near home to take the test | Very inconvenient | 0 Participants |
| DI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 12- A nurse coming home to give the injection | Very convenient | 3 Participants |
| DI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 12- A nurse coming home to give the injection | Somewhat convenient | 0 Participants |
| DI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 12- A nurse coming home to give the injection | Neither convenient nor inconvenient | 0 Participants |
| DI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 12- A nurse coming home to give the injection | Somewhat inconvenient | 0 Participants |
| DI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 12- A nurse coming home to give the injection | Very inconvenient | 0 Participants |
| RI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 12- Doctor ordering HIV test at a lab near home to take the test | Very inconvenient | 0 Participants |
| RI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 6- A nurse coming home to give an HIV test | Very convenient | 2 Participants |
| RI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 12- A nurse coming home to give the injection | Somewhat inconvenient | 0 Participants |
| RI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 12- Doctor ordering HIV test at a lab near home to take the test | Very convenient | 9 Participants |
| RI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 12- A nurse coming home to give an HIV test | Very convenient | 2 Participants |
| RI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 6- A nurse coming home to give an HIV test | Somewhat convenient | 0 Participants |
| RI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 12- Scheduling your injection appointment online | Neither convenient nor inconvenient | 1 Participants |
| RI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 6- A nurse coming home to give an HIV test | Neither convenient nor inconvenient | 0 Participants |
| RI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 12- A nurse coming home to give an HIV test | Somewhat convenient | 0 Participants |
| RI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 6- A nurse coming home to give an HIV test | Somewhat inconvenient | 0 Participants |
| RI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 6- Doctor ordering HIV test at a lab near home to take the test | Very inconvenient | 0 Participants |
| RI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 6- A nurse coming home to give an HIV test | Very inconvenient | 0 Participants |
| RI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 12- A nurse coming home to give an HIV test | Neither convenient nor inconvenient | 0 Participants |
| RI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 6- Receiving reminders about scheduled injection appointment | Very convenient | 18 Participants |
| RI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 12- Scheduling your injection appointment online | Somewhat inconvenient | 0 Participants |
| RI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 6- Receiving reminders about scheduled injection appointment | Somewhat convenient | 4 Participants |
| RI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 12- A nurse coming home to give an HIV test | Somewhat inconvenient | 0 Participants |
| RI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 6- Receiving reminders about scheduled injection appointment | Neither convenient nor inconvenient | 0 Participants |
| RI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 12- Scheduling your injection appointment online | Very inconvenient | 0 Participants |
| RI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 6- Receiving reminders about scheduled injection appointment | Somewhat inconvenient | 0 Participants |
| RI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 12- A nurse coming home to give an HIV test | Very inconvenient | 0 Participants |
| RI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 6- Receiving reminders about scheduled injection appointment | Very inconvenient | 0 Participants |
| RI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 12- A nurse coming home to give the injection | Neither convenient nor inconvenient | 0 Participants |
| RI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 6- Scheduling your injection appointment online | Very convenient | 13 Participants |
| RI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 6- Doctor ordering HIV test at a lab near home to take the test | Neither convenient nor inconvenient | 1 Participants |
| RI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 6- Scheduling your injection appointment online | Somewhat convenient | 1 Participants |
| RI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 12- Receiving reminders about scheduled injection appointment | Very convenient | 22 Participants |
| RI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 6- Scheduling your injection appointment online | Neither convenient nor inconvenient | 0 Participants |
| RI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 6- Doctor ordering HIV test at a lab near home to take the test | Very convenient | 8 Participants |
| RI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 6- Scheduling your injection appointment online | Somewhat inconvenient | 1 Participants |
| RI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 12- Receiving reminders about scheduled injection appointment | Somewhat convenient | 2 Participants |
| RI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 6- Scheduling your injection appointment online | Very inconvenient | 0 Participants |
| RI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 12- A nurse coming home to give the injection | Very convenient | 2 Participants |
| RI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 6- A nurse coming home to give the injection | Very convenient | 1 Participants |
| RI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 12- Receiving reminders about scheduled injection appointment | Neither convenient nor inconvenient | 1 Participants |
| RI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 6- A nurse coming home to give the injection | Somewhat convenient | 0 Participants |
| RI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 6- Doctor ordering HIV test at a lab near home to take the test | Somewhat convenient | 0 Participants |
| RI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 6- A nurse coming home to give the injection | Neither convenient nor inconvenient | 0 Participants |
| RI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 12- Receiving reminders about scheduled injection appointment | Somewhat inconvenient | 0 Participants |
| RI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 6- A nurse coming home to give the injection | Somewhat inconvenient | 0 Participants |
| RI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 12- A nurse coming home to give the injection | Very inconvenient | 0 Participants |
| RI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 6- A nurse coming home to give the injection | Very inconvenient | 1 Participants |
| RI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 12- Receiving reminders about scheduled injection appointment | Very inconvenient | 0 Participants |
| RI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 12- A nurse coming home to give the injection | Somewhat convenient | 0 Participants |
| RI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 12- Doctor ordering HIV test at a lab near home to take the test | Somewhat convenient | 0 Participants |
| RI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 12- Scheduling your injection appointment online | Very convenient | 11 Participants |
| RI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 12- Doctor ordering HIV test at a lab near home to take the test | Neither convenient nor inconvenient | 1 Participants |
| RI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 6- Doctor ordering HIV test at a lab near home to take the test | Somewhat inconvenient | 0 Participants |
| RI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 12- Doctor ordering HIV test at a lab near home to take the test | Somewhat inconvenient | 0 Participants |
| RI - SSP | Number of PSPs With Response to the ISQs Regarding the Convenience of Telehealth Services Used | Month 12- Scheduling your injection appointment online | Somewhat convenient | 1 Participants |
Secondary
Number of SSPs Assessed for Perception of Barriers
General perceptions of barriers for APRETUDE intervention and implementation were measured among SSPs from themes emerging from Proctor and CFIR guided semi-structured qualitative interviews. In this outcome measure, SSPs discuss feelings and perspectives while implementing APRETUDE. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).
Time frame: Up to Month 12
Population: Analysis was performed on the SSPs who were interviewed and had data available at the specified time points.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| DI - SSP | Number of SSPs Assessed for Perception of Barriers | Staff having mixed feelings | 9 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Barriers | Initial negative response due to extra workload | 2 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Barriers | Staff having mixed feelings | 4 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Barriers | Initial negative response due to extra workload | 2 Participants |
Secondary
Number of SSPs Assessed for Perception of Facilitators
General perceptions of facilitators for APRETUDE intervention and implementation were measured among SSPs from themes emerging from Proctor and CFIR guided semi-structured qualitative interviews. In this outcome measure, SSPs discuss clinic culture and implementation motivations. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).
Time frame: Up to Month 12
Population: Analysis was performed on the SSPs who were interviewed and had data available at the specified time points.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators | Leadership being actively involved in the process | 4 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators | Team adaptability | 8 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators | Leadership willing to help/support | 6 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators | Staff being supportive of the clinic offering APRETUDE | 11 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators | APRETUDE positively accepted | 10 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators | Aiming to improve patient's health | 2 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators | Supportive leadership for implementation | 11 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators | Aiming to improve patient's health | 2 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators | Supportive leadership for implementation | 11 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators | Leadership willing to help/support | 8 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators | Leadership being actively involved in the process | 5 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators | APRETUDE positively accepted | 5 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators | Team adaptability | 3 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators | Staff being supportive of the clinic offering APRETUDE | 6 Participants |
Secondary
Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery
Barriers and facilitators to the feasibility and acceptability of telehealth use for APRETUDE were measured from themes emerging from Proctor and Consolidated Framework for Implementation Research (CFIR) guided semi-structured qualitative interviews. In this outcome measure, SSPs were asked their perceptions of these facilitators and barriers for telehealth services used. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).
Time frame: Up to Month 12
Population: Analysis was performed on the SSPs who were interviewed and had data available for the specified analysis at the specified time points.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Text reminders | Neither easy nor difficult | 2 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Video consultation | Neither easy nor difficult | 6 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Patient portal conversations: ability for patients to send messages to providers | Somewhat easy | 4 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | At-home testing services | Somewhat Difficult | 0 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | At-home testing services | Very Difficult | 0 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | At-home testing services | I don't use this system | 3 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Send and receiving patient reported outcomes questionnaires via an online system | Very easy | 3 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Send and receiving patient reported outcomes questionnaires via an online system | Somewhat easy | 4 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Insurance/benefits verification | Very Difficult | 1 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Insurance/benefits verification | I don't use this system | 2 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Text reminders | Somewhat Difficult | 0 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Text reminders | Very Difficult | 0 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Text reminders | I don't use this system | 3 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Automated phone call reminders | Very easy | 9 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Automated phone call reminders | Somewhat easy | 4 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Automated phone call reminders | Neither easy nor difficult | 4 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Automated phone call reminders | Somewhat Difficult | 0 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Automated phone call reminders | Very Difficult | 0 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Automated phone call reminders | I don't use this system | 2 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Staff phone call reminder | Very easy | 9 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Staff phone call reminder | Somewhat easy | 6 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Staff phone call reminder | Neither easy nor difficult | 1 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Video consultation | Somewhat easy | 3 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Video consultation | Somewhat Difficult | 0 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Video consultation | Very Difficult | 0 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Video consultation | I don't use this system | 6 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Telephone consultation | Very easy | 14 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Telephone consultation | Somewhat easy | 4 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Telephone consultation | Neither easy nor difficult | 3 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Telephone consultation | Somewhat Difficult | 1 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Telephone consultation | Very Difficult | 0 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Telephone consultation | I don't use this system | 3 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Remote monitoring of patients | Very easy | 3 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Remote monitoring of patients | Somewhat easy | 5 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Remote monitoring of patients | Neither easy nor difficult | 2 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Remote monitoring of patients | Somewhat Difficult | 0 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Remote monitoring of patients | Very Difficult | 0 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Remote monitoring of patients | I don't use this system | 1 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Online appointment scheduling | Very easy | 3 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Online appointment scheduling | Somewhat easy | 2 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Online appointment scheduling | Neither easy nor difficult | 3 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Online appointment scheduling | Somewhat Difficult | 0 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Online appointment scheduling | Very Difficult | 0 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Online appointment scheduling | I don't use this system | 2 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Patient portal conversations: ability for patients to send messages to providers | Very easy | 13 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Patient portal conversations: ability for patients to send messages to providers | Neither easy nor difficult | 4 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Patient portal conversations: ability for patients to send messages to providers | Somewhat Difficult | 0 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Patient portal conversations: ability for patients to send messages to providers | Very Difficult | 0 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Patient portal conversations: ability for patients to send messages to providers | I don't use this system | 2 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | At-home testing services | Very easy | 4 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | At-home testing services | Somewhat easy | 1 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | At-home testing services | Neither easy nor difficult | 2 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Staff phone call reminder | Somewhat Difficult | 0 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Staff phone call reminder | Very Difficult | 0 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Staff phone call reminder | I don't use this system | 2 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Sending motivational reminders to help patients persist on APRETUDE | Very easy | 2 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Sending motivational reminders to help patients persist on APRETUDE | Somewhat easy | 0 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Sending motivational reminders to help patients persist on APRETUDE | Neither easy nor difficult | 0 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Sending motivational reminders to help patients persist on APRETUDE | Somewhat Difficult | 0 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Sending motivational reminders to help patients persist on APRETUDE | Very Difficult | 0 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Sending motivational reminders to help patients persist on APRETUDE | I don't use this system | 0 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Sending cabotegravir oral lead in to patient's home | Very easy | 4 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Sending cabotegravir oral lead in to patient's home | Somewhat easy | 1 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Sending cabotegravir oral lead in to patient's home | Neither easy nor difficult | 1 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Sending cabotegravir oral lead in to patient's home | Somewhat Difficult | 0 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Sending cabotegravir oral lead in to patient's home | Very Difficult | 0 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Sending cabotegravir oral lead in to patient's home | I don't use this system | 1 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Insurance/benefits verification | Very easy | 10 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Insurance/benefits verification | Somewhat easy | 7 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Insurance/benefits verification | Neither easy nor difficult | 3 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Insurance/benefits verification | Somewhat Difficult | 1 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Send and receiving patient reported outcomes questionnaires via an online system | Neither easy nor difficult | 3 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Send and receiving patient reported outcomes questionnaires via an online system | Somewhat Difficult | 0 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Send and receiving patient reported outcomes questionnaires via an online system | Very Difficult | 0 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Send and receiving patient reported outcomes questionnaires via an online system | I don't use this system | 2 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Online prescription refills | Very easy | 14 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Online prescription refills | Somewhat easy | 3 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Online prescription refills | Neither easy nor difficult | 4 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Online prescription refills | Somewhat Difficult | 0 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Online prescription refills | Very Difficult | 0 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Online prescription refills | I don't use this system | 2 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Online portal for patients to access medical documents, such as visit summaries and test results | Very easy | 12 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Online portal for patients to access medical documents, such as visit summaries and test results | Somewhat easy | 6 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Online portal for patients to access medical documents, such as visit summaries and test results | Neither easy nor difficult | 4 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Online portal for patients to access medical documents, such as visit summaries and test results | Somewhat Difficult | 0 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Text messaging with patients about care | Neither easy nor difficult | 2 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Online portal for patients to access medical documents, such as visit summaries and test results | Very Difficult | 0 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Online portal for patients to access medical documents, such as visit summaries and test results | I don't use this system | 2 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Text messaging with patients about care | Very easy | 7 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Text messaging with patients about care | Somewhat easy | 3 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Text messaging with patients about care | Somewhat Difficult | 0 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Text messaging with patients about care | Very Difficult | 0 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Text messaging with patients about care | I don't use this system | 1 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Email reminders to patient about upcoming visits | Very easy | 10 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Email reminders to patient about upcoming visits | Somewhat easy | 4 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Email reminders to patient about upcoming visits | Neither easy nor difficult | 2 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Email reminders to patient about upcoming visits | Somewhat Difficult | 0 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Email reminders to patient about upcoming visits | Very Difficult | 0 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Email reminders to patient about upcoming visits | I don't use this system | 3 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Text reminders | Very easy | 12 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Text reminders | Somewhat easy | 5 Participants |
| DI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Video consultation | Very easy | 12 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Online prescription refills | Somewhat easy | 0 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Staff phone call reminder | Somewhat Difficult | 0 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Video consultation | Neither easy nor difficult | 1 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Remote monitoring of patients | Neither easy nor difficult | 1 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Online appointment scheduling | Very Difficult | 0 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Patient portal conversations: ability for patients to send messages to providers | Very easy | 7 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Text messaging with patients about care | Somewhat easy | 1 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Patient portal conversations: ability for patients to send messages to providers | Neither easy nor difficult | 0 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | At-home testing services | Neither easy nor difficult | 0 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Staff phone call reminder | Very Difficult | 0 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Online prescription refills | Neither easy nor difficult | 0 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Staff phone call reminder | I don't use this system | 0 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Text messaging with patients about care | Neither easy nor difficult | 1 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Sending motivational reminders to help patients persist on APRETUDE | Very easy | 1 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Send and receiving patient reported outcomes questionnaires via an online system | Somewhat easy | 1 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Online prescription refills | Somewhat Difficult | 0 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Insurance/benefits verification | Very Difficult | 0 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Sending motivational reminders to help patients persist on APRETUDE | Somewhat easy | 0 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Insurance/benefits verification | I don't use this system | 0 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Text reminders | Neither easy nor difficult | 1 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Email reminders to patient about upcoming visits | Neither easy nor difficult | 0 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Text reminders | Somewhat Difficult | 0 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Sending motivational reminders to help patients persist on APRETUDE | Neither easy nor difficult | 0 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Text reminders | Very Difficult | 0 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Online prescription refills | Very Difficult | 0 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Text reminders | I don't use this system | 0 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Sending motivational reminders to help patients persist on APRETUDE | Somewhat Difficult | 0 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Automated phone call reminders | Very easy | 4 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Text messaging with patients about care | Somewhat Difficult | 0 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Automated phone call reminders | Somewhat easy | 1 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Sending motivational reminders to help patients persist on APRETUDE | Very Difficult | 0 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Automated phone call reminders | Neither easy nor difficult | 0 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Online prescription refills | I don't use this system | 0 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Automated phone call reminders | Somewhat Difficult | 0 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Sending motivational reminders to help patients persist on APRETUDE | I don't use this system | 0 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Automated phone call reminders | Very Difficult | 0 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Email reminders to patient about upcoming visits | I don't use this system | 0 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Automated phone call reminders | I don't use this system | 0 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Sending cabotegravir oral lead in to patient's home | Very easy | 1 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Staff phone call reminder | Very easy | 7 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Online portal for patients to access medical documents, such as visit summaries and test results | Very easy | 6 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Staff phone call reminder | Somewhat easy | 1 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Sending cabotegravir oral lead in to patient's home | Somewhat easy | 0 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Video consultation | Very easy | 4 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Text messaging with patients about care | Very Difficult | 0 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Video consultation | Somewhat easy | 2 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Sending cabotegravir oral lead in to patient's home | Neither easy nor difficult | 1 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Video consultation | Somewhat Difficult | 0 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Online portal for patients to access medical documents, such as visit summaries and test results | Somewhat easy | 0 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Video consultation | Very Difficult | 0 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Sending cabotegravir oral lead in to patient's home | Somewhat Difficult | 0 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Video consultation | I don't use this system | 1 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Email reminders to patient about upcoming visits | Somewhat Difficult | 0 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Telephone consultation | Very easy | 2 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Sending cabotegravir oral lead in to patient's home | Very Difficult | 0 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Telephone consultation | Somewhat easy | 2 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Online portal for patients to access medical documents, such as visit summaries and test results | Neither easy nor difficult | 0 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Telephone consultation | Neither easy nor difficult | 0 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Sending cabotegravir oral lead in to patient's home | I don't use this system | 0 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Telephone consultation | Somewhat Difficult | 0 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Text messaging with patients about care | I don't use this system | 0 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Telephone consultation | Very Difficult | 0 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Insurance/benefits verification | Very easy | 5 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Telephone consultation | I don't use this system | 0 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Online portal for patients to access medical documents, such as visit summaries and test results | Somewhat Difficult | 0 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Remote monitoring of patients | Very easy | 1 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Insurance/benefits verification | Somewhat easy | 1 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Remote monitoring of patients | Somewhat easy | 0 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Text reminders | Somewhat easy | 1 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Insurance/benefits verification | Neither easy nor difficult | 1 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Remote monitoring of patients | Somewhat Difficult | 0 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Email reminders to patient about upcoming visits | Very easy | 3 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Remote monitoring of patients | Very Difficult | 0 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Insurance/benefits verification | Somewhat Difficult | 0 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Remote monitoring of patients | I don't use this system | 1 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | At-home testing services | Very Difficult | 0 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Online appointment scheduling | Very easy | 3 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | At-home testing services | I don't use this system | 0 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Online appointment scheduling | Somewhat easy | 0 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Send and receiving patient reported outcomes questionnaires via an online system | Very easy | 1 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Online appointment scheduling | Neither easy nor difficult | 0 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Online portal for patients to access medical documents, such as visit summaries and test results | Very Difficult | 0 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Online appointment scheduling | Somewhat Difficult | 0 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Send and receiving patient reported outcomes questionnaires via an online system | Neither easy nor difficult | 0 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Email reminders to patient about upcoming visits | Very Difficult | 0 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Online appointment scheduling | I don't use this system | 0 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Send and receiving patient reported outcomes questionnaires via an online system | Somewhat Difficult | 0 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Patient portal conversations: ability for patients to send messages to providers | Somewhat easy | 0 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Online portal for patients to access medical documents, such as visit summaries and test results | I don't use this system | 0 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Send and receiving patient reported outcomes questionnaires via an online system | Very Difficult | 0 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Patient portal conversations: ability for patients to send messages to providers | Somewhat Difficult | 1 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Email reminders to patient about upcoming visits | Somewhat easy | 1 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Patient portal conversations: ability for patients to send messages to providers | Very Difficult | 0 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Send and receiving patient reported outcomes questionnaires via an online system | I don't use this system | 0 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Patient portal conversations: ability for patients to send messages to providers | I don't use this system | 0 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Text messaging with patients about care | Very easy | 4 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | At-home testing services | Very easy | 1 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Online prescription refills | Very easy | 6 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | At-home testing services | Somewhat easy | 1 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Text reminders | Very easy | 6 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | At-home testing services | Somewhat Difficult | 0 Participants |
| RI - SSP | Number of SSPs Assessed for Perception of Facilitators and Barriers to Feasibility and Acceptability for Telehealth Delivery | Staff phone call reminder | Neither easy nor difficult | 0 Participants |
Secondary
Number of SSPs Assessed for Perceptions of Barriers to RI, DI and Overall Implementation of PrEP Into Routine Care Through Month 12
Perception of barriers to RI, DI and overall implementation of PrEP measured from themes emerging from Proctor and CFIR guided semi-structured qualitative interview. In this outcome measure, SSPs were asked about the barriers/challenges of the overall implementation of APRETUDE into clinic infrastructure, evaluating feasibility of DI and RI study arms. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).
Time frame: Up to Month 12
Population: Analysis was performed on the SSPs who were interviewed and had data available for the specified analysis at the specified time points.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| DI - SSP | Number of SSPs Assessed for Perceptions of Barriers to RI, DI and Overall Implementation of PrEP Into Routine Care Through Month 12 | Follow-up with pharmacies needed to obtain APRETUDE | 2 Participants |
| DI - SSP | Number of SSPs Assessed for Perceptions of Barriers to RI, DI and Overall Implementation of PrEP Into Routine Care Through Month 12 | Staff burden to integrate the new process | 7 Participants |
| DI - SSP | Number of SSPs Assessed for Perceptions of Barriers to RI, DI and Overall Implementation of PrEP Into Routine Care Through Month 12 | Complex team coordination | 4 Participants |
| DI - SSP | Number of SSPs Assessed for Perceptions of Barriers to RI, DI and Overall Implementation of PrEP Into Routine Care Through Month 12 | Insurance challenges related to infrastructure | 4 Participants |
| DI - SSP | Number of SSPs Assessed for Perceptions of Barriers to RI, DI and Overall Implementation of PrEP Into Routine Care Through Month 12 | Infrastructure Logistic challenges | 3 Participants |
| RI - SSP | Number of SSPs Assessed for Perceptions of Barriers to RI, DI and Overall Implementation of PrEP Into Routine Care Through Month 12 | Infrastructure Logistic challenges | 2 Participants |
| RI - SSP | Number of SSPs Assessed for Perceptions of Barriers to RI, DI and Overall Implementation of PrEP Into Routine Care Through Month 12 | Insurance challenges related to infrastructure | 2 Participants |
| RI - SSP | Number of SSPs Assessed for Perceptions of Barriers to RI, DI and Overall Implementation of PrEP Into Routine Care Through Month 12 | Staff burden to integrate the new process | 3 Participants |
| RI - SSP | Number of SSPs Assessed for Perceptions of Barriers to RI, DI and Overall Implementation of PrEP Into Routine Care Through Month 12 | Follow-up with pharmacies needed to obtain APRETUDE | 2 Participants |
| RI - SSP | Number of SSPs Assessed for Perceptions of Barriers to RI, DI and Overall Implementation of PrEP Into Routine Care Through Month 12 | Complex team coordination | 2 Participants |
Secondary
Number of SSPs Assessed for Perceptions of Facilitators to RI, DI and Overall Implementation of PrEP Into Routine Care Through Month 12
Perception of facilitators to RI, DI and overall implementation of PrEP measured from themes emerging from Proctor and Consolidated Framework for Implementation Research (CFIR) guided semi-structured qualitative interviews. In this outcome measure, SSPs were asked about the facilitators of the overall implementation of APRETUDE into clinic infrastructure, evaluating feasibility of DI and RI study arms. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).
Time frame: Up to Month 12
Population: Analysis was performed on the SSPs who were interviewed and had data available for the specified analysis at the specified time points.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| DI - SSP | Number of SSPs Assessed for Perceptions of Facilitators to RI, DI and Overall Implementation of PrEP Into Routine Care Through Month 12 | Scheduling appointments in advance | 6 Participants |
| DI - SSP | Number of SSPs Assessed for Perceptions of Facilitators to RI, DI and Overall Implementation of PrEP Into Routine Care Through Month 12 | Increased communication for vulnerable populations | 3 Participants |
| DI - SSP | Number of SSPs Assessed for Perceptions of Facilitators to RI, DI and Overall Implementation of PrEP Into Routine Care Through Month 12 | Clinic being flexible with scheduling (injection/ lab visits) | 5 Participants |
| DI - SSP | Number of SSPs Assessed for Perceptions of Facilitators to RI, DI and Overall Implementation of PrEP Into Routine Care Through Month 12 | Previous experience with CABENUVA/ APRETUDE | 2 Participants |
| DI - SSP | Number of SSPs Assessed for Perceptions of Facilitators to RI, DI and Overall Implementation of PrEP Into Routine Care Through Month 12 | Training and consistent information provided to staff | 5 Participants |
| RI - SSP | Number of SSPs Assessed for Perceptions of Facilitators to RI, DI and Overall Implementation of PrEP Into Routine Care Through Month 12 | Previous experience with CABENUVA/ APRETUDE | 2 Participants |
| RI - SSP | Number of SSPs Assessed for Perceptions of Facilitators to RI, DI and Overall Implementation of PrEP Into Routine Care Through Month 12 | Scheduling appointments in advance | 0 Participants |
| RI - SSP | Number of SSPs Assessed for Perceptions of Facilitators to RI, DI and Overall Implementation of PrEP Into Routine Care Through Month 12 | Training and consistent information provided to staff | 0 Participants |
| RI - SSP | Number of SSPs Assessed for Perceptions of Facilitators to RI, DI and Overall Implementation of PrEP Into Routine Care Through Month 12 | Increased communication for vulnerable populations | 1 Participants |
| RI - SSP | Number of SSPs Assessed for Perceptions of Facilitators to RI, DI and Overall Implementation of PrEP Into Routine Care Through Month 12 | Clinic being flexible with scheduling (injection/ lab visits) | 1 Participants |
Secondary
Number of SSPs Assessed for Perceptions of Utility of Implementation Strategies and Facilitators and Barriers to Acceptability of RI and DI
Perceptions of Utility of Implementation Strategies and Facilitators and Barriers to Acceptability of RI and DI measured from themes emerging from Proctor and CFIR guided semi-structured qualitative interview. In this outcome measure, SSPs provided their insights on the tools and strategies used for implementing APRETUDE during the PILLAR study. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).
Time frame: Up to Month 12
Population: Analysis was performed on the SSPs who were interviewed and had data available for the specified analysis at the specified time points. All questions were not administered to both RI and DI arms; hence only participants with data available for the specified analysis at the specified time points were included.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| DI - SSP | Number of SSPs Assessed for Perceptions of Utility of Implementation Strategies and Facilitators and Barriers to Acceptability of RI and DI | Medication Administration Planner | 7 Participants |
| DI - SSP | Number of SSPs Assessed for Perceptions of Utility of Implementation Strategies and Facilitators and Barriers to Acceptability of RI and DI | Injection Education Video | 13 Participants |
| DI - SSP | Number of SSPs Assessed for Perceptions of Utility of Implementation Strategies and Facilitators and Barriers to Acceptability of RI and DI | Drop-in visits (DI) | 11 Participants |
| DI - SSP | Number of SSPs Assessed for Perceptions of Utility of Implementation Strategies and Facilitators and Barriers to Acceptability of RI and DI | Frequently Asked Questions (FAQs) | 11 Participants |
| DI - SSP | Number of SSPs Assessed for Perceptions of Utility of Implementation Strategies and Facilitators and Barriers to Acceptability of RI and DI | Readiness Considerations | 4 Participants |
| DI - SSP | Number of SSPs Assessed for Perceptions of Utility of Implementation Strategies and Facilitators and Barriers to Acceptability of RI and DI | Getting Started Overview | 4 Participants |
| DI - SSP | Number of SSPs Assessed for Perceptions of Utility of Implementation Strategies and Facilitators and Barriers to Acceptability of RI and DI | Designated injection days (DI) | 5 Participants |
| DI - SSP | Number of SSPs Assessed for Perceptions of Utility of Implementation Strategies and Facilitators and Barriers to Acceptability of RI and DI | Prescheduled Appointments (DI) | 18 Participants |
| DI - SSP | Number of SSPs Assessed for Perceptions of Utility of Implementation Strategies and Facilitators and Barriers to Acceptability of RI and DI | Transportation services (DI) | 10 Participants |
| DI - SSP | Number of SSPs Assessed for Perceptions of Utility of Implementation Strategies and Facilitators and Barriers to Acceptability of RI and DI | PrEP Communication Options Tool (DI) | 8 Participants |
| DI - SSP | Number of SSPs Assessed for Perceptions of Utility of Implementation Strategies and Facilitators and Barriers to Acceptability of RI and DI | Implementation guidance video (DI) | 10 Participants |
| DI - SSP | Number of SSPs Assessed for Perceptions of Utility of Implementation Strategies and Facilitators and Barriers to Acceptability of RI and DI | How to discuss sexual health guidance (DI) | 3 Participants |
| DI - SSP | Number of SSPs Assessed for Perceptions of Utility of Implementation Strategies and Facilitators and Barriers to Acceptability of RI and DI | Acquisition Tracker (DI) | 1 Participants |
| RI - SSP | Number of SSPs Assessed for Perceptions of Utility of Implementation Strategies and Facilitators and Barriers to Acceptability of RI and DI | PrEP Communication Options Tool (DI) | 0 Participants |
| RI - SSP | Number of SSPs Assessed for Perceptions of Utility of Implementation Strategies and Facilitators and Barriers to Acceptability of RI and DI | Medication Administration Planner | 4 Participants |
| RI - SSP | Number of SSPs Assessed for Perceptions of Utility of Implementation Strategies and Facilitators and Barriers to Acceptability of RI and DI | Getting Started Overview | 11 Participants |
| RI - SSP | Number of SSPs Assessed for Perceptions of Utility of Implementation Strategies and Facilitators and Barriers to Acceptability of RI and DI | How to discuss sexual health guidance (DI) | 0 Participants |
| RI - SSP | Number of SSPs Assessed for Perceptions of Utility of Implementation Strategies and Facilitators and Barriers to Acceptability of RI and DI | Injection Education Video | 10 Participants |
| RI - SSP | Number of SSPs Assessed for Perceptions of Utility of Implementation Strategies and Facilitators and Barriers to Acceptability of RI and DI | Prescheduled Appointments (DI) | 0 Participants |
| RI - SSP | Number of SSPs Assessed for Perceptions of Utility of Implementation Strategies and Facilitators and Barriers to Acceptability of RI and DI | Designated injection days (DI) | 0 Participants |
| RI - SSP | Number of SSPs Assessed for Perceptions of Utility of Implementation Strategies and Facilitators and Barriers to Acceptability of RI and DI | Implementation guidance video (DI) | 0 Participants |
| RI - SSP | Number of SSPs Assessed for Perceptions of Utility of Implementation Strategies and Facilitators and Barriers to Acceptability of RI and DI | Frequently Asked Questions (FAQs) | 8 Participants |
| RI - SSP | Number of SSPs Assessed for Perceptions of Utility of Implementation Strategies and Facilitators and Barriers to Acceptability of RI and DI | Transportation services (DI) | 0 Participants |
| RI - SSP | Number of SSPs Assessed for Perceptions of Utility of Implementation Strategies and Facilitators and Barriers to Acceptability of RI and DI | Readiness Considerations | 4 Participants |
| RI - SSP | Number of SSPs Assessed for Perceptions of Utility of Implementation Strategies and Facilitators and Barriers to Acceptability of RI and DI | Acquisition Tracker (DI) | 0 Participants |
| RI - SSP | Number of SSPs Assessed for Perceptions of Utility of Implementation Strategies and Facilitators and Barriers to Acceptability of RI and DI | Drop-in visits (DI) | 0 Participants |
Secondary
Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use
The ISQ uses a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, SSPs were asked about the usefulness of various implementation strategies used for implementing APRETUDE in their clinic/practice. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).
Time frame: Up to Month 12
Population: Analysis was performed on SSPs who completed at least one survey at any timepoint. All questions were not administered to both RI and DI arms; hence only participants with data available for the specified analysis at the specified time points were included.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| DI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Drop-in Injection Visits Guidance (DI) | Somewhat useful | 4 Participants |
| DI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Frequently Asked Questions Brochure | A little useful | 3 Participants |
| DI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Frequently Asked Questions Brochure | Somewhat useful | 5 Participants |
| DI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Frequently Asked Questions Brochure | Useful | 5 Participants |
| DI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Frequently Asked Questions Brochure | Very Useful | 5 Participants |
| DI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Readiness Consideration | Not at all useful | 0 Participants |
| DI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Readiness Consideration | A little useful | 2 Participants |
| DI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Readiness Consideration | Somewhat useful | 3 Participants |
| DI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Readiness Consideration | Very Useful | 6 Participants |
| DI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Get Started Overview-Init/Adm Guide | Not at all useful | 0 Participants |
| DI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Get Started Overview-Init/Adm Guide | Somewhat useful | 4 Participants |
| DI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Get Started Overview-Init/Adm Guide | Useful | 6 Participants |
| DI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Get Started Overview-Init/Adm Guide | Very Useful | 6 Participants |
| DI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Injection Education Video | Not at all useful | 0 Participants |
| DI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Injection Education Video | A little useful | 0 Participants |
| DI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Injection Education Video | Somewhat useful | 5 Participants |
| DI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Injection Education Video | Useful | 8 Participants |
| DI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Provider Website- location where all materials and videos on APRETUDE are located (RI) | A little useful | 0 Participants |
| DI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Provider Website- location where all materials and videos on APRETUDE are located (RI) | Somewhat useful | 0 Participants |
| DI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Provider Website- location where all materials and videos on APRETUDE are located (RI) | Useful | 0 Participants |
| DI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Provider Website- location where all materials and videos on APRETUDE are located (RI) | Very Useful | 0 Participants |
| DI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Patient Materials | Not at all useful | 0 Participants |
| DI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Patient Materials | Useful | 7 Participants |
| DI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Patient Materials | A little useful | 3 Participants |
| DI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Patient Materials | Somewhat useful | 3 Participants |
| DI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Patient Materials | Very Useful | 8 Participants |
| DI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Implementation Guidance Video (DI) | Not at all useful | 0 Participants |
| DI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Implementation Guidance Video (DI) | A little useful | 2 Participants |
| DI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Implementation Guidance Video (DI) | Somewhat useful | 2 Participants |
| DI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Implementation Guidance Video (DI) | Useful | 9 Participants |
| DI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Implementation Guidance Video (DI) | Very Useful | 4 Participants |
| DI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Appointment Scheduler | Not at all useful | 1 Participants |
| DI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Appointment Scheduler | A little useful | 0 Participants |
| DI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Appointment Scheduler | Somewhat useful | 2 Participants |
| DI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Appointment Scheduler | Useful | 6 Participants |
| DI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Appointment Scheduler | Very Useful | 6 Participants |
| DI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Pre-scheduled Appointment Guidance (DI) | Not at all useful | 0 Participants |
| DI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Pre-scheduled Appointment Guidance (DI) | A little useful | 0 Participants |
| DI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Pre-scheduled Appointment Guidance (DI) | Somewhat useful | 3 Participants |
| DI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Pre-scheduled Appointment Guidance (DI) | Useful | 6 Participants |
| DI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Pre-scheduled Appointment Guidance (DI) | Very Useful | 6 Participants |
| DI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Designated Injection Days Guidance (DI) | Not at all useful | 0 Participants |
| DI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Designated Injection Days Guidance (DI) | A little useful | 1 Participants |
| DI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Designated Injection Days Guidance (DI) | Somewhat useful | 5 Participants |
| DI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Designated Injection Days Guidance (DI) | Useful | 7 Participants |
| DI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Designated Injection Days Guidance (DI) | Very Useful | 2 Participants |
| DI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Drop-in Injection Visits Guidance (DI) | Not at all useful | 0 Participants |
| DI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Drop-in Injection Visits Guidance (DI) | A little useful | 0 Participants |
| DI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Drop-in Injection Visits Guidance (DI) | Useful | 4 Participants |
| DI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Drop-in Injection Visits Guidance (DI) | Very Useful | 4 Participants |
| DI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Transport Support to Patient Appt (DI) | Not at all useful | 0 Participants |
| DI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Transport Support to Patient Appt (DI) | A little useful | 0 Participants |
| DI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Transport Support to Patient Appt (DI) | Somewhat useful | 4 Participants |
| DI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Transport Support to Patient Appt (DI) | Useful | 5 Participants |
| DI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Transport Support to Patient Appt (DI) | Very Useful | 11 Participants |
| DI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Monthly Implement Facilitation Call (DI) | Not at all useful | 2 Participants |
| DI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Monthly Implement Facilitation Call (DI) | A little useful | 0 Participants |
| DI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Monthly Implement Facilitation Call (DI) | Somewhat useful | 5 Participants |
| DI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Monthly Implement Facilitation Call (DI) | Useful | 9 Participants |
| DI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Monthly Implement Facilitation Call (DI) | Very Useful | 8 Participants |
| DI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Group Implement Facilitation Calls (DI) | Not at all useful | 1 Participants |
| DI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Group Implement Facilitation Calls (DI) | A little useful | 1 Participants |
| DI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Group Implement Facilitation Calls (DI) | Somewhat useful | 5 Participants |
| DI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Group Implement Facilitation Calls (DI) | Useful | 8 Participants |
| DI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Group Implement Facilitation Calls (DI) | Very Useful | 9 Participants |
| DI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Document on How Discuss Sex Health (DI) | Not at all useful | 0 Participants |
| DI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Document on How Discuss Sex Health (DI) | A little useful | 1 Participants |
| DI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Document on How Discuss Sex Health (DI) | Somewhat useful | 3 Participants |
| DI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Document on How Discuss Sex Health (DI) | Useful | 6 Participants |
| DI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Document on How Discuss Sex Health (DI) | Very Useful | 4 Participants |
| DI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | PILLAR Spot (DI) | Not at all useful | 1 Participants |
| DI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | PILLAR Spot (DI) | A little useful | 3 Participants |
| DI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | PILLAR Spot (DI) | Somewhat useful | 7 Participants |
| DI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | PILLAR Spot (DI) | Useful | 13 Participants |
| DI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | PILLAR Spot (DI) | Very Useful | 10 Participants |
| DI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Readiness Consideration | Useful | 5 Participants |
| DI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Get Started Overview-Init/Adm Guide | A little useful | 3 Participants |
| DI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Injection Education Video | Very Useful | 15 Participants |
| DI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Provider Website- location where all materials and videos on APRETUDE are located (RI) | Not at all useful | 0 Participants |
| DI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Frequently Asked Questions Brochure | Not at all useful | 1 Participants |
| RI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Monthly Implement Facilitation Call (DI) | Very Useful | 0 Participants |
| RI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Frequently Asked Questions Brochure | Not at all useful | 0 Participants |
| RI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Pre-scheduled Appointment Guidance (DI) | Very Useful | 0 Participants |
| RI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Frequently Asked Questions Brochure | A little useful | 1 Participants |
| RI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Document on How Discuss Sex Health (DI) | Very Useful | 0 Participants |
| RI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Frequently Asked Questions Brochure | Somewhat useful | 1 Participants |
| RI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Designated Injection Days Guidance (DI) | Not at all useful | 0 Participants |
| RI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Frequently Asked Questions Brochure | Useful | 8 Participants |
| RI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Group Implement Facilitation Calls (DI) | Not at all useful | 0 Participants |
| RI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Frequently Asked Questions Brochure | Very Useful | 2 Participants |
| RI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Designated Injection Days Guidance (DI) | A little useful | 0 Participants |
| RI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Readiness Consideration | Not at all useful | 0 Participants |
| RI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | PILLAR Spot (DI) | Very Useful | 0 Participants |
| RI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Readiness Consideration | A little useful | 0 Participants |
| RI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Designated Injection Days Guidance (DI) | Somewhat useful | 0 Participants |
| RI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Readiness Consideration | Somewhat useful | 2 Participants |
| RI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Readiness Consideration | Useful | 7 Participants |
| RI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Group Implement Facilitation Calls (DI) | A little useful | 0 Participants |
| RI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Readiness Consideration | Very Useful | 2 Participants |
| RI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Designated Injection Days Guidance (DI) | Useful | 0 Participants |
| RI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Get Started Overview-Init/Adm Guide | Not at all useful | 0 Participants |
| RI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Get Started Overview-Init/Adm Guide | A little useful | 0 Participants |
| RI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | PILLAR Spot (DI) | Not at all useful | 0 Participants |
| RI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Get Started Overview-Init/Adm Guide | Somewhat useful | 2 Participants |
| RI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Designated Injection Days Guidance (DI) | Very Useful | 0 Participants |
| RI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Get Started Overview-Init/Adm Guide | Useful | 7 Participants |
| RI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Group Implement Facilitation Calls (DI) | Somewhat useful | 0 Participants |
| RI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Get Started Overview-Init/Adm Guide | Very Useful | 2 Participants |
| RI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Drop-in Injection Visits Guidance (DI) | Not at all useful | 0 Participants |
| RI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Injection Education Video | Not at all useful | 0 Participants |
| RI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Injection Education Video | Very Useful | 6 Participants |
| RI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Injection Education Video | A little useful | 0 Participants |
| RI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Drop-in Injection Visits Guidance (DI) | A little useful | 0 Participants |
| RI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Injection Education Video | Somewhat useful | 5 Participants |
| RI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Drop-in Injection Visits Guidance (DI) | Somewhat useful | 0 Participants |
| RI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Provider Website- location where all materials and videos on APRETUDE are located (RI) | Not at all useful | 2 Participants |
| RI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Group Implement Facilitation Calls (DI) | Useful | 0 Participants |
| RI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Provider Website- location where all materials and videos on APRETUDE are located (RI) | A little useful | 0 Participants |
| RI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Drop-in Injection Visits Guidance (DI) | Useful | 0 Participants |
| RI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Provider Website- location where all materials and videos on APRETUDE are located (RI) | Somewhat useful | 2 Participants |
| RI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | PILLAR Spot (DI) | A little useful | 0 Participants |
| RI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Provider Website- location where all materials and videos on APRETUDE are located (RI) | Useful | 8 Participants |
| RI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Drop-in Injection Visits Guidance (DI) | Very Useful | 0 Participants |
| RI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Provider Website- location where all materials and videos on APRETUDE are located (RI) | Very Useful | 1 Participants |
| RI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Group Implement Facilitation Calls (DI) | Very Useful | 0 Participants |
| RI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Transport Support to Patient Appt (DI) | Not at all useful | 0 Participants |
| RI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Patient Materials | Not at all useful | 0 Participants |
| RI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Pre-scheduled Appointment Guidance (DI) | Useful | 0 Participants |
| RI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Patient Materials | A little useful | 0 Participants |
| RI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Transport Support to Patient Appt (DI) | A little useful | 0 Participants |
| RI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Patient Materials | Somewhat useful | 2 Participants |
| RI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Patient Materials | Useful | 10 Participants |
| RI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Document on How Discuss Sex Health (DI) | Not at all useful | 0 Participants |
| RI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Patient Materials | Very Useful | 3 Participants |
| RI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Transport Support to Patient Appt (DI) | Somewhat useful | 0 Participants |
| RI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Implementation Guidance Video (DI) | Not at all useful | 0 Participants |
| RI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | PILLAR Spot (DI) | Somewhat useful | 0 Participants |
| RI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Implementation Guidance Video (DI) | A little useful | 0 Participants |
| RI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Transport Support to Patient Appt (DI) | Useful | 0 Participants |
| RI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Implementation Guidance Video (DI) | Somewhat useful | 0 Participants |
| RI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Document on How Discuss Sex Health (DI) | A little useful | 0 Participants |
| RI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Implementation Guidance Video (DI) | Useful | 0 Participants |
| RI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Transport Support to Patient Appt (DI) | Very Useful | 0 Participants |
| RI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Implementation Guidance Video (DI) | Very Useful | 0 Participants |
| RI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Injection Education Video | Useful | 7 Participants |
| RI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Appointment Scheduler | Not at all useful | 0 Participants |
| RI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Monthly Implement Facilitation Call (DI) | Not at all useful | 0 Participants |
| RI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Appointment Scheduler | A little useful | 0 Participants |
| RI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Document on How Discuss Sex Health (DI) | Somewhat useful | 0 Participants |
| RI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Appointment Scheduler | Somewhat useful | 0 Participants |
| RI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Monthly Implement Facilitation Call (DI) | A little useful | 0 Participants |
| RI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | PILLAR Spot (DI) | Useful | 0 Participants |
| RI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Appointment Scheduler | Very Useful | 2 Participants |
| RI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Monthly Implement Facilitation Call (DI) | Somewhat useful | 0 Participants |
| RI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Pre-scheduled Appointment Guidance (DI) | Not at all useful | 0 Participants |
| RI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Document on How Discuss Sex Health (DI) | Useful | 0 Participants |
| RI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Pre-scheduled Appointment Guidance (DI) | A little useful | 0 Participants |
| RI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Monthly Implement Facilitation Call (DI) | Useful | 0 Participants |
| RI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Pre-scheduled Appointment Guidance (DI) | Somewhat useful | 0 Participants |
| RI - SSP | Number of SSPs That Respond in Agreement on Relevant Items on the ISQ That Each Implementation Strategy is Fit for Use | Appointment Scheduler | Useful | 5 Participants |
Secondary
Number of SSPs Who Administer Sexual Health Assessment (SHA)
In this outcome measure, SSPs answered questions about their administration of the sexual health assessment (SHA). The SHA was only administered by SSPs at the DI sites, hence it was not assessed for RI sites. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).
Time frame: Up to Month 12
Population: Analysis was performed on SSPs who completed at least one survey at any timepoint. Only those participants with data available for the specified analysis at the specified time points were included.
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| DI - SSP | Number of SSPs Who Administer Sexual Health Assessment (SHA) | Yes | 14 Participants |
| DI - SSP | Number of SSPs Who Administer Sexual Health Assessment (SHA) | No And Not Planning to Use the Sexual Health Assessment | 14 Participants |
| DI - SSP | Number of SSPs Who Administer Sexual Health Assessment (SHA) | No But Planning to Use the Sexual Health Assessment | 4 Participants |
| DI - SSP | Number of SSPs Who Administer Sexual Health Assessment (SHA) | I don't know | 20 Participants |
Secondary
Number of SSPs With Perceptions of Barriers to Fidelity to Injections
Perceptions of utility of implementation strategies and facilitators and barriers to acceptability of RI and DI measured from themes emerging from Proctor and CFIR guided semi-structured qualitative interviews. In this outcome measure, SSPs provided insights regarding the barriers and challenges in enabling patient adherence to APRETUDE. The barriers were categorized as patient barriers and staff challenges. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).
Time frame: Up to Month 12
Population: Analysis was performed on the SSPs who were interviewed and had data available for the specified analysis at the specified time points.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| DI - SSP | Number of SSPs With Perceptions of Barriers to Fidelity to Injections | Patient Barriers: Scheduling Barriers | 4 Participants |
| DI - SSP | Number of SSPs With Perceptions of Barriers to Fidelity to Injections | Patient Barriers: Vulnerable Population | 2 Participants |
| DI - SSP | Number of SSPs With Perceptions of Barriers to Fidelity to Injections | Patient Barriers: Traveling | 2 Participants |
| DI - SSP | Number of SSPs With Perceptions of Barriers to Fidelity to Injections | Patient Barriers: Patients hard to contact (e.g., no phone access) | 2 Participants |
| DI - SSP | Number of SSPs With Perceptions of Barriers to Fidelity to Injections | Staff Challenges: Concern about patients missing injection window | 4 Participants |
| DI - SSP | Number of SSPs With Perceptions of Barriers to Fidelity to Injections | Staff Challenges: Not being able to contact patients who miss an appointment | 1 Participants |
| RI - SSP | Number of SSPs With Perceptions of Barriers to Fidelity to Injections | Staff Challenges: Concern about patients missing injection window | 2 Participants |
| RI - SSP | Number of SSPs With Perceptions of Barriers to Fidelity to Injections | Patient Barriers: Scheduling Barriers | 2 Participants |
| RI - SSP | Number of SSPs With Perceptions of Barriers to Fidelity to Injections | Patient Barriers: Patients hard to contact (e.g., no phone access) | 2 Participants |
| RI - SSP | Number of SSPs With Perceptions of Barriers to Fidelity to Injections | Patient Barriers: Vulnerable Population | 2 Participants |
| RI - SSP | Number of SSPs With Perceptions of Barriers to Fidelity to Injections | Staff Challenges: Not being able to contact patients who miss an appointment | 3 Participants |
| RI - SSP | Number of SSPs With Perceptions of Barriers to Fidelity to Injections | Patient Barriers: Traveling | 2 Participants |
Secondary
Number of SSPs With Perceptions of Facilitators to Fidelity to Injections
Perceptions of utility of implementation strategies and facilitators and barriers to acceptability of RI and DI measured from themes emerging from Proctor and CFIR guided semi-structured qualitative interviews. In this outcome measure, SSPs provided insights regarding the facilitators for adherence to APRETUDE and the support provided to enable patient adherence. These facilitators were categorized as resources, support, patient communication and patient feasibility. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).
Time frame: Up to Month 12
Population: Analysis was performed on the SSPs who were interviewed and had data available for the specified analysis at the specified time points.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| DI - SSP | Number of SSPs With Perceptions of Facilitators to Fidelity to Injections | Resources: Dedicated support staff for each step: education, authorization, etc | 4 Participants |
| DI - SSP | Number of SSPs With Perceptions of Facilitators to Fidelity to Injections | Patient Communication: Increasing global communication | 6 Participants |
| DI - SSP | Number of SSPs With Perceptions of Facilitators to Fidelity to Injections | Resources: Flexibility of using oral PrEP for bridging when needed | 1 Participants |
| DI - SSP | Number of SSPs With Perceptions of Facilitators to Fidelity to Injections | Patient Communication: Encouraging proactively engaging patients with scheduling | 6 Participants |
| DI - SSP | Number of SSPs With Perceptions of Facilitators to Fidelity to Injections | Resources: Patient education about importance of adherence | 1 Participants |
| DI - SSP | Number of SSPs With Perceptions of Facilitators to Fidelity to Injections | Patient Communication: Accessibility for patients for open line communication | 8 Participants |
| DI - SSP | Number of SSPs With Perceptions of Facilitators to Fidelity to Injections | Support: Scheduling appointments in advance | 4 Participants |
| DI - SSP | Number of SSPs With Perceptions of Facilitators to Fidelity to Injections | Patient feasibility: APRETUDE is feasible for patients | 9 Participants |
| DI - SSP | Number of SSPs With Perceptions of Facilitators to Fidelity to Injections | Resources: Communication (call, email and text) | 7 Participants |
| DI - SSP | Number of SSPs With Perceptions of Facilitators to Fidelity to Injections | Patient feasibility: Clinical staff making the process run smoothly | 4 Participants |
| DI - SSP | Number of SSPs With Perceptions of Facilitators to Fidelity to Injections | Support: Team dedicated for follow-up | 5 Participants |
| DI - SSP | Number of SSPs With Perceptions of Facilitators to Fidelity to Injections | Patient feasibility: Working around patient schedule helps with feasibility | 3 Participants |
| DI - SSP | Number of SSPs With Perceptions of Facilitators to Fidelity to Injections | Resources: Dedicated injection nurse for follow-up | 2 Participants |
| RI - SSP | Number of SSPs With Perceptions of Facilitators to Fidelity to Injections | Patient feasibility: Working around patient schedule helps with feasibility | 3 Participants |
| RI - SSP | Number of SSPs With Perceptions of Facilitators to Fidelity to Injections | Resources: Dedicated support staff for each step: education, authorization, etc | 0 Participants |
| RI - SSP | Number of SSPs With Perceptions of Facilitators to Fidelity to Injections | Resources: Communication (call, email and text) | 2 Participants |
| RI - SSP | Number of SSPs With Perceptions of Facilitators to Fidelity to Injections | Resources: Dedicated injection nurse for follow-up | 3 Participants |
| RI - SSP | Number of SSPs With Perceptions of Facilitators to Fidelity to Injections | Resources: Patient education about importance of adherence | 4 Participants |
| RI - SSP | Number of SSPs With Perceptions of Facilitators to Fidelity to Injections | Resources: Flexibility of using oral PrEP for bridging when needed | 3 Participants |
| RI - SSP | Number of SSPs With Perceptions of Facilitators to Fidelity to Injections | Support: Scheduling appointments in advance | 3 Participants |
| RI - SSP | Number of SSPs With Perceptions of Facilitators to Fidelity to Injections | Support: Team dedicated for follow-up | 1 Participants |
| RI - SSP | Number of SSPs With Perceptions of Facilitators to Fidelity to Injections | Patient Communication: Increasing global communication | 5 Participants |
| RI - SSP | Number of SSPs With Perceptions of Facilitators to Fidelity to Injections | Patient Communication: Encouraging proactively engaging patients with scheduling | 3 Participants |
| RI - SSP | Number of SSPs With Perceptions of Facilitators to Fidelity to Injections | Patient Communication: Accessibility for patients for open line communication | 2 Participants |
| RI - SSP | Number of SSPs With Perceptions of Facilitators to Fidelity to Injections | Patient feasibility: APRETUDE is feasible for patients | 3 Participants |
| RI - SSP | Number of SSPs With Perceptions of Facilitators to Fidelity to Injections | Patient feasibility: Clinical staff making the process run smoothly | 4 Participants |
Secondary
Number of SSPs With Perceptions of SHA
In this outcome measure, SSPs provided insights regarding the use and implementation of SHA tool in their clinic/practice. The SHA was only administered by SSPs at the DI sites, hence it was not assessed for RI sites. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).
Time frame: Up to Month 12
Population: Analysis was performed on SSPs who completed at least one survey at any timepoint. Only those participants with data available for the specified analysis at the specified time points were included.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| DI - SSP | Number of SSPs With Perceptions of SHA | The Sexual Health Assessment helps/will help to facilitate conversations about PrEP with patients | Agree | 8 Participants |
| DI - SSP | Number of SSPs With Perceptions of SHA | The Sexual Health Assessment is/will be easy to implement in my clinic/practice | Completely disagree | 1 Participants |
| DI - SSP | Number of SSPs With Perceptions of SHA | The Sexual Health Assessment is/will be easy to implement in my clinic/practice | Disagree | 1 Participants |
| DI - SSP | Number of SSPs With Perceptions of SHA | The Sexual Health Assessment is/will be easy to implement in my clinic/practice | Neither agree nor disagree | 3 Participants |
| DI - SSP | Number of SSPs With Perceptions of SHA | The Sexual Health Assessment is/will be easy to implement in my clinic/practice | Agree | 8 Participants |
| DI - SSP | Number of SSPs With Perceptions of SHA | The Sexual Health Assessment is/will be easy to implement in my clinic/practice | Completely agree | 5 Participants |
| DI - SSP | Number of SSPs With Perceptions of SHA | The Sexual Health Assessment is/will be an easy way to identify individuals interested in PrEP | Completely disagree | 1 Participants |
| DI - SSP | Number of SSPs With Perceptions of SHA | The Sexual Health Assessment is/will be an easy way to identify individuals interested in PrEP | Disagree | 0 Participants |
| DI - SSP | Number of SSPs With Perceptions of SHA | The Sexual Health Assessment is/will be an easy way to identify individuals interested in PrEP | Neither agree nor disagree | 3 Participants |
| DI - SSP | Number of SSPs With Perceptions of SHA | The Sexual Health Assessment is/will be an easy way to identify individuals interested in PrEP | Agree | 10 Participants |
| DI - SSP | Number of SSPs With Perceptions of SHA | The Sexual Health Assessment is/will be an easy way to identify individuals interested in PrEP | Completely agree | 4 Participants |
| DI - SSP | Number of SSPs With Perceptions of SHA | The Sexual Health Assessment helps/will help to facilitate conversations about PrEP with patients | Completely disagree | 1 Participants |
| DI - SSP | Number of SSPs With Perceptions of SHA | The Sexual Health Assessment helps/will help to facilitate conversations about PrEP with patients | Disagree | 0 Participants |
| DI - SSP | Number of SSPs With Perceptions of SHA | The Sexual Health Assessment helps/will help to facilitate conversations about PrEP with patients | Neither agree nor disagree | 3 Participants |
| DI - SSP | Number of SSPs With Perceptions of SHA | The Sexual Health Assessment helps/will help to facilitate conversations about PrEP with patients | Completely agree | 6 Participants |
Secondary
Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE
The ISQ uses a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, SSPs were asked about the perceived barriers to managing delivery of APRETUDE. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI).
Time frame: At Baseline (Month 1), Month 4 and Month 12
Population: Analysis was performed on all SSPs who completed at least one survey at any timepoint. Only those participants with data available for the specified analysis at the specified time points were included.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| DI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Baseline- Management of rescheduling appointments during correct injection windows | Moderately concerned | 4 Participants |
| DI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 4- Ability to schedule/reschedule patients who missed APRETUDE visits within injection windows | Somewhat concerned | 11 Participants |
| DI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Baseline- Ability to identify and flag missed injection visits to providers (in a timely manner) | Moderately concerned | 5 Participants |
| DI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 4- Ability to schedule/reschedule patients who missed APRETUDE visits within injection windows | Slightly concerned | 7 Participants |
| DI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Baseline- Management of scheduling injection appointments during correct injection windows | Moderately concerned | 5 Participants |
| DI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 4- Ability to schedule/reschedule patients who missed APRETUDE visits within injection windows | Not at all concerned | 27 Participants |
| DI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Baseline- Ability to identify and flag missed injection visits to providers (in a timely manner) | Somewhat concerned | 15 Participants |
| DI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 4- Ability to identify and flag missed injection visits to providers (in a timely manner) | Extremely concerned | 3 Participants |
| DI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Baseline- Management of rescheduling appointments during correct injection windows | Somewhat concerned | 15 Participants |
| DI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 4- Ability to identify and flag missed injection visits to providers (in a timely manner) | Moderately concerned | 7 Participants |
| DI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Baseline- Ability to identify and flag missed injection visits to providers (in a timely manner) | Slightly concerned | 5 Participants |
| DI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 4- Ability to identify and flag missed injection visits to providers (in a timely manner) | Somewhat concerned | 10 Participants |
| DI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 12- Ability to identify and flag missed injection visits to providers (in a timely manner) | Extremely concerned | 4 Participants |
| DI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 4- Ability to identify and flag missed injection visits to providers (in a timely manner) | Slightly concerned | 6 Participants |
| DI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Baseline- Ability to identify and flag missed injection visits to providers (in a timely manner) | Not at all concerned | 26 Participants |
| DI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 4- Ability to identify and flag missed injection visits to providers (in a timely manner) | Not at all concerned | 25 Participants |
| DI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Baseline- Management of rescheduling appointments during correct injection windows | Slightly concerned | 6 Participants |
| DI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 4- Ability to manage patients presenting to APRETUDE appointments with other care needs | Extremely concerned | 1 Participants |
| DI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Baseline- Ability to manage patients presenting to APRETUDE appointments with other care needs | Extremely concerned | 5 Participants |
| DI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 4- Ability to manage patients presenting to APRETUDE appointments with other care needs | Moderately concerned | 5 Participants |
| DI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Baseline- Management of scheduling injection appointments during correct injection windows | Somewhat concerned | 13 Participants |
| DI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 4- Ability to manage patients presenting to APRETUDE appointments with other care needs | Somewhat concerned | 15 Participants |
| DI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Baseline- Ability to manage patients presenting to APRETUDE appointments with other care needs | Moderately concerned | 4 Participants |
| DI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 4- Ability to manage patients presenting to APRETUDE appointments with other care needs | Slightly concerned | 5 Participants |
| DI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Baseline- Management of rescheduling appointments during correct injection windows | Not at all concerned | 27 Participants |
| DI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 4- Ability to manage patients presenting to APRETUDE appointments with other care needs | Not at all concerned | 25 Participants |
| DI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Baseline- Ability to manage patients presenting to APRETUDE appointments with other care needs | Somewhat concerned | 11 Participants |
| DI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 12- Management of scheduling injection appointments every 2 months during injection windows | Extremely concerned | 0 Participants |
| DI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 12- Ability to manage patients presenting to APRETUDE appointments with other care needs | Not at all concerned | 29 Participants |
| DI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 12- Management of scheduling injection appointments every 2 months during injection windows | Moderately concerned | 4 Participants |
| DI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Baseline- Ability to manage patients presenting to APRETUDE appointments with other care needs | Slightly concerned | 9 Participants |
| DI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 12- Management of scheduling injection appointments every 2 months during injection windows | Somewhat concerned | 5 Participants |
| DI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Baseline- Ability to schedule/reschedule patients who missed APRETUDE visits | Extremely concerned | 4 Participants |
| DI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 12- Management of scheduling injection appointments every 2 months during injection windows | Slightly concerned | 7 Participants |
| DI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Baseline- Ability to manage patients presenting to APRETUDE appointments with other care needs | Not at all concerned | 27 Participants |
| DI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 12- Management of scheduling injection appointments every 2 months during injection windows | Not at all concerned | 36 Participants |
| DI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Baseline- Management of scheduling injection appointments during correct injection windows | Slightly concerned | 5 Participants |
| DI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 12- Management of rescheduling appointments during correct injection windows | Extremely concerned | 1 Participants |
| DI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 4- Management of scheduling injection appointments during correct injection windows | Extremely concerned | 2 Participants |
| DI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 12- Management of rescheduling appointments during correct injection windows | Moderately concerned | 4 Participants |
| DI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Baseline- Ability to schedule/reschedule patients who missed APRETUDE visits | Moderately concerned | 5 Participants |
| DI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 12- Management of rescheduling appointments during correct injection windows | Somewhat concerned | 8 Participants |
| DI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 4- Management of scheduling injection appointments during correct injection windows | Moderately concerned | 5 Participants |
| DI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 12- Management of rescheduling appointments during correct injection windows | Slightly concerned | 10 Participants |
| DI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Baseline- Management of scheduling injection appointments during correct injection windows | Extremely concerned | 3 Participants |
| DI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 12- Management of rescheduling appointments during correct injection windows | Not at all concerned | 29 Participants |
| DI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 4- Management of scheduling injection appointments during correct injection windows | Somewhat concerned | 6 Participants |
| DI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 12- Ability to schedule/reschedule patients who missed APRETUDE visits | Extremely concerned | 2 Participants |
| DI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Baseline- Ability to schedule/reschedule patients who missed APRETUDE visits | Somewhat concerned | 16 Participants |
| DI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 12- Ability to schedule/reschedule patients who missed APRETUDE visits | Moderately concerned | 3 Participants |
| DI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 4- Management of scheduling injection appointments during correct injection windows | Slightly concerned | 3 Participants |
| DI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 12- Ability to schedule/reschedule patients who missed APRETUDE visits | Somewhat concerned | 8 Participants |
| DI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Baseline- Management of scheduling injection appointments during correct injection windows | Not at all concerned | 30 Participants |
| DI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 12- Ability to schedule/reschedule patients who missed APRETUDE visits | Slightly concerned | 11 Participants |
| DI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 4- Management of scheduling injection appointments during correct injection windows | Not at all concerned | 35 Participants |
| DI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 12- Ability to schedule/reschedule patients who missed APRETUDE visits | Not at all concerned | 28 Participants |
| DI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Baseline- Ability to schedule/reschedule patients who missed APRETUDE visits | Slightly concerned | 4 Participants |
| DI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 4- Management of rescheduling appointments during correct injection windows | Extremely concerned | 2 Participants |
| DI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 12- Ability to identify and flag missed injection visits to providers (in a timely manner) | Moderately concerned | 4 Participants |
| DI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 4- Management of rescheduling appointments during correct injection windows | Somewhat concerned | 8 Participants |
| DI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 12- Ability to identify and flag missed injection visits to providers (in a timely manner) | Somewhat concerned | 8 Participants |
| DI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 4- Management of rescheduling appointments during correct injection windows | Moderately concerned | 5 Participants |
| DI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 12- Ability to identify and flag missed injection visits to providers (in a timely manner) | Slightly concerned | 10 Participants |
| DI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 4- Management of rescheduling appointments during correct injection windows | Slightly concerned | 4 Participants |
| DI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 12- Ability to identify and flag missed injection visits to providers (in a timely manner) | Not at all concerned | 26 Participants |
| DI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Baseline- Ability to schedule/reschedule patients who missed APRETUDE visits | Not at all concerned | 27 Participants |
| DI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 12- Ability to manage patients presenting to APRETUDE appointments with other care needs | Extremely concerned | 1 Participants |
| DI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 4- Management of rescheduling appointments during correct injection windows | Not at all concerned | 32 Participants |
| DI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 12- Ability to manage patients presenting to APRETUDE appointments with other care needs | Moderately concerned | 3 Participants |
| DI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Baseline- Management of rescheduling appointments during correct injection windows | Extremely concerned | 4 Participants |
| DI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 12- Ability to manage patients presenting to APRETUDE appointments with other care needs | Somewhat concerned | 10 Participants |
| DI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 4- Ability to schedule/reschedule patients who missed APRETUDE visits within injection windows | Extremely concerned | 1 Participants |
| DI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 12- Ability to manage patients presenting to APRETUDE appointments with other care needs | Slightly concerned | 9 Participants |
| DI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Baseline- Ability to identify and flag missed injection visits to providers (in a timely manner) | Extremely concerned | 5 Participants |
| DI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 4- Ability to schedule/reschedule patients who missed APRETUDE visits within injection windows | Moderately concerned | 5 Participants |
| RI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 12- Ability to manage patients presenting to APRETUDE appointments with other care needs | Not at all concerned | 17 Participants |
| RI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 4- Management of rescheduling appointments during correct injection windows | Moderately concerned | 1 Participants |
| RI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 4- Management of rescheduling appointments during correct injection windows | Somewhat concerned | 2 Participants |
| RI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Baseline- Management of scheduling injection appointments during correct injection windows | Extremely concerned | 2 Participants |
| RI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Baseline- Management of scheduling injection appointments during correct injection windows | Moderately concerned | 4 Participants |
| RI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Baseline- Management of scheduling injection appointments during correct injection windows | Somewhat concerned | 2 Participants |
| RI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Baseline- Management of scheduling injection appointments during correct injection windows | Slightly concerned | 7 Participants |
| RI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Baseline- Management of scheduling injection appointments during correct injection windows | Not at all concerned | 15 Participants |
| RI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Baseline- Management of rescheduling appointments during correct injection windows | Moderately concerned | 6 Participants |
| RI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Baseline- Management of rescheduling appointments during correct injection windows | Somewhat concerned | 3 Participants |
| RI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Baseline- Management of rescheduling appointments during correct injection windows | Slightly concerned | 9 Participants |
| RI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Baseline- Management of rescheduling appointments during correct injection windows | Not at all concerned | 10 Participants |
| RI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Baseline- Ability to schedule/reschedule patients who missed APRETUDE visits | Extremely concerned | 3 Participants |
| RI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Baseline- Ability to schedule/reschedule patients who missed APRETUDE visits | Moderately concerned | 4 Participants |
| RI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Baseline- Ability to schedule/reschedule patients who missed APRETUDE visits | Somewhat concerned | 5 Participants |
| RI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Baseline- Ability to schedule/reschedule patients who missed APRETUDE visits | Slightly concerned | 9 Participants |
| RI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Baseline- Ability to schedule/reschedule patients who missed APRETUDE visits | Not at all concerned | 9 Participants |
| RI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Baseline- Ability to identify and flag missed injection visits to providers (in a timely manner) | Extremely concerned | 5 Participants |
| RI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Baseline- Ability to identify and flag missed injection visits to providers (in a timely manner) | Moderately concerned | 5 Participants |
| RI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Baseline- Ability to identify and flag missed injection visits to providers (in a timely manner) | Somewhat concerned | 4 Participants |
| RI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Baseline- Ability to identify and flag missed injection visits to providers (in a timely manner) | Slightly concerned | 4 Participants |
| RI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Baseline- Ability to identify and flag missed injection visits to providers (in a timely manner) | Not at all concerned | 12 Participants |
| RI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Baseline- Ability to manage patients presenting to APRETUDE appointments with other care needs | Extremely concerned | 3 Participants |
| RI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Baseline- Ability to manage patients presenting to APRETUDE appointments with other care needs | Moderately concerned | 4 Participants |
| RI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Baseline- Ability to manage patients presenting to APRETUDE appointments with other care needs | Somewhat concerned | 4 Participants |
| RI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Baseline- Ability to manage patients presenting to APRETUDE appointments with other care needs | Slightly concerned | 5 Participants |
| RI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Baseline- Ability to manage patients presenting to APRETUDE appointments with other care needs | Not at all concerned | 14 Participants |
| RI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 4- Management of scheduling injection appointments during correct injection windows | Extremely concerned | 2 Participants |
| RI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 4- Management of scheduling injection appointments during correct injection windows | Moderately concerned | 0 Participants |
| RI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 4- Management of scheduling injection appointments during correct injection windows | Somewhat concerned | 2 Participants |
| RI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 4- Management of scheduling injection appointments during correct injection windows | Slightly concerned | 4 Participants |
| RI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 4- Management of scheduling injection appointments during correct injection windows | Not at all concerned | 21 Participants |
| RI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 4- Management of rescheduling appointments during correct injection windows | Extremely concerned | 2 Participants |
| RI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 4- Management of rescheduling appointments during correct injection windows | Slightly concerned | 9 Participants |
| RI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 4- Management of rescheduling appointments during correct injection windows | Not at all concerned | 15 Participants |
| RI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 4- Ability to schedule/reschedule patients who missed APRETUDE visits within injection windows | Extremely concerned | 2 Participants |
| RI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 4- Ability to schedule/reschedule patients who missed APRETUDE visits within injection windows | Moderately concerned | 1 Participants |
| RI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 4- Ability to schedule/reschedule patients who missed APRETUDE visits within injection windows | Somewhat concerned | 1 Participants |
| RI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 4- Ability to schedule/reschedule patients who missed APRETUDE visits within injection windows | Slightly concerned | 10 Participants |
| RI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 4- Ability to schedule/reschedule patients who missed APRETUDE visits within injection windows | Not at all concerned | 15 Participants |
| RI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 4- Ability to identify and flag missed injection visits to providers (in a timely manner) | Extremely concerned | 2 Participants |
| RI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 4- Ability to identify and flag missed injection visits to providers (in a timely manner) | Moderately concerned | 2 Participants |
| RI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 4- Ability to identify and flag missed injection visits to providers (in a timely manner) | Somewhat concerned | 2 Participants |
| RI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 4- Ability to identify and flag missed injection visits to providers (in a timely manner) | Slightly concerned | 7 Participants |
| RI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 4- Ability to identify and flag missed injection visits to providers (in a timely manner) | Not at all concerned | 16 Participants |
| RI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 4- Ability to manage patients presenting to APRETUDE appointments with other care needs | Extremely concerned | 3 Participants |
| RI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 4- Ability to manage patients presenting to APRETUDE appointments with other care needs | Moderately concerned | 2 Participants |
| RI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 4- Ability to manage patients presenting to APRETUDE appointments with other care needs | Somewhat concerned | 1 Participants |
| RI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 4- Ability to manage patients presenting to APRETUDE appointments with other care needs | Slightly concerned | 3 Participants |
| RI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 4- Ability to manage patients presenting to APRETUDE appointments with other care needs | Not at all concerned | 20 Participants |
| RI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 12- Management of scheduling injection appointments every 2 months during injection windows | Extremely concerned | 1 Participants |
| RI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 12- Management of scheduling injection appointments every 2 months during injection windows | Moderately concerned | 2 Participants |
| RI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 12- Management of scheduling injection appointments every 2 months during injection windows | Somewhat concerned | 2 Participants |
| RI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 12- Management of scheduling injection appointments every 2 months during injection windows | Slightly concerned | 4 Participants |
| RI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 12- Management of scheduling injection appointments every 2 months during injection windows | Not at all concerned | 20 Participants |
| RI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 12- Management of rescheduling appointments during correct injection windows | Extremely concerned | 1 Participants |
| RI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 12- Management of rescheduling appointments during correct injection windows | Moderately concerned | 3 Participants |
| RI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 12- Management of rescheduling appointments during correct injection windows | Somewhat concerned | 1 Participants |
| RI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 12- Management of rescheduling appointments during correct injection windows | Slightly concerned | 7 Participants |
| RI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 12- Management of rescheduling appointments during correct injection windows | Not at all concerned | 17 Participants |
| RI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 12- Ability to schedule/reschedule patients who missed APRETUDE visits | Extremely concerned | 1 Participants |
| RI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 12- Ability to schedule/reschedule patients who missed APRETUDE visits | Moderately concerned | 2 Participants |
| RI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 12- Ability to schedule/reschedule patients who missed APRETUDE visits | Somewhat concerned | 3 Participants |
| RI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 12- Ability to schedule/reschedule patients who missed APRETUDE visits | Slightly concerned | 9 Participants |
| RI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 12- Ability to schedule/reschedule patients who missed APRETUDE visits | Not at all concerned | 14 Participants |
| RI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 12- Ability to identify and flag missed injection visits to providers (in a timely manner) | Extremely concerned | 3 Participants |
| RI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 12- Ability to identify and flag missed injection visits to providers (in a timely manner) | Moderately concerned | 0 Participants |
| RI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 12- Ability to identify and flag missed injection visits to providers (in a timely manner) | Somewhat concerned | 5 Participants |
| RI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 12- Ability to identify and flag missed injection visits to providers (in a timely manner) | Slightly concerned | 9 Participants |
| RI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 12- Ability to identify and flag missed injection visits to providers (in a timely manner) | Not at all concerned | 12 Participants |
| RI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 12- Ability to manage patients presenting to APRETUDE appointments with other care needs | Extremely concerned | 1 Participants |
| RI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 12- Ability to manage patients presenting to APRETUDE appointments with other care needs | Moderately concerned | 3 Participants |
| RI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 12- Ability to manage patients presenting to APRETUDE appointments with other care needs | Somewhat concerned | 2 Participants |
| RI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Month 12- Ability to manage patients presenting to APRETUDE appointments with other care needs | Slightly concerned | 6 Participants |
| RI - SSP | Number of SSPs With Responses to ISQs Regarding Managing Delivery of APRETUDE | Baseline- Management of rescheduling appointments during correct injection windows | Extremely concerned | 2 Participants |
Secondary
Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used
The ISQ used a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, SSPs were asked about the helpfulness of the telehealth services/systems used at their clinic/practice. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI).
Time frame: At Month 4 and Month 12
Population: Analysis was performed on SSPs who completed at least one survey at any timepoint. The use and adoption of these telehealth services were only assessed among DI SSPs at M4, but were assessed among both DI and RI SSPs at M12.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 4 - Video/virtual consultations for initial and follow-up visits | Helpful | 5 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 12 - Online system for scheduling/rescheduling consultations and injection appointments | Very helpful | 9 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 4 - Injection Administration: home health nurse to administer injection | A little helpful | 0 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 12 - Online system for scheduling/rescheduling consultations and injection appointments | Helpful | 7 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 4 - Online system for scheduling/rescheduling consultations and injection appointments | Very helpful | 10 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 12 - Online system for scheduling/rescheduling consultations and injection appointments | Somewhat helpful | 4 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 4 - Injection Administration: home health nurse to administer injection | Not at all helpful | 0 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 12 - Online system for scheduling/rescheduling consultations and injection appointments | A little helpful | 0 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 4 - Video/virtual consultations for initial and follow-up visits | Somewhat helpful | 2 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 12 - Online system for scheduling/rescheduling consultations and injection appointments | Not at all helpful | 0 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 4 - Injection Administration: home health nurse to administer injection | I have not personally used this | 2 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 12 - Online system for scheduling/rescheduling consultations and injection appointments | I have not personally used this | 2 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 4 - Online system for scheduling/rescheduling consultations and injection appointments | Not at all helpful | 0 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 12 - Video/virtual consultations for initial and follow-up visits | Very helpful | 13 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 4 - Injection appointment reminders: text/digital/email | Very helpful | 14 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 12 - Video/virtual consultations for initial and follow-up visits | Helpful | 6 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 12 - Video/virtual consultations for initial and follow-up visits | Somewhat helpful | 3 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 4 - Video/virtual consultations for initial and follow-up visits | A little helpful | 0 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 12 - Video/virtual consultations for initial and follow-up visits | A little helpful | 0 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 4 - Injection appointment reminders: text/digital/email | Helpful | 3 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 12 - Video/virtual consultations for initial and follow-up visits | Not at all helpful | 0 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 4 - Online system for scheduling/rescheduling consultations and injection appointments | Somewhat helpful | 1 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 12 - Video/virtual consultations for initial and follow-up visits | I have not personally used this | 4 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 4 - Injection appointment reminders: text/digital/email | Somewhat helpful | 1 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 12 - Injection Administration: home health nurse to administer injection | Very helpful | 5 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 4 - Video/virtual consultations for initial and follow-up visits | Not at all helpful | 0 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 12 - Injection Administration: home health nurse to administer injection | Helpful | 2 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 4 - Injection appointment reminders: text/digital/email | A little helpful | 0 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 12 - Injection Administration: home health nurse to administer injection | Somewhat helpful | 1 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 4 - Online system for scheduling/rescheduling consultations and injection appointments | I have not personally used this | 1 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 12 - Injection Administration: home health nurse to administer injection | A little helpful | 0 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 4 - Injection appointment reminders: text/digital/email | Not at all helpful | 1 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 12 - Injection Administration: home health nurse to administer injection | Not at all helpful | 0 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 4 - Video/virtual consultations for initial and follow-up visits | I have not personally used this | 3 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 12 - Injection Administration: home health nurse to administer injection | I have not personally used this | 4 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 4 - Injection appointment reminders: text/digital/email | I have not personally used this | 3 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 12 - Injection appointment reminders: text/digital/email | Very helpful | 16 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 4 - Online system for scheduling/rescheduling consultations and injection appointments | Helpful | 3 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 12 - Injection appointment reminders: text/digital/email | Helpful | 4 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 4 - HIV testing services: at home nurse testing | Very helpful | 3 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 12 - Injection appointment reminders: text/digital/email | Somewhat helpful | 1 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 4 - Injection Administration: home health nurse to administer injection | Very helpful | 2 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 12 - Injection appointment reminders: text/digital/email | A little helpful | 1 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 4 - HIV testing services: at home nurse testing | Helpful | 2 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 12 - Injection appointment reminders: text/digital/email | Not at all helpful | 0 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 4 - Video/virtual consultations for initial and follow-up visits | Very helpful | 14 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 12 - Injection appointment reminders: text/digital/email | I have not personally used this | 2 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 4 - HIV testing services: at home nurse testing | Somewhat helpful | 1 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 12 - HIV testing services: at home nurse testing | Very helpful | 9 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 4 - Injection Administration: home health nurse to administer injection | Helpful | 2 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 12 - HIV testing services: at home nurse testing | Helpful | 1 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 4 - HIV testing services: at home nurse testing | A little helpful | 0 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 12 - HIV testing services: at home nurse testing | Somewhat helpful | 1 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 4 - Online system for scheduling/rescheduling consultations and injection appointments | A little helpful | 0 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 12 - HIV testing services: at home nurse testing | A little helpful | 0 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 4 - HIV testing services: at home nurse testing | Not at all helpful | 1 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 12 - HIV testing services: at home nurse testing | Not at all helpful | 0 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 4 - Injection Administration: home health nurse to administer injection | Somewhat helpful | 1 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 12 - HIV testing services: at home nurse testing | I have not personally used this | 4 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 4 - HIV testing services: at home nurse testing | I have not personally used this | 4 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 12 - HIV testing services: at home nurse testing | I have not personally used this | 1 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 4 - Online system for scheduling/rescheduling consultations and injection appointments | Very helpful | 0 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 4 - Online system for scheduling/rescheduling consultations and injection appointments | Helpful | 0 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 4 - Online system for scheduling/rescheduling consultations and injection appointments | Somewhat helpful | 0 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 4 - Online system for scheduling/rescheduling consultations and injection appointments | A little helpful | 0 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 4 - Online system for scheduling/rescheduling consultations and injection appointments | Not at all helpful | 0 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 4 - Online system for scheduling/rescheduling consultations and injection appointments | I have not personally used this | 0 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 4 - Video/virtual consultations for initial and follow-up visits | Very helpful | 0 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 4 - Video/virtual consultations for initial and follow-up visits | Helpful | 0 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 4 - Video/virtual consultations for initial and follow-up visits | Somewhat helpful | 0 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 4 - Video/virtual consultations for initial and follow-up visits | A little helpful | 0 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 4 - Video/virtual consultations for initial and follow-up visits | Not at all helpful | 0 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 4 - Video/virtual consultations for initial and follow-up visits | I have not personally used this | 0 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 4 - Injection Administration: home health nurse to administer injection | Very helpful | 0 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 4 - Injection Administration: home health nurse to administer injection | Helpful | 0 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 4 - Injection Administration: home health nurse to administer injection | Somewhat helpful | 0 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 4 - Injection Administration: home health nurse to administer injection | A little helpful | 0 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 4 - Injection Administration: home health nurse to administer injection | Not at all helpful | 0 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 4 - Injection Administration: home health nurse to administer injection | I have not personally used this | 0 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 4 - Injection appointment reminders: text/digital/email | Very helpful | 0 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 4 - Injection appointment reminders: text/digital/email | Helpful | 0 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 4 - Injection appointment reminders: text/digital/email | Somewhat helpful | 0 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 4 - Injection appointment reminders: text/digital/email | A little helpful | 0 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 4 - Injection appointment reminders: text/digital/email | Not at all helpful | 0 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 4 - Injection appointment reminders: text/digital/email | I have not personally used this | 0 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 4 - HIV testing services: at home nurse testing | Very helpful | 0 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 4 - HIV testing services: at home nurse testing | Helpful | 0 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 4 - HIV testing services: at home nurse testing | Somewhat helpful | 0 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 4 - HIV testing services: at home nurse testing | A little helpful | 0 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 4 - HIV testing services: at home nurse testing | Not at all helpful | 0 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 4 - HIV testing services: at home nurse testing | I have not personally used this | 0 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 12 - Online system for scheduling/rescheduling consultations and injection appointments | Very helpful | 4 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 12 - Online system for scheduling/rescheduling consultations and injection appointments | Helpful | 2 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 12 - Online system for scheduling/rescheduling consultations and injection appointments | Somewhat helpful | 0 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 12 - Online system for scheduling/rescheduling consultations and injection appointments | A little helpful | 0 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 12 - Online system for scheduling/rescheduling consultations and injection appointments | Not at all helpful | 0 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 12 - Online system for scheduling/rescheduling consultations and injection appointments | I have not personally used this | 0 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 12 - Video/virtual consultations for initial and follow-up visits | Very helpful | 4 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 12 - Video/virtual consultations for initial and follow-up visits | Somewhat helpful | 2 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 12 - Video/virtual consultations for initial and follow-up visits | A little helpful | 0 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 12 - Video/virtual consultations for initial and follow-up visits | Not at all helpful | 0 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 12 - Video/virtual consultations for initial and follow-up visits | I have not personally used this | 0 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 12 - Injection Administration: home health nurse to administer injection | Very helpful | 1 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 12 - Injection Administration: home health nurse to administer injection | Helpful | 0 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 12 - Injection Administration: home health nurse to administer injection | Somewhat helpful | 0 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 12 - Injection Administration: home health nurse to administer injection | A little helpful | 0 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 12 - Injection Administration: home health nurse to administer injection | Not at all helpful | 0 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 12 - Injection Administration: home health nurse to administer injection | I have not personally used this | 1 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 12 - Injection appointment reminders: text/digital/email | Very helpful | 4 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 12 - Injection appointment reminders: text/digital/email | Helpful | 2 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 12 - Injection appointment reminders: text/digital/email | Somewhat helpful | 0 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 12 - Injection appointment reminders: text/digital/email | A little helpful | 0 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 12 - Injection appointment reminders: text/digital/email | Not at all helpful | 0 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 12 - Injection appointment reminders: text/digital/email | I have not personally used this | 0 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 12 - HIV testing services: at home nurse testing | Very helpful | 1 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 12 - HIV testing services: at home nurse testing | Helpful | 0 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 12 - HIV testing services: at home nurse testing | Somewhat helpful | 0 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 12 - HIV testing services: at home nurse testing | A little helpful | 0 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 12 - HIV testing services: at home nurse testing | Not at all helpful | 0 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating the Helpfulness of Telehealth Services Used | Month 12 - Video/virtual consultations for initial and follow-up visits | Helpful | 1 Participants |
Secondary
Number of SSPs With Responses to the ISQs Indicating Which Telehealth Services Were Used
The ISQ used a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, SSPs were asked about which telehealth services/systems were used at their clinic/practice to deliver APRETUDE during the PILLAR study. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI).
Time frame: At Month 4 and Month 12
Population: Analysis was performed on the SSPs who completed at least one survey at any time point. The use and adoption of these telehealth services were only assessed among DI SSPs at M4 but were assessed among both DI and RI SSPs at M12.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating Which Telehealth Services Were Used | Month 4 - Video/virtual consultations for initial and follow-up visits | I don't know | 4 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating Which Telehealth Services Were Used | Month 4 - Online system for scheduling/rescheduling consultations and injection appointments | Yes, services/systems offered through PILLAR study | 1 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating Which Telehealth Services Were Used | Month 4 - Injection Administration: home health nurse to administer injection | Yes, services/systems offered through PILLAR study | 3 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating Which Telehealth Services Were Used | Month 12 - Video/virtual consultations for initial and follow-up visits | Yes, at my clinic's service/system | 24 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating Which Telehealth Services Were Used | Month 12 - Video/virtual consultations for initial and follow-up visits | I don't know | 2 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating Which Telehealth Services Were Used | Month 12 - Injection appointment reminders: text/digital/email | No | 2 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating Which Telehealth Services Were Used | Month 4 - Online system for scheduling/rescheduling consultations and injection appointments | Yes, at my clinic's service/system | 14 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating Which Telehealth Services Were Used | Month 4 - Online system for scheduling/rescheduling consultations and injection appointments | No | 8 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating Which Telehealth Services Were Used | Month 4 - Online system for scheduling/rescheduling consultations and injection appointments | I don't know | 6 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating Which Telehealth Services Were Used | Month 4 - Video/virtual consultations for initial and follow-up visits | Yes, at my clinic's service/system | 23 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating Which Telehealth Services Were Used | Month 4 - Video/virtual consultations for initial and follow-up visits | Yes, services/systems offered through PILLAR study | 1 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating Which Telehealth Services Were Used | Month 4 - Video/virtual consultations for initial and follow-up visits | No | 1 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating Which Telehealth Services Were Used | Month 4 - Injection Administration: home health nurse to administer injection | Yes, at my clinic's service/system | 4 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating Which Telehealth Services Were Used | Month 4 - Injection Administration: home health nurse to administer injection | No | 17 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating Which Telehealth Services Were Used | Month 4 - Injection Administration: home health nurse to administer injection | I don't know | 5 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating Which Telehealth Services Were Used | Month 4 - Injection appointment reminders: text/digital/email | Yes, at my clinic's service/system | 21 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating Which Telehealth Services Were Used | Month 4 - Injection appointment reminders: text/digital/email | Yes, services/systems offered through PILLAR study | 1 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating Which Telehealth Services Were Used | Month 4 - Injection appointment reminders: text/digital/email | No | 1 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating Which Telehealth Services Were Used | Month 4 - Injection appointment reminders: text/digital/email | I don't know | 6 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating Which Telehealth Services Were Used | Month 4 - HIV testing services: at home nurse testing | Yes, at my clinic's service/system | 8 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating Which Telehealth Services Were Used | Month 4 - HIV testing services: at home nurse testing | Yes, services/systems offered through PILLAR study | 3 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating Which Telehealth Services Were Used | Month 4 - HIV testing services: at home nurse testing | No | 14 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating Which Telehealth Services Were Used | Month 4 - HIV testing services: at home nurse testing | I don't know | 4 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating Which Telehealth Services Were Used | Month 12 - Online system for scheduling/rescheduling consultations and injection appointments | Yes, at my clinic's service/system | 21 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating Which Telehealth Services Were Used | Month 12 - Online system for scheduling/rescheduling consultations and injection appointments | Yes, services/systems offered through PILLAR study | 1 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating Which Telehealth Services Were Used | Month 12 - Online system for scheduling/rescheduling consultations and injection appointments | No | 5 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating Which Telehealth Services Were Used | Month 12 - Online system for scheduling/rescheduling consultations and injection appointments | I don't know | 3 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating Which Telehealth Services Were Used | Month 12 - Video/virtual consultations for initial and follow-up visits | Yes, services/systems offered through PILLAR study | 2 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating Which Telehealth Services Were Used | Month 12 - Video/virtual consultations for initial and follow-up visits | No | 2 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating Which Telehealth Services Were Used | Month 12 - Injection Administration: home health nurse to administer injection | Yes, at my clinic's service/system | 6 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating Which Telehealth Services Were Used | Month 12 - Injection Administration: home health nurse to administer injection | Yes, services/systems offered through PILLAR study | 6 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating Which Telehealth Services Were Used | Month 12 - Injection Administration: home health nurse to administer injection | No | 16 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating Which Telehealth Services Were Used | Month 12 - Injection Administration: home health nurse to administer injection | I don't know | 2 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating Which Telehealth Services Were Used | Month 12 - Injection appointment reminders: text/digital/email | Yes, at my clinic's service/system | 23 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating Which Telehealth Services Were Used | Month 12 - Injection appointment reminders: text/digital/email | Yes, services/systems offered through PILLAR study | 1 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating Which Telehealth Services Were Used | Month 12 - Injection appointment reminders: text/digital/email | I don't know | 4 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating Which Telehealth Services Were Used | Month 12 - HIV testing services: at home nurse testing | Yes, at my clinic's service/system | 9 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating Which Telehealth Services Were Used | Month 12 - HIV testing services: at home nurse testing | Yes, services/systems offered through PILLAR study | 6 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating Which Telehealth Services Were Used | Month 12 - HIV testing services: at home nurse testing | No | 13 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Indicating Which Telehealth Services Were Used | Month 12 - HIV testing services: at home nurse testing | I don't know | 2 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating Which Telehealth Services Were Used | Month 12 - Injection Administration: home health nurse to administer injection | Yes, services/systems offered through PILLAR study | 1 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating Which Telehealth Services Were Used | Month 4 - HIV testing services: at home nurse testing | No | 0 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating Which Telehealth Services Were Used | Month 12 - Injection appointment reminders: text/digital/email | I don't know | 0 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating Which Telehealth Services Were Used | Month 4 - Injection Administration: home health nurse to administer injection | No | 0 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating Which Telehealth Services Were Used | Month 4 - HIV testing services: at home nurse testing | I don't know | 0 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating Which Telehealth Services Were Used | Month 12 - Injection Administration: home health nurse to administer injection | No | 7 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating Which Telehealth Services Were Used | Month 12 - Injection Administration: home health nurse to administer injection | I don't know | 0 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating Which Telehealth Services Were Used | Month 12 - Online system for scheduling/rescheduling consultations and injection appointments | Yes, at my clinic's service/system | 5 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating Which Telehealth Services Were Used | Month 12 - HIV testing services: at home nurse testing | I don't know | 0 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating Which Telehealth Services Were Used | Month 4 - Online system for scheduling/rescheduling consultations and injection appointments | Yes, services/systems offered through PILLAR study | 0 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating Which Telehealth Services Were Used | Month 12 - Online system for scheduling/rescheduling consultations and injection appointments | Yes, services/systems offered through PILLAR study | 1 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating Which Telehealth Services Were Used | Month 4 - Online system for scheduling/rescheduling consultations and injection appointments | No | 0 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating Which Telehealth Services Were Used | Month 12 - HIV testing services: at home nurse testing | Yes, at my clinic's service/system | 1 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating Which Telehealth Services Were Used | Month 4 - Online system for scheduling/rescheduling consultations and injection appointments | I don't know | 0 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating Which Telehealth Services Were Used | Month 12 - Online system for scheduling/rescheduling consultations and injection appointments | No | 3 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating Which Telehealth Services Were Used | Month 4 - Video/virtual consultations for initial and follow-up visits | Yes, at my clinic's service/system | 0 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating Which Telehealth Services Were Used | Month 12 - Injection appointment reminders: text/digital/email | Yes, at my clinic's service/system | 5 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating Which Telehealth Services Were Used | Month 4 - Video/virtual consultations for initial and follow-up visits | Yes, services/systems offered through PILLAR study | 0 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating Which Telehealth Services Were Used | Month 12 - Online system for scheduling/rescheduling consultations and injection appointments | I don't know | 0 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating Which Telehealth Services Were Used | Month 4 - Video/virtual consultations for initial and follow-up visits | No | 0 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating Which Telehealth Services Were Used | Month 4 - Online system for scheduling/rescheduling consultations and injection appointments | Yes, at my clinic's service/system | 0 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating Which Telehealth Services Were Used | Month 4 - Video/virtual consultations for initial and follow-up visits | I don't know | 0 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating Which Telehealth Services Were Used | Month 12 - Video/virtual consultations for initial and follow-up visits | Yes, at my clinic's service/system | 6 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating Which Telehealth Services Were Used | Month 4 - Injection Administration: home health nurse to administer injection | Yes, at my clinic's service/system | 0 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating Which Telehealth Services Were Used | Month 4 - Injection Administration: home health nurse to administer injection | Yes, services/systems offered through PILLAR study | 0 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating Which Telehealth Services Were Used | Month 12 - HIV testing services: at home nurse testing | No | 7 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating Which Telehealth Services Were Used | Month 12 - Video/virtual consultations for initial and follow-up visits | Yes, services/systems offered through PILLAR study | 1 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating Which Telehealth Services Were Used | Month 4 - Injection Administration: home health nurse to administer injection | I don't know | 0 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating Which Telehealth Services Were Used | Month 12 - Injection appointment reminders: text/digital/email | Yes, services/systems offered through PILLAR study | 1 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating Which Telehealth Services Were Used | Month 4 - Injection appointment reminders: text/digital/email | Yes, at my clinic's service/system | 0 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating Which Telehealth Services Were Used | Month 12 - Video/virtual consultations for initial and follow-up visits | No | 2 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating Which Telehealth Services Were Used | Month 4 - Injection appointment reminders: text/digital/email | Yes, services/systems offered through PILLAR study | 0 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating Which Telehealth Services Were Used | Month 12 - Video/virtual consultations for initial and follow-up visits | I don't know | 0 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating Which Telehealth Services Were Used | Month 4 - Injection appointment reminders: text/digital/email | No | 0 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating Which Telehealth Services Were Used | Month 12 - Injection appointment reminders: text/digital/email | No | 3 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating Which Telehealth Services Were Used | Month 4 - Injection appointment reminders: text/digital/email | I don't know | 0 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating Which Telehealth Services Were Used | Month 12 - Injection Administration: home health nurse to administer injection | Yes, at my clinic's service/system | 1 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating Which Telehealth Services Were Used | Month 4 - HIV testing services: at home nurse testing | Yes, at my clinic's service/system | 0 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating Which Telehealth Services Were Used | Month 12 - HIV testing services: at home nurse testing | Yes, services/systems offered through PILLAR study | 1 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Indicating Which Telehealth Services Were Used | Month 4 - HIV testing services: at home nurse testing | Yes, services/systems offered through PILLAR study | 0 Participants |
Secondary
Number of SSPs With Responses to the ISQs Regarding Use of Telehealth Delivery
The ISQ used a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, SSPs were asked about the use of telehealth services at their clinic/practice. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI).
Time frame: At Baseline (Month 1), Month 4 and Month 12
Population: Analysis was performed on SSPs who completed at least one survey at any timepoint. Only those participants with data available for the specified analysis at the specified time points were included.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| DI - SSP | Number of SSPs With Responses to the ISQs Regarding Use of Telehealth Delivery | Month 1 - Does your clinic/practice use any form of telehealth for APRETUDE delivery? | Yes | 54 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Regarding Use of Telehealth Delivery | Month 4 - Does your clinic/practice use any form of telehealth for APRETUDE delivery? | No | 15 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Regarding Use of Telehealth Delivery | Month 4 - Does your clinic/practice use any form of telehealth for APRETUDE delivery? | I Don't Know | 7 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Regarding Use of Telehealth Delivery | Month 1 - Does your clinic/practice use any form of telehealth for APRETUDE delivery? | No | 1 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Regarding Use of Telehealth Delivery | Month 4 - Does your clinic/practice use any form of telehealth for APRETUDE delivery? | Yes | 29 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Regarding Use of Telehealth Delivery | Month 12 - Does your clinic/practice use any form of telehealth for APRETUDE delivery? | No | 11 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Regarding Use of Telehealth Delivery | Month 1 - Does your clinic/practice use any form of telehealth for APRETUDE delivery? | I Don't Know | 1 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Regarding Use of Telehealth Delivery | Month 12 - Does your clinic/practice use any form of telehealth for APRETUDE delivery? | I Don't Know | 11 Participants |
| DI - SSP | Number of SSPs With Responses to the ISQs Regarding Use of Telehealth Delivery | Month 12 - Does your clinic/practice use any form of telehealth for APRETUDE delivery? | Yes | 30 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Regarding Use of Telehealth Delivery | Month 12 - Does your clinic/practice use any form of telehealth for APRETUDE delivery? | I Don't Know | 8 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Regarding Use of Telehealth Delivery | Month 1 - Does your clinic/practice use any form of telehealth for APRETUDE delivery? | Yes | 28 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Regarding Use of Telehealth Delivery | Month 1 - Does your clinic/practice use any form of telehealth for APRETUDE delivery? | No | 0 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Regarding Use of Telehealth Delivery | Month 1 - Does your clinic/practice use any form of telehealth for APRETUDE delivery? | I Don't Know | 2 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Regarding Use of Telehealth Delivery | Month 4 - Does your clinic/practice use any form of telehealth for APRETUDE delivery? | Yes | 10 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Regarding Use of Telehealth Delivery | Month 4 - Does your clinic/practice use any form of telehealth for APRETUDE delivery? | I Don't Know | 5 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Regarding Use of Telehealth Delivery | Month 12 - Does your clinic/practice use any form of telehealth for APRETUDE delivery? | Yes | 9 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Regarding Use of Telehealth Delivery | Month 12 - Does your clinic/practice use any form of telehealth for APRETUDE delivery? | No | 12 Participants |
| RI - SSP | Number of SSPs With Responses to the ISQs Regarding Use of Telehealth Delivery | Month 4 - Does your clinic/practice use any form of telehealth for APRETUDE delivery? | No | 14 Participants |
Secondary
Percentage of PSPs With Change From Baseline in ISQ Responses
The ISQ used a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs indicated their feelings about taking APRETUDE and how acceptable it was for them to go to the clinic for APRETUDE injections. Timeframe for evaluation of this outcome measure is BL, M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI). The change from baseline is calculated as a difference of percentages resulted at each timepoint as following: M6 minus (-) BL, and M12-BL. Q2M = a schedule of injection administration at every 2 months.
Time frame: At Month 6 and Month 12 compared to Baseline (Month 1)
Population: Analysis was performed on PSPs who were administered at least one dose of APRETUDE injection or of CAB tablets for PrEP and who completed at least one ISQ survey at any timepoint. Only those participants with data available for the specified analysis at the specified time points were included.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses | Change BL to M12 - How the participant felt about taking APRETUDE-Very negative | 0.0 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses | Change BL to M6-How the participant felt about taking APRETUDE- Neither positive nor negative | -4.5 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses | Change BL to M6 - Participant' acceptability for injection visits Q2M - Very acceptable | -3.9 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses | Change BL to M12 - How the participant felt about taking APRETUDE-Very positive | 10.5 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses | Change BL to M6 - Participant' acceptability for injection visits Q2M - Acceptable | 4.2 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses | Change BL to M6 - How the participant felt about taking APRETUDE - Somewhat positive | -0.7 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses | Change BL to M6 - Participant' acceptability for injection visits Q2M - Somewhat acceptable | -0.8 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses | Change BL to M12 - How the participant felt about taking APRETUDE-Somewhat positive | -5.1 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses | Change BL to M6 - Participant' acceptability for injection visits Q2M - A little acceptable | -0.5 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses | Change BL to M6 - Participant' acceptability for injection visits Q2M - Not at all acceptable | 1.1 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses | Change BL to M6 - How the participant felt about taking APRETUDE - Somewhat negative | 2.2 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses | Change BL to M12 - Participant' acceptability for injection visits Q2M - Very acceptable | -3.2 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses | Change BL to M12-How the participant felt about taking APRETUDE-Neither positive nor negative | -6.7 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses | Change BL to M12 - Participant' acceptability for injection visits Q2M - Acceptable | -1.9 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses | Change BL to M6 - How the participant felt about taking APRETUDE - Very positive | 3.0 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses | Change BL to M12 - Participant' acceptability for injection visits Q2M - Somewhat acceptable | 4.9 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses | Change BL to M12 - How the participant felt about taking APRETUDE-Somewhat negative | 1.3 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses | Change BL to M12 - Participant' acceptability for injection visits Q2M - A little acceptable | 0.1 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses | Change BL to M12 - Participant' acceptability for injection visits Q2M - Not at all acceptable | 0.0 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses | Change BL to M6 - How the participant felt about taking APRETUDE - Very negative | 0.0 Percentage of participants |
| RI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses | Change BL to M12 - Participant' acceptability for injection visits Q2M - Not at all acceptable | 0.0 Percentage of participants |
| RI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses | Change BL to M12 - Participant' acceptability for injection visits Q2M - A little acceptable | 1.6 Percentage of participants |
| RI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses | Change BL to M6 - How the participant felt about taking APRETUDE - Very positive | -2.8 Percentage of participants |
| RI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses | Change BL to M6 - How the participant felt about taking APRETUDE - Somewhat positive | 1.0 Percentage of participants |
| RI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses | Change BL to M6-How the participant felt about taking APRETUDE- Neither positive nor negative | 0.3 Percentage of participants |
| RI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses | Change BL to M6 - How the participant felt about taking APRETUDE - Somewhat negative | 1.6 Percentage of participants |
| RI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses | Change BL to M6 - How the participant felt about taking APRETUDE - Very negative | 0.0 Percentage of participants |
| RI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses | Change BL to M12 - How the participant felt about taking APRETUDE-Very positive | 2.0 Percentage of participants |
| RI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses | Change BL to M12 - How the participant felt about taking APRETUDE-Somewhat positive | -2.2 Percentage of participants |
| RI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses | Change BL to M12-How the participant felt about taking APRETUDE-Neither positive nor negative | 0.3 Percentage of participants |
| RI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses | Change BL to M12 - How the participant felt about taking APRETUDE-Somewhat negative | 0.0 Percentage of participants |
| RI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses | Change BL to M12 - How the participant felt about taking APRETUDE-Very negative | 0.0 Percentage of participants |
| RI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses | Change BL to M6 - Participant' acceptability for injection visits Q2M - Very acceptable | -8.9 Percentage of participants |
| RI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses | Change BL to M6 - Participant' acceptability for injection visits Q2M - Acceptable | 0.4 Percentage of participants |
| RI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses | Change BL to M6 - Participant' acceptability for injection visits Q2M - Somewhat acceptable | 6.9 Percentage of participants |
| RI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses | Change BL to M6 - Participant' acceptability for injection visits Q2M - Not at all acceptable | 1.6 Percentage of participants |
| RI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses | Change BL to M12 - Participant' acceptability for injection visits Q2M - Very acceptable | -10.5 Percentage of participants |
| RI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses | Change BL to M12 - Participant' acceptability for injection visits Q2M - Acceptable | 3.6 Percentage of participants |
| RI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses | Change BL to M12 - Participant' acceptability for injection visits Q2M - Somewhat acceptable | 5.3 Percentage of participants |
| RI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses | Change BL to M6 - Participant' acceptability for injection visits Q2M - A little acceptable | 0.0 Percentage of participants |
Secondary
Percentage of PSPs With Change From Baseline in ISQ Responses Regarding Telehealth Delivery
The ISQ used a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, PSPs were asked about the use of telehealth (TEL) services such as completing forms online, video chatting with their provider, getting reminders about their injection, or scheduling injection appointments online. Timeframe for evaluation of this outcome measure is BL, M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI). The change from baseline is calculated as a difference of percentages resulted at each timepoint as following: M6 minus (-) BL, and M12-BL.
Time frame: At Month 6 and Month 12 compared to Baseline (Month 1)
Population: Analysis was performed on PSPs who were administered at least one dose of APRETUDE injection or of CAB tablets for PrEP and who completed at least one ISQ survey at any timepoint. Only those participants with data available for the specified analysis at the specified time points were included.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Regarding Telehealth Delivery | Change BL to M6-Have you used telehealth for any APRETUDE services in the last 6 months? - YES | -40.1 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Regarding Telehealth Delivery | Change BL to M6-Have you used telehealth for any APRETUDE services in the last 6 months? - NO | 35.8 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Regarding Telehealth Delivery | Change BL to M6-Have you used telehealth for any APRETUDE services in the last 6 months?-DON'T KNOW | 4.3 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Regarding Telehealth Delivery | Change BL to M12 - Have you used telehealth for any APRETUDE services in the last 6 months? - YES | -46.1 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Regarding Telehealth Delivery | Change BL to M12 - Have you used telehealth for any APRETUDE services in the last 6 months? - NO | 44.8 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Regarding Telehealth Delivery | Change BL to M12-Have you used telehealth for any APRETUDE services in the last 6 months?-DON'T KNOW | 1.3 Percentage of participants |
| RI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Regarding Telehealth Delivery | Change BL to M12 - Have you used telehealth for any APRETUDE services in the last 6 months? - NO | 43.1 Percentage of participants |
| RI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Regarding Telehealth Delivery | Change BL to M6-Have you used telehealth for any APRETUDE services in the last 6 months? - YES | -45.8 Percentage of participants |
| RI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Regarding Telehealth Delivery | Change BL to M12 - Have you used telehealth for any APRETUDE services in the last 6 months? - YES | -43.1 Percentage of participants |
| RI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Regarding Telehealth Delivery | Change BL to M6-Have you used telehealth for any APRETUDE services in the last 6 months? - NO | 35.1 Percentage of participants |
| RI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Regarding Telehealth Delivery | Change BL to M12-Have you used telehealth for any APRETUDE services in the last 6 months?-DON'T KNOW | 0.0 Percentage of participants |
| RI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Regarding Telehealth Delivery | Change BL to M6-Have you used telehealth for any APRETUDE services in the last 6 months?-DON'T KNOW | 10.8 Percentage of participants |
Secondary
Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy
In this outcome measure, usong the ISQ, PSPs were asked about the helpfulness of various knowledge materials (I1= Getting Started Brochure that gives an overview of how to get started with APRETUDE, I2 = Patient Brochure helps understand the process of receiving APRETUDE, I3 = HIV & PrEP video gives key facts about HIV and PrEP options (DI), I4 = APRETUDE Myths and Facts video, addressing common myths about APRETUDE (DI), I5 = The What to Expect video which shows what to expect during the APRETUDE process (DI), I6 = The ViiV Connect program Video and frequently asked questions (DI), I7 = The study website to access APRETDUE information (RI), I8 = The study app to access APRETUDE information (DI). Timeframe for evaluation of this outcome measure is M6 and M12 (equivalent to M7 and M13 for PSPs who received OLI). The change from baseline is calculated as a difference of percentages resulted at each timepoint as following: M6 minus (-) BL, and M12-BL.
Time frame: At Month 6 and Month 12 compared to Baseline (Month 1)
Population: Analysis was performed on PSPs who were administered at least one dose of APRETUDE injection or of CAB tablets for PrEP and who completed at least one ISQ survey at any timepoint. All questions were not administered to both RI and DI arms; hence, certain Rows have 0 participants analyzed within each Arm/Group.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M6 - I2: Not at all helpful | 0.1 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M12 - I6: A little helpful | -1.8 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M12 - I6: Not at all helpful | 0.0 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M12 - I6: I did not use it | -7.9 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M12 - I8: Very helpful | 6.7 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M12 - I8: Helpful | 3.7 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M12 - I8: Somewhat helpful | 0.3 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M12 - I8: A little helpful | 4.7 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M12 - I8: Not at all helpful | 1.3 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M12 - I8: I did not use it | -16.6 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M12 - I1: Somewhat helpful | -4.9 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M12 - I1: A little helpful | -0.2 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M6 - I1: Not at all helpful | 0.1 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M6 - I1: Very helpful | -2.9 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M6 - I2: I did not use it | 8.7 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M6 - I3: Helpful | -3.2 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M6 - I3: Somewhat helpful | 1.1 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M6 - I3: I did not use it | 4.3 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M6 - I4: Very helpful | -3.6 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M6 - I4: A little helpful | -0.3 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M6 - I4: I did not use it | 0.8 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M6 - I5: Very helpful | -0.3 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M6 - I5: Helpful | -6.4 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M6 - I5: Somewhat helpful | 3.1 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M6 - I5: A little helpful | -0.4 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M6 - I5: Not at all helpful | 1.1 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M6 - I5: I did not use it | 2.9 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M6 - I6: Very helpful | -0.8 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M6 - I6: Somewhat helpful | 2.3 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M6 - I8: Very helpful | 4.2 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M6 - I8: Helpful | -2.5 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M6 - I8: Somewhat helpful | 4.9 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M6 - I8: A little helpful | 3.0 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M12 - I2: Not at all helpful | -1.0 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M12 - I2: I did not use it | 0.5 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M12 - I3: I did not use it | -3.2 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M12 - I5: Helpful | -1.7 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M6 - I1: Helpful | -7.2 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M6 - I1: Somewhat helpful | 8.1 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M6 - I1: A little helpful | -3.4 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M6 - I1: I did not use it | 5.3 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M6 - I2: Very helpful | -3.7 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M6 - I2: Helpful | -7.2 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M6 - I2: Somewhat helpful | 4.7 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M6 - I2: A little helpful | -2.6 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M6 - I3: Very helpful | -1.1 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M6 - I3: A little helpful | -1.2 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M6 - I3: Not at all helpful | 0.1 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M6 - I4: Helpful | 0.8 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M6 - I4: Somewhat helpful | 1.1 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M6 - I4: Not at all helpful | 1.2 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M6 - I6: Helpful | -5.6 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M6 - I6: A little helpful | 0.8 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M6 - I6: Not at all helpful | 1.1 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M6 - I6: I did not use it | 2.3 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M6 - I8: Not at all helpful | 5.4 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M6 - I8: I did not use it | -15.0 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M12 - I1: Very helpful | -3.5 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M12 - I1: Helpful | 8.1 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M12 - I1: Not at all helpful | -1.0 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M12 - I1: I did not use it | 1.5 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M12 - I2: Very helpful | -6.7 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M12 - I2: Helpful | 9.4 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M12 - I2: Somewhat helpful | -2.7 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M12 - I2: A little helpful | 0.4 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M12 - I3: Very helpful | 2.0 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M12 - I3: Helpful | 2.2 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M12 - I3: Somewhat helpful | 0.2 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M12 - I3: A little helpful | -0.2 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M12 - I3: Not at all helpful | -1.0 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M12 - I4: Very helpful | 3.9 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M12 - I4: Helpful | 2.4 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M12 - I4: Somewhat helpful | 1.5 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M12 - I4: A little helpful | -1.8 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M12 - I4: Not at all helpful | -1.0 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M12 - I4: I did not use it | -5.0 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M12 - I5: Very helpful | 5.2 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M12 - I5: Somewhat helpful | 1.1 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M12 - I5: A little helpful | 1.7 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M12 - I5: Not at all helpful | 0.0 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M12 - I5: I did not use it | -6.3 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M12 - I6: Very helpful | 3.8 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M12 - I6: Helpful | 4.1 Percentage of participants |
| DI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M12 - I6: Somewhat helpful | 1.8 Percentage of participants |
| RI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M6 - I1: Very helpful | -4.6 Percentage of participants |
| RI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M12 - I7: I did not use it | 6.0 Percentage of participants |
| RI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M6 - I1: Helpful | -3.7 Percentage of participants |
| RI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M12 - I1: Not at all helpful | 0.5 Percentage of participants |
| RI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M6 - I1: Somewhat helpful | -3.8 Percentage of participants |
| RI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M6 - I2: Somewhat helpful | -2.2 Percentage of participants |
| RI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M6 - I1: A little helpful | -2.7 Percentage of participants |
| RI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M6 - I1: Not at all helpful | -2.7 Percentage of participants |
| RI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M12 - I1: I did not use it | 12.6 Percentage of participants |
| RI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M6 - I2: A little helpful | -2.4 Percentage of participants |
| RI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M6 - I2: Very helpful | -6.7 Percentage of participants |
| RI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M12 - I2: Very helpful | -5.1 Percentage of participants |
| RI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M6 - I2: Helpful | -4.8 Percentage of participants |
| RI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M6 - I7: I did not use it | 9.1 Percentage of participants |
| RI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M12 - I2: Helpful | -11.1 Percentage of participants |
| RI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M6 - I2: I did not use it | 16.1 Percentage of participants |
| RI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M6 - I2: Not at all helpful | 0.0 Percentage of participants |
| RI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M12 - I2: Somewhat helpful | 2.5 Percentage of participants |
| RI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M12 - I7: A little helpful | 5.8 Percentage of participants |
| RI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M12 - I2: A little helpful | 0.8 Percentage of participants |
| RI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M12 - I2: I did not use it | 11.3 Percentage of participants |
| RI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M12 - I2: Not at all helpful | 1.6 Percentage of participants |
| RI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M6 - I7: Very helpful | -4.0 Percentage of participants |
| RI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M12 - I1: A little helpful | 0.5 Percentage of participants |
| RI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M6 - I7: A little helpful | -2.2 Percentage of participants |
| RI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M6 - I1: I did not use it | 17.4 Percentage of participants |
| RI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M6 - I7: Helpful | 0.1 Percentage of participants |
| RI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M6 - I7: Somewhat helpful | -4.6 Percentage of participants |
| RI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M6 - I7: Not at all helpful | 1.6 Percentage of participants |
| RI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M12 - I7: Very helpful | -7.2 Percentage of participants |
| RI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M12 - I7: Helpful | 0.1 Percentage of participants |
| RI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M12 - I7: Somewhat helpful | -6.2 Percentage of participants |
| RI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M12 - I1: Very helpful | -4.6 Percentage of participants |
| RI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M12 - I7: Not at all helpful | 1.6 Percentage of participants |
| RI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M12 - I1: Helpful | -8.4 Percentage of participants |
| RI - SSP | Percentage of PSPs With Change From Baseline in ISQ Responses Under Implementation Strategy | Change BL to M12 - I1: Somewhat helpful | -0.6 Percentage of participants |
Secondary
Percentage of SSPs With Change From Baseline in ISQ Responses for Telehealth Delivery
The ISQ used a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, SSPs were asked about the use of telehealth services at their clinic/practice. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). The change from baseline is calculated as a difference of percentages resulted at each timepoint as following: M4 minus (-) BL, and M12-BL.
Time frame: At Month 4 and Month 12 compared to Baseline (Month 1)
Population: Analysis was performed on SSPs who completed at least one survey at any timepoint. Only those participants with data available for the specified analysis at the specified time points were included.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| DI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses for Telehealth Delivery | Change BL to M4 - Does your clinic/practice use any form of telehealth for APRETUDE delivery? - YES | -39.6 Percentage of participants |
| DI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses for Telehealth Delivery | Change BL to M4 - Does your clinic/practice use any form of telehealth for APRETUDE delivery? - NO | 27.6 Percentage of participants |
| DI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses for Telehealth Delivery | Change BL to M4-Does clinic/practice use any form of telehealth for APRETUDE delivery?-I DON'T KNOW | 11.9 Percentage of participants |
| DI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses for Telehealth Delivery | Change BL to M12 - Does your clinic/practice use any form of telehealth for APRETUDE delivery? - YES | -38.7 Percentage of participants |
| DI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses for Telehealth Delivery | Change BL to M12 - Does your clinic/practice use any form of telehealth for APRETUDE delivery? - NO | 19.4 Percentage of participants |
| DI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses for Telehealth Delivery | Change BL to M12-Does clinic/practice use any form of telehealth for APRETUDE delivery?-I DON'T KNOW | 19.4 Percentage of participants |
| RI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses for Telehealth Delivery | Change BL to M12 - Does your clinic/practice use any form of telehealth for APRETUDE delivery? - NO | 41.4 Percentage of participants |
| RI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses for Telehealth Delivery | Change BL to M4 - Does your clinic/practice use any form of telehealth for APRETUDE delivery? - YES | -58.9 Percentage of participants |
| RI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses for Telehealth Delivery | Change BL to M12 - Does your clinic/practice use any form of telehealth for APRETUDE delivery? - YES | -62.3 Percentage of participants |
| RI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses for Telehealth Delivery | Change BL to M4 - Does your clinic/practice use any form of telehealth for APRETUDE delivery? - NO | 48.3 Percentage of participants |
| RI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses for Telehealth Delivery | Change BL to M12-Does clinic/practice use any form of telehealth for APRETUDE delivery?-I DON'T KNOW | 20.9 Percentage of participants |
| RI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses for Telehealth Delivery | Change BL to M4-Does clinic/practice use any form of telehealth for APRETUDE delivery?-I DON'T KNOW | 10.6 Percentage of participants |
Secondary
Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE
The ISQ used a variety of questions to assess outcomes spanning acceptability of, feasibility of, utility of, and experiences with the intervention and the implementation approach. In this outcome measure, SSPs were asked about the perceived barriers to managing delivery of APRETUDE (Item \[I\]1= Management of scheduling injection appointments during correct injection windows, I2= Management of rescheduling appointments during correct injection windows, I3= Ability to schedule/reschedule patients who missed APRETUDE visits, I4= Ability to identify and flag missed injection visits to providers (in a timely manner), I5= Ability to manage patients presenting to APRETUDE appointments with other care needs). Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). The change from baseline is calculated as a difference of percentages resulted at each timepoint as following: M4 minus (-) BL, and M12-BL.
Time frame: At Month 4 and 12 compared to Baseline (Month 1)
Population: Analysis was performed on all SSPs who completed at least one survey at any timepoint. Only those participants with data available for the specified analysis at the specified time points were included.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| DI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M4 - I3: Somewhat concerned | -7.0 Percentage of participants |
| DI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M12 - I1: Extremely concerned | -5.4 Percentage of participants |
| DI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M4 - I2: Moderately concerned | 2.7 Percentage of participants |
| DI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M12 - I1: Moderately concerned | -1.2 Percentage of participants |
| DI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M4 - I3: Slightly concerned | 6.6 Percentage of participants |
| DI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M12 - I1: Somewhat concerned | -13.6 Percentage of participants |
| DI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M4 - I1: Slightly concerned | -3.0 Percentage of participants |
| DI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M12 - I1: Slightly concerned | 4.5 Percentage of participants |
| DI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M4 - I3: Not at all concerned | 4.7 Percentage of participants |
| DI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M12 - I1: Not at all concerned | 15.7 Percentage of participants |
| DI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M4 - I2: Somewhat concerned | -11.1 Percentage of participants |
| DI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M12 - I2: Extremely concerned | -5.2 Percentage of participants |
| DI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M12 - I5: Extremely concerned | -7.0 Percentage of participants |
| DI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M12 - I2: Moderately concerned | 0.5 Percentage of participants |
| DI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M4 - I4: Extremely concerned | -3.0 Percentage of participants |
| DI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M12 - I2: Somewhat concerned | -11.4 Percentage of participants |
| DI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M4 - I1: Extremely concerned | -1.4 Percentage of participants |
| DI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M12 - I2: Slightly concerned | 8.5 Percentage of participants |
| DI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M4 - I4: Moderately concerned | 4.8 Percentage of participants |
| DI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M12 - I2: Not at all concerned | 7.6 Percentage of participants |
| DI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M4 - I2: Slightly concerned | -2.9 Percentage of participants |
| DI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M12 - I3: Extremely concerned | -3.3 Percentage of participants |
| DI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M4 - I4: Somewhat concerned | -7.2 Percentage of participants |
| DI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M12 - I3: Moderately concerned | -3.2 Percentage of participants |
| DI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M4 - I1: Not at all concerned | 15.1 Percentage of participants |
| DI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M12 - I3: Somewhat concerned | -13.2 Percentage of participants |
| DI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M4 - I4: Slightly concerned | 2.8 Percentage of participants |
| DI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M12 - I3: Slightly concerned | 14.0 Percentage of participants |
| DI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M4 - I2: Not at all concerned | 14.5 Percentage of participants |
| DI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M12 - I3: Not at all concerned | 5.6 Percentage of participants |
| DI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M4 - I4: Not at all concerned | 2.6 Percentage of participants |
| DI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M12 - I4: Extremely concerned | -1.2 Percentage of participants |
| DI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M4 - I1: Somewhat concerned | -11.4 Percentage of participants |
| DI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M12 - I4: Moderately concerned | -1.2 Percentage of participants |
| DI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M4 - I5: Extremely concerned | -7.0 Percentage of participants |
| DI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M12 - I4: Somewhat concerned | -11.4 Percentage of participants |
| DI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M4 - I3: Extremely concerned | -5.2 Percentage of participants |
| DI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M12 - I4: Slightly concerned | 10.3 Percentage of participants |
| DI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M4 - I5: Moderately concerned | 2.7 Percentage of participants |
| DI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M12 - I4: Not at all concerned | 3.6 Percentage of participants |
| DI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M4 - I2: Extremely concerned | -3.2 Percentage of participants |
| DI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M4 - I5: Somewhat concerned | 9.8 Percentage of participants |
| DI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M12 - I5: Moderately concerned | -1.4 Percentage of participants |
| DI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M4 - I3: Moderately concerned | 0.9 Percentage of participants |
| DI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M12 - I5: Somewhat concerned | -0.4 Percentage of participants |
| DI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M4 - I5: Slightly concerned | -6.3 Percentage of participants |
| DI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M12 - I5: Slightly concerned | 1.2 Percentage of participants |
| DI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M4 - I1: Moderately concerned | 0.9 Percentage of participants |
| DI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M12 - I5: Not at all concerned | 7.6 Percentage of participants |
| DI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M4 - I5: Not at all concerned | 0.8 Percentage of participants |
| RI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M12 - I2: Extremely concerned | -3.2 Percentage of participants |
| RI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M4 - I1: Extremely concerned | 0.2 Percentage of participants |
| RI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M4 - I1: Moderately concerned | -13.3 Percentage of participants |
| RI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M4 - I1: Somewhat concerned | 0.2 Percentage of participants |
| RI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M4 - I1: Slightly concerned | -9.5 Percentage of participants |
| RI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M4 - I1: Not at all concerned | 22.4 Percentage of participants |
| RI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M4 - I2: Extremely concerned | 0.2 Percentage of participants |
| RI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M4 - I2: Moderately concerned | -16.6 Percentage of participants |
| RI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M4 - I2: Somewhat concerned | -3.1 Percentage of participants |
| RI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M4 - I2: Slightly concerned | 1.0 Percentage of participants |
| RI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M4 - I2: Not at all concerned | 18.4 Percentage of participants |
| RI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M4 - I3: Extremely concerned | -3.1 Percentage of participants |
| RI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M4 - I3: Moderately concerned | -9.9 Percentage of participants |
| RI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M4 - I3: Somewhat concerned | -13.2 Percentage of participants |
| RI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M4 - I3: Slightly concerned | 4.5 Percentage of participants |
| RI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M4 - I3: Not at all concerned | 21.7 Percentage of participants |
| RI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M4 - I4: Extremely concerned | -9.8 Percentage of participants |
| RI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M4 - I4: Moderately concerned | -9.8 Percentage of participants |
| RI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M4 - I4: Somewhat concerned | -6.4 Percentage of participants |
| RI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M4 - I4: Slightly concerned | 10.8 Percentage of participants |
| RI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M4 - I4: Not at all concerned | 15.2 Percentage of participants |
| RI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M4 - I5: Extremely concerned | 0.3 Percentage of participants |
| RI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M4 - I5: Moderately concerned | -6.4 Percentage of participants |
| RI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M4 - I5: Somewhat concerned | -9.9 Percentage of participants |
| RI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M4 - I5: Slightly concerned | -6.3 Percentage of participants |
| RI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M4 - I5: Not at all concerned | 22.3 Percentage of participants |
| RI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M12 - I1: Extremely concerned | -3.2 Percentage of participants |
| RI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M12 - I1: Moderately concerned | -6.4 Percentage of participants |
| RI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M12 - I1: Somewhat concerned | 0.2 Percentage of participants |
| RI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M12 - I1: Slightly concerned | -9.5 Percentage of participants |
| RI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M12 - I1: Not at all concerned | 19.0 Percentage of participants |
| RI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M12 - I2: Moderately concerned | -9.7 Percentage of participants |
| RI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M12 - I2: Somewhat concerned | -6.6 Percentage of participants |
| RI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M12 - I2: Slightly concerned | -5.9 Percentage of participants |
| RI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M12 - I2: Not at all concerned | 25.3 Percentage of participants |
| RI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M12 - I3: Extremely concerned | -6.6 Percentage of participants |
| RI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M12 - I3: Moderately concerned | -6.4 Percentage of participants |
| RI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M12 - I3: Somewhat concerned | -6.3 Percentage of participants |
| RI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M12 - I3: Slightly concerned | 1.0 Percentage of participants |
| RI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M12 - I3: Not at all concerned | 18.3 Percentage of participants |
| RI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M12 - I4: Extremely concerned | -6.3 Percentage of participants |
| RI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M12 - I4: Moderately concerned | -16.7 Percentage of participants |
| RI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M12 - I4: Somewhat concerned | 3.9 Percentage of participants |
| RI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M12 - I4: Slightly concerned | 17.7 Percentage of participants |
| RI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M12 - I4: Not at all concerned | 1.4 Percentage of participants |
| RI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M12 - I5: Extremely concerned | -6.6 Percentage of participants |
| RI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M12 - I5: Moderately concerned | -3.0 Percentage of participants |
| RI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M12 - I5: Somewhat concerned | -6.4 Percentage of participants |
| RI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M12 - I5: Slightly concerned | 4.0 Percentage of participants |
| RI - SSP | Percentage of SSPs With Change From Baseline in ISQ Responses Regarding Managing Delivery of APRETUDE | Change BL to M12 - I5: Not at all concerned | 12.0 Percentage of participants |